[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"_public_publisher_all{\"sortAscending\":false,\"sortField\":\"updateTime\",\"page\":0,\"size\":10,\"facet\":true,\"searchKey\":\"\"}":3,"_public_publisher_byId_41150c9f-7cee-4971-84ac-6cec7a607266":656,"_public_publication_all{\"sortAscending\":false,\"sortField\":\"totalCitation\",\"page\":0,\"size\":10,\"facet\":true,\"searchKey\":\"publisherId:41150c9f-7cee-4971-84ac-6cec7a607266,\"}":700},{"meta":4,"data":6},{"total":5},"117",[7,60,176,207,299,413,445,480,543,572],{"id":8,"createTime":9,"updateTime":10,"relativeEntities":11,"slug":12,"properties":13,"entityType":24,"verifyStatus":25,"verifyTime":26,"verifyNote":27,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":29,"subjectFields":30,"manageAffiliations":31,"indexDatabases":32,"url":33,"thumbnailPath":34,"statistic":35,"gsStatistic":26,"type":26,"analyzePriority":26},"5a09599f-54d1-44c3-8f16-3847ac552024","2023-08-17T04:28:50.832+00:00","2025-10-13T23:58:52.517+00:00",[],"T%E1%BA%A1p-ch%C3%AD-Truy%E1%BB%81n-nhi%E1%BB%85m-Vi%E1%BB%87t-Nam",{"country":14,"issn":16,"introduce":18,"title":21},{"VOID":15},"VN",{"VOID":17},"08667829",{"EN":19,"VI":20},"{\"ops\":[{\"insert\":\"Vietnam Journal of Infectious Diseases is a social - professional forum of the Vietnam Society for Infectious Diseases, whose responsibility is to introduce the researches, the scientific advances in Vietnam and from the world; to contribute to the improvement of knowledges for health care staffs about clinic, treatment, guideline, prevention, epidemiology for infectious diseases, HIV\u002FAIDS and community health care; to provide, exchange and publish scientific information to the public accurately and promptly.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Vietnam Journal of Infectious Diseases publishes in the whole country; serves the professional work for researchers, clinical staffs, administrators, undergraduate and postgraduate students who are working and studying in the infections, tropical diseases and HIV\u002FAIDS from central to local levels, also organizations and individuals in the world who are interested in infectious and tropical diseases and prevention for HIV\u002FAIDS.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Editor in Chief:\"},{\"attributes\":{\"header\":4},\"insert\":\"\\n\"},{\"insert\":\"Prof. Dr. Nguyen Van Kinh. - Chairman of Editorial Board\"},{\"attributes\":{\"align\":\"justify\",\"blockquote\":true},\"insert\":\"\\n\"},{\"insert\":\"Prof. Dr. Nguyen Van Mui.\"},{\"attributes\":{\"align\":\"justify\",\"blockquote\":true},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Headquarter:\"},{\"attributes\":{\"header\":4},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Address:\"},{\"insert\":\" Level 6, National Hospital for Tropical Diseases, No. 78 Giai Phong Street, Dong Da District, Hanoi city, Vietnam.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Tel:\"},{\"insert\":\" \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Ftel:02435765464\"},\"insert\":\"02435765464\"},{\"insert\":\"; \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Ftel:0913552672\"},\"insert\":\"0913552672\"},{\"insert\":\"; \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Ftel:0913228072\"},\"insert\":\"0913228072\"},{\"insert\":\".\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Email\"},{\"insert\":\": \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Findex\u002Fadmin\u002Fcontexts\u002Fmailto:tungphamvan52@gmail.com\"},\"insert\":\"tungphamvan52@gmail.com\"},{\"insert\":\"; \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Fmailto:tapchitruyennhiem@gmail.com\"},\"insert\":\"tapchitruyennhiem@gmail.com\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Bank account:\"},{\"insert\":\" 0021000275119, Vietcombank Hanoi Branch. Transaction office No. 7, 402 Tran Khat Chan, Hai Ba Trung District, Hanoi city, Vietnam.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"\\n\"}]}","{\"ops\":[{\"insert\":\"Tạp chí Truyền nhiễm Việt Nam là cơ quan ngôn luận của Hội Truyền nhiễm Việt Nam, chịu sự lãnh đạo, chỉ đạo trực tiếp của Thường vụ Ban Chấp hành Hội Truyền nhiễm Việt Nam; sự kiểm tra, giám sát về nghiệp vụ báo chí của các cơ quan chức năng quản lý báo chí thuộc Bộ Thông tin và Truyền thông và Ban Tuyên giáo Trung ương Đảng.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Tạp chí có trách nhiệm giới thiệu các công trình nghiên cứu khoa học, những tiến bộ khoa học trên thế giới và trong nước, góp phần nâng cao kiến thức khoa học cho cán bộ y tế về lâm sàng, điều trị, hướng dẫn, dự phòng, dịch tễ học các bệnh truyền nhiễm, HIV\u002FAIDS và chăm sóc sức khỏe cộng đồng; cung cấp, trao đổi, phổ biến các thông tin khoa học tới công chúng chính xác và kịp thời.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Tạp chí xuất bản 03 tháng\u002F01 kỳ và được phát hành qua Bưu điện và tự phát hành trong phạm vi toàn quốc.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Lãnh đạo Tạp chí: \"},{\"attributes\":{\"header\":4},\"insert\":\"\\n\"},{\"insert\":\"Tổng Biên tập: ThS.BSCKII Nguyễn Trung Cấp\"},{\"attributes\":{\"align\":\"justify\",\"blockquote\":true},\"insert\":\"\\n\"},{\"insert\":\"Phó Tổng Biên tập:\"},{\"attributes\":{\"align\":\"justify\",\"blockquote\":true},\"insert\":\"\\n\"},{\"insert\":\"            TS.BSCKII Phạm Ngọc Thạch\"},{\"attributes\":{\"align\":\"justify\",\"blockquote\":true},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Trụ sở tòa soạn:\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Địa chỉ: Tầng 6, Bệnh viện Bệnh Nhiệt đới Trung ương, 78 đường Giải Phóng, phường Phương Mai, quận Đống Đa, thành phố Hà Nội.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Điện thoại:\"},{\"insert\":\" \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Ftel:02435765464\"},\"insert\":\"02435765464\"},{\"insert\":\" - \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Ftel:0913228072\"},\"insert\":\"0913228072\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Email\"},{\"insert\":\": \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Findex\u002Fadmin\u002Fcontexts\u002Fmailto:tungphamvan52@gmail.com\"},\"insert\":\"tungphamvan52@gmail.com\"},{\"insert\":\"; \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Fmailto:tapchitruyennhiem@gmail.com\"},\"insert\":\"tapchitruyennhiem@gmail.com\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Tài khoản:\"},{\"insert\":\" Số 0021000275119 Ngân hàng Ngoại thương Việt Nam, chi nhánh Hà Nội (Vietcombank Hà Nội). Phòng giao dịch số 7, 402 Trần Khát Chân, quận Hai Bà Trưng, Thành phố Hà Nội.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"\\n\"}]}",{"EN":22,"VI":23},"Vietnam Journal of Infectious Diseases","Tạp chí Truyền nhiễm Việt Nam","PUBLISHER","VERIFIED",null,"Admin update database","PENDING",51,[],[],[],"https:\u002F\u002Ftruyennhiemvietnam.vn\u002Findex.php\u002Fvjid","\u002Fapi\u002Fpublic\u002Ffile\u002Fpublisher\u002F5a09599f-54d1-44c3-8f16-3847ac552024\u002Fadb0e52bf25e0de580fd4289519cb8bf.jpg",{"impactFactor":36,"impactFactorByYear":37,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":41,"totalPublicationByYear":42,"totalCitation":48,"totalCitationByYear":49,"totalCitationPerPublication":54,"totalCitationPerPublicationByYear":55,"hindexLast5Year":59,"hindex":59},0,{"2022":38,"2023":39,"2024":40},0.01,0.03,0.13,315,{"2020":43,"2021":44,"2022":45,"2023":46,"2024":47},63,58,57,65,72,43,{"2020":50,"2021":51,"2022":52,"2023":53},8,15,9,11,0.14,{"2020":40,"2021":56,"2022":57,"2023":58},0.26,0.16,0.17,3,{"id":61,"createTime":62,"updateTime":63,"relativeEntities":64,"slug":65,"properties":66,"entityType":24,"verifyStatus":25,"verifyTime":78,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":79,"subjectFields":80,"manageAffiliations":81,"indexDatabases":136,"url":137,"thumbnailPath":26,"statistic":138,"gsStatistic":155,"type":175,"analyzePriority":26},"25b6bd10-676c-40c0-8dc3-356d1679a284","2023-05-19T02:22:33.430+00:00","2026-06-18T23:33:57.141+00:00",[],"T%E1%BA%A1p-ch%C3%AD-Y-D%C6%B0%E1%BB%A3c-h%E1%BB%8Dc-C%E1%BA%A7n-Th%C6%A1",{"country":67,"issn":68,"introduce":70,"title":73,"gsId":76},{"VOID":15},{"VOID":69},"23541210",{"EN":71,"VI":72},"\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">04\u002F10\u002F2015 Ministry of Information and Communications allowed Can Tho journal of medicine and pharmacy to operate (102 \u002FGP-BTTTT)\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">07\u002F16\u002F2015 Can Tho journal of medicine and pharmacy is internationally recognized: ISSN 2354-1210\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">In 2016, The journal has been included in the list of medical science journals by The State Council for professorship which is awarded a work score of 0-0.5 points for a published article.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Can Tho Journal of Medicine and Pharmacy welcome original works that haven’t been submitted or published in other medical journals. Posts must contain content related to one of the journal’s categories.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">The content published\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">The journal is divided into 3 categories:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Scientific research article: are valuable scientific works, which have been researched and accepted.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Overview of medicine, biology and pharmacy: serving the objective of continuing training in the fields of medicine, biology and pharmacy; to systematize classical and modern knowledge.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Update information on new knowledge about medicine, biology, pharmacy in the country and in the world.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Scope\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Publication and introduction of scientific research in the fields:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">+ Medicine (internal medicine, surgery, pediatrics, obstetrics and gynecology, odonto-stomatology, laboratory, oncology, traditional medicine, nursing).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">+ Biology (genetics, biotechnology).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">+ Pharmacology (pharmaceutics, drug quality analysis-control, synthetic pharmaceutical chemistry, biochemistry, pharmacognosy, botany, clinical pharmacy).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- To enhance the quality of undergraduate, postgraduate education, scientifically researching and meet the necessary treatment in hospital.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Introducing the updated domestic and oversea information about science technology to promote scientific research and exchanging technology in local, other universities.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Exchanging pharmaceutical and medical information for social health developing in the Mekong Delta and Vietnam.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">The object\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Postgraduate students, student of Can Tho University of Medicine and Pharmacy, scientists from schools, research institutes, hospitals, health centers, pharmaceutical companies of the Mekong Delta; other provinces and regions in Vietnam and other country.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Address\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Headquarters of Can Tho Journal of Medicine and Pharmacy, located Scientific Research and International Cooperation Office: 179 Nguyen Van Cu Street, An Khanh Ward, Ninh Kieu District, Can Tho City, Vietnam.\u003C\u002Fspan>\u003C\u002Fp>","\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Ngày 16\u002F7\u002F2015, Tạp chí Y Dược học Cần Thơ được cấp chỉ số quốc tế: ISSN 2354-1210.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Từ tháng 4\u002F2016, Tạp chí đã được Hội đồng Giáo sư ngành Y đưa vào danh sách các tạp chí khoa học Y học được tính điểm công trình 0-0,5 điểm cho một bài báo đăng.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Năm 2020 Tạp chí Y Dược học Cần Thơ đã được phê duyệt vào danh mục của các Hội đồng Giáo sư ngành Dược học được tính điểm công trình 0-0,5 điểm cho một bài báo đăng.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tạp chí Y Dược học Cần Thơ ra 12 số\u002Fnăm, 180-200 trang\u002Fsố.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Từ tháng 12\u002F2022 Tạp chí Y Dược học Cần Thơ là thành viên của hệ thống Crossref và từ tháng 01\u002F2023 tạp chí thực hiện bình duyệt online kín 2 chiều nhằm tăng tính minh bạch, tin cậy của các công trình nghiên cứu khoa học và đảm bảo tốt nhất chất lượng khoa học của bài viết.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tôn chỉ, mục đích và phạm vi của tạp chí\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tôn chỉ và mục đích hoạt động của tạp chí: xuất bản nhằm mục đích phổ biến kết quả từ các đề tài nghiên cứu khoa học; giao lưu trao đổi khoa học, chia sẻ kinh nghiệm, học tập, đồng thời cập nhật thông tin khoa học mới trong các lĩnh vực y, sinh, dược học trong và ngoài nước.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Phạm vi của tạp chí: Tạp chí xuất bản được chia thành 3 chuyên mục: (i) Bài báo nghiên cứu khoa học là kết quả công trình nghiên cứu khoa học có giá trị đã được triển khai nghiên cứu, (ii) Bài tổng quan y, sinh, dược học: phục vụ mục tiêu đào tạo liên tục trong lĩnh vực y, sinh, dược học; nhằm hệ thống hóa những kiến thức kinh điển và hiện đại; (iii) Thông tin cập nhật kiến thức mới về y, sinh, dược học trong nước và trên thế giới.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Chính sách truy cập mở\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tạp chí Y Dược học Cần Thơ áp dụng chính sách truy cập mở đối với các bài báo đã xuất bản đến với độc giả, nhằm mở rộng cơ hội tiếp cận các kết quả nghiên cứu chất lượng cao và tăng cường trao đổi kiến thức. Tạp chí đăng tải trực tuyến (miễn phí) toàn văn các bài báo được công bố trên website của Tạp chí (https:\u002F\u002Ftapchi.ctump.edu.vn).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Đạo đức xuất bản\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tạp chí Y Dược học Cần Thơ cam kết tuân thủ đạo đức xuất bản phù hợp với các hướng dẫn và tiêu chuẩn của the Committee on Publication Ethics (COPE), tuân thủ các nguyên tắc của COPE’s Core Practices, Best Practices Guidelines for Journal Editors và Guidelines on Good Publication Practices.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Bản thảo bài báo chỉ được chấp nhận khi được tác giả chịu trách nhiệm chính cam kết các nội dung sau: Các nội dung của bản thảo chưa được đăng tải toàn bộ hoặc một phần ở các tạp chí khác; Tất cả các tác giả đều có đóng góp một cách đáng kể vào quá trình nghiên cứu hoặc chuẩn bị bản thảo và cùng chịu trách nhiệm về các nội dung của bản thảo; Tuân thủ các biện pháp đảm bảo đạo đức nghiên cứu (ví dụ thỏa thuận đồng ý tham gia nghiên cứu).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Cam kết bảo mật\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tạp chí cam kết thực hiện và tuân thủ các quy định của luật và các văn bản hướng dẫn liên quan đến bảo mật thông tin cá nhân trên không gian mạng. Các thông tin mà người dùng (tác giả, độc giả, biên tập viên, người phản biện) nhập vào các biểu mẫu trên Hệ thống Quản lý xuất bản trực tuyến của tạp chí chỉ được sử dụng vào các mục đích đã được tuyên bố rõ ràng và sẽ không được cung cấp cho bất kỳ bên thứ ba nào khác, hay dùng vào bất kỳ mục đích nào khác.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Phí gửi bài\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Lệ phí gửi đăng bài: 1.000.000đ\u002Fbài báo\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Lệ phí gửi đăng nhanh: 1.500.000đ\u002Fbài báo\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Đối với tác giả là cán bộ viên chức thuộc Trường Đại học Y Dược Cần Thơ thì được hỗ trợ 50% lệ phí gửi đăng bài.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Đối với sinh viên thực hiện đề tài nghiên cứu khoa học cấp trường được hỗ trợ 100% lệ phí đăng bài ( Tác giả gửi đính kèm “ Quyết định về việc giao tổ chức thực hiện đề tài nghiên cứu khoa học cấp Trường của sinh viên”).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Hình thức nộp lệ phí:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">1. Tiền mặt:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Nộp trực tiếp tại Phòng Tài chính - Kế toán, Trường Đại học Y Dược Cần Thơ, số 179 Nguyễn Văn Cừ, P. An Khánh, Q. Ninh Kiều, thành phố Cần Thơ.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">2. Chuyển khoản:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tên Tài khoản: Trường ĐHYD Cần Thơ, Số TK: 0111000115668, tại ngân hàng Vietcombank chi nhánh Cần Thơ.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Thời gian: Áp dụng từ ngày 01\u002F02\u002F2023.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">* Phí gửi bài không được hoàn trả khi bài viết bị từ chối hoặc tác giả xin rút bài viết.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Quy trình phản biện bài báo\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tạp chí Y Dược học Cần Thơ thực hiện quy trình phản biện kín hai chiều nghiêm ngặt. Danh tính của những người phản biện không được tiết lộ cho các tác giả và ngược lại. Quy trình thẩm định bài báo đăng gồm các bước sau:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tiếp nhận bản thảo\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tác giả liên hệ gửi bản thảo đến Tạp chí qua hệ thống trực tuyến tại website: https:\u002F\u002Ftapchi.ctump.edu.vn. Hướng dẫn về cách đăng ký, gửi bài và chuẩn bị bản thảo được cung cấp trên website của Tạp chí.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Sàng lọc sơ bộ\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Sau khi Tòa soạn nhận được bài báo của tác giả, Ban Thư ký sẽ tiến hành kiểm tra sơ bộ bài báo (các yêu cầu về nội dung và hình thức). Những bài báo không đúng quy cách hoặc có nội dung không phù hợp hoặc vi phạm bản quyền sẽ bị từ chối (Ban Thư ký thông báo phản hồi đến tác giả trong vòng 1 tuần). Những bài báo đủ điều kiện, được Ban Thư ký tòa soạn chuyển đến Ban Biên tập có cùng chuyên môn với nội dung bài báo để đề xuất người phản biện. Thời gian kể từ khi Ban Biên tập nhận bài báo đến khi đề xuất người phản biện bài báo chậm nhất là 5 ngày.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Vòng phản biện\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">1. Ban Thư ký gửi bài và yêu cầu phản biện đến 02 phản biện độc lập.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">2. Các phản biện gởi nhận xét cho Ban Thư ký. Thời gian từ khi gửi bài cho phản biện đến khi nhận ý kiến của phản biện tối đa là 20 ngày.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Xử ký kết quả phản biện\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">1. Nếu ý kiến đồng ý cho đăng và không cần chỉnh sửa, Ban Thư ký tiếp tục đăng bài theo qui trình.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">2. Nếu ý kiến đồng ý đăng và cần chỉnh sửa, Ban Thư ký sẽ thông tin đến tác giả chỉnh sửa theo yêu cầu của người phản biện. Thời gian chỉnh sửa và gửi lại kéo dài không quá 2 tuần, từ khi tác giả bài báo nhận được thông tin (Quá trình này có thể lặp lại tối đa 2 lần\u002F1 bài báo). Khi có sự thống nhất, đồng ý của người phản biện; bài báo được tiếp tục đăng theo qui trình.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">3. Những bài báo có chất lượng không đạt yêu cầu, cả 2 phản biện không đồng ý cho đăng sẽ bị Tòa soạn từ chối đăng.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Xuất bản\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">1. Ban Thư ký tổng hợp các bản thảo đã được tác giả hoàn thiện sau thẩm định trình Ban Biên tập xem xét, Tổng Biên tập phê duyệt, quyết định bài đăng theo các tiêu chí: sự phù hợp nội dung với tôn chỉ và mục đích, thể loại bài viết (ưu tiên các bài có bài có nghiên cứu chuyên sâu, hàm lượng khoa học cao), đóng góp mới bài báo, bài báo được ưu tiên đăng trong số gần nhất của Tạp chí theo thứ tự: tính thời sự, chất lượng bài báo và thời gian gửi bài.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">2. Ban Biên tập và Ban Thư ký biên tập bản thảo, chế bản, đọc rà soát lỗi. Thời gian hoàn thành từ 10-15 ngày.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">3. Ban Thư ký có trách nhiệm thông báo cho tác giả bài báo (bằng e-mail) về tình hình phê duyệt bài báo, thời gian, số kỳ, tập xuất bản bài báo theo qui định.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">4. Danh sách bài báo theo số Tạp chí được in ấn và phát hành trong năm định kỳ được công bố chính thức trên website: https:\u002F\u002Ftapchi.ctump.edu.vn\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>",{"EN":74,"VI":75},"Cantho Journal of Medicine and Pharmacy","Tạp chí Y Dược học Cần Thơ",{"VOID":77},"wcQ1uqwAAAAJ","2023-05-30T08:17:21.868+00:00",32,[],[82],{"id":83,"createTime":84,"updateTime":85,"relativeEntities":86,"slug":87,"properties":88,"entityType":98,"verifyStatus":25,"verifyTime":99,"verifyNote":26,"syncStatus":28,"languages":100,"translateLanguages":26,"viewCount":103,"url":104,"parentIds":105,"statistic":106},"6413896b-eca9-442b-a73f-182a58a0ce40","2023-06-12T14:59:13.446+00:00","2026-06-19T02:29:32.871+00:00",[],"Tr%C6%B0%E1%BB%9Dng-%C4%90%E1%BA%A1i-h%E1%BB%8Dc-Y-D%C6%B0%E1%BB%A3c-C%E1%BA%A7n-Th%C6%A1",{"country":89,"title":90,"address":93,"abbreviation":96},{"VOID":15},{"EN":91,"VI":92},"Can Tho University of Medicine and Pharmacy","Trường Đại học Y Dược Cần Thơ",{"VI":94,"EN":95},"Số 179, đường Nguyễn Văn Cừ, phường An Khánh, quận Ninh Kiều, thành phố Cần Thơ, Việt Nam","No 179, Nguyen Van Cu street, An Khanh ward, Ninh Kieu district, Can Tho city, Vietnam",{"VOID":97},"ctump","AFFILIATION","2023-08-01T14:07:27.977+00:00",[101,102],"VI","EN",12,"http:\u002F\u002Fwww.ctump.edu.vn\u002F",[],{"impactFactor":36,"impactFactorByYear":107,"i10Index":111,"i10IndexLast5Year":59,"totalPublication":112,"totalPublicationByYear":113,"totalCitation":122,"totalCitationByYear":123,"totalCitationPerPublication":128,"totalCitationPerPublicationByYear":129,"hindexLast5Year":135,"hindex":135},{"2022":108,"2023":109,"2024":110,"2025":38},0.1,0.05,0.07,4,1489,{"2013":114,"2014":115,"2015":115,"2016":111,"2017":115,"2018":59,"2019":114,"2020":116,"2021":117,"2022":118,"2023":119,"2024":120,"2025":121,"2026":111},2,1,10,84,281,680,260,156,313,{"2013":59,"2014":114,"2018":124,"2021":125,"2022":126,"2023":127},17,36,123,132,0.21,{"2013":130,"2014":114,"2018":131,"2021":132,"2022":133,"2023":134},1.5,5.67,0.43,0.44,0.19,6,[],"https:\u002F\u002Ftapchi.ctump.edu.vn\u002Findex.php\u002Fctump",{"impactFactor":36,"impactFactorByYear":139,"i10Index":114,"i10IndexLast5Year":114,"totalPublication":140,"totalPublicationByYear":141,"totalCitation":147,"totalCitationByYear":148,"totalCitationPerPublication":151,"totalCitationPerPublicationByYear":152,"hindexLast5Year":135,"hindex":135},{"2022":38,"2023":36,"2024":39,"2025":38},1956,{"0":114,"2019":114,"2020":50,"2021":142,"2022":143,"2023":144,"2024":145,"2025":146},76,403,789,305,371,524,{"0":114,"2019":135,"2021":124,"2022":149,"2023":150,"2024":111,"2025":114},287,206,0.27,{"0":115,"2019":59,"2021":153,"2022":154,"2023":56,"2024":38,"2025":38},0.22,0.71,{"impactFactor":26,"impactFactorByYear":26,"i10Index":114,"i10IndexLast5Year":114,"totalPublication":156,"totalPublicationByYear":157,"totalCitation":163,"totalCitationByYear":164,"totalCitationPerPublication":169,"totalCitationPerPublicationByYear":170,"hindexLast5Year":135,"hindex":135},461,{"0":158,"2019":114,"2021":159,"2022":160,"2023":161,"2024":158,"2025":162},7,37,296,107,5,419,{"2021":59,"2022":59,"2023":165,"2024":166,"2025":167,"2026":168},71,126,171,41,0.91,{"2021":171,"2022":38,"2023":172,"2024":173,"2025":174},0.08,0.66,18,34.2,"JOURNAL",{"id":177,"createTime":178,"updateTime":179,"relativeEntities":180,"slug":181,"properties":182,"entityType":24,"verifyStatus":25,"verifyTime":193,"verifyNote":26,"syncStatus":28,"languages":194,"translateLanguages":26,"viewCount":36,"subjectFields":195,"manageAffiliations":196,"indexDatabases":197,"url":198,"thumbnailPath":26,"statistic":26,"gsStatistic":199,"type":175,"analyzePriority":26},"f8d0bf97-8d89-482e-b58c-2fc481a0b79b","2025-10-27T06:27:08.591+00:00","2026-06-18T23:33:41.667+00:00",[],"T%E1%BA%A1p-ch%C3%AD-Khoa-h%E1%BB%8Dc-v%C3%A0-C%C3%B4ng-ngh%E1%BB%87-nhi%E1%BB%87t-%C4%91%E1%BB%9Bi",{"country":183,"introduce":184,"gsId":186,"title":188,"issn":191},{"VOID":15},{"EN":185},"\u003Cp style=\"text-align:justify;\">     Journal of Tropical Science and Engineering (JTSE) is a multidisciplinary scientific journal, licensed to operate as a print journal in 2012 and an electronic journal in 2024 (License No.1479\u002FGP-BTTTT dated August 20, 2012 and No.91\u002FGP-BTTTT dated April 9, 2024 issued by the Ministry of Information and Communications of Vietnam). The JTSE is headquartered in Hanoi.\u003C\u002Fp>\u003Cp style=\"text-align:justify;\">        The JTSE is published every 3 months (4 issues\u002Fyear), publishing research results and overview articles in 3 groups of fields: Tropical Ecology and Environment; Chemistry and Material Sciences; Biomedicine and Pharmacy. In 2022, the JTSE registered the international identifier Digital Object Identifier (DOI): 10.58334\u002Fvrtc.jtst and assigned DOI codes to all articles of the journal. The members of the Editorial Board of the JTSE are prestigious scientists and leading scientists from Vietnam and many countries in the world. The JTSE has been recognized by the Vietnam State Council for Professorship to score scientific articles in Chemistry, Medicine and Biology with scores ranging from 0-0.75 points.\u003C\u002Fp>\u003Cp style=\"text-align:justify;\">      Currently, the JTSE is building and perfecting a set of criteria and making efforts to join the List of prestigious  international journals with a roadmap to enter Scopus and SCIE in the coming time.\u003C\u002Fp>",{"VOID":187},"MS2_GJQAAAAJ",{"VI":189,"EN":190},"Tạp chí Khoa học và Công nghệ nhiệt đới","Journal of Tropical Science and Engineering",{"VOID":192},"08667535","2025-10-27T06:27:25.058+00:00",[101,102],[],[],[],"https:\u002F\u002Ftapchikhcnnd.com.vn",{"impactFactor":26,"impactFactorByYear":26,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":200,"totalPublicationByYear":201,"totalCitation":161,"totalCitationByYear":203,"totalCitationPerPublication":153,"totalCitationPerPublicationByYear":205,"hindexLast5Year":114,"hindex":114},481,{"0":115,"2020":115,"2021":115,"2022":114,"2024":115,"2025":202,"2026":115},474,{"2017":114,"2018":115,"2019":111,"2020":162,"2021":162,"2022":116,"2023":50,"2024":162,"2025":204,"2026":52},52,{"2020":162,"2021":162,"2022":162,"2024":162,"2025":206,"2026":52},0.11,{"id":208,"createTime":209,"updateTime":210,"relativeEntities":211,"slug":212,"properties":213,"entityType":24,"verifyStatus":25,"verifyTime":221,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":222,"subjectFields":223,"manageAffiliations":224,"indexDatabases":225,"url":226,"thumbnailPath":26,"statistic":227,"gsStatistic":276,"type":175,"analyzePriority":26},"a3d1e82a-57e2-40f9-940e-f5fa8b9ef64a","2023-06-01T07:11:26.039+00:00","2026-06-18T23:33:28.573+00:00",[],"VNU-Journal-of-Science-Earth-and-Environmental-Sciences",{"issn":214,"title":216,"country":218,"gsId":219},{"VOID":215},"26159279",{"EN":217},"VNU Journal of Science: Earth and Environmental Sciences",{"VOID":15},{"VOID":220},"UmXD8vEAAAAJ","2023-06-01T07:17:59.210+00:00",27,[],[],[],"https:\u002F\u002Fjs.vnu.edu.vn\u002FEES",{"impactFactor":36,"impactFactorByYear":228,"i10Index":234,"i10IndexLast5Year":36,"totalPublication":235,"totalPublicationByYear":236,"totalCitation":246,"totalCitationByYear":247,"totalCitationPerPublication":261,"totalCitationPerPublicationByYear":262,"hindexLast5Year":103,"hindex":103},{"2010":229,"2012":40,"2013":230,"2014":230,"2015":231,"2016":54,"2017":171,"2018":109,"2019":110,"2020":57,"2021":232,"2022":233,"2023":151,"2024":58},0.02,0.04,0.09,0.31,0.4,19,656,{"2008":237,"2009":238,"2010":239,"2011":238,"2012":240,"2013":241,"2014":239,"2015":242,"2016":243,"2017":244,"2018":245,"2019":165,"2020":125,"2021":168,"2022":125,"2023":222,"2024":111},23,24,22,28,25,20,146,29,78,1038,{"2008":248,"2009":249,"2010":250,"2011":251,"2012":252,"2013":253,"2014":254,"2015":255,"2016":256,"2017":257,"2018":161,"2019":258,"2020":259,"2021":29,"2022":260},119,64,66,86,38,73,59,31,129,39,97,53,26,1.58,{"2008":263,"2009":264,"2010":59,"2011":265,"2012":266,"2013":267,"2014":268,"2015":269,"2016":270,"2017":271,"2018":272,"2019":272,"2020":273,"2021":274,"2022":275},5.17,2.67,3.58,1.36,2.92,2.68,1.55,0.88,1.34,1.37,1.47,1.24,0.72,{"impactFactor":26,"impactFactorByYear":26,"i10Index":173,"i10IndexLast5Year":135,"totalPublication":277,"totalPublicationByYear":278,"totalCitation":279,"totalCitationByYear":280,"totalCitationPerPublication":288,"totalCitationPerPublicationByYear":289,"hindexLast5Year":158,"hindex":298},113,{"2007":114,"2008":103,"2009":173,"2010":116,"2011":51,"2012":239,"2013":103,"2014":162,"2015":53,"2016":135},616,{"2009":162,"2010":114,"2011":52,"2012":124,"2013":222,"2014":255,"2015":48,"2016":44,"2017":281,"2018":282,"2019":259,"2020":283,"2021":284,"2022":285,"2023":286,"2024":257,"2025":287,"2026":59},54,60,49,47,34,44,33,5.45,{"2009":290,"2010":291,"2011":292,"2012":293,"2013":294,"2014":295,"2015":296,"2016":297},0.28,0.2,0.6,0.77,2.25,6.2,3.91,9.67,14,{"id":300,"createTime":301,"updateTime":302,"relativeEntities":303,"slug":304,"properties":305,"entityType":24,"verifyStatus":25,"verifyTime":316,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":234,"subjectFields":317,"manageAffiliations":318,"indexDatabases":388,"url":389,"thumbnailPath":390,"statistic":391,"gsStatistic":409,"type":175,"analyzePriority":26},"a7166325-6c9e-4db3-8a59-7c879701a372","2023-07-31T04:28:49.231+00:00","2026-06-18T23:33:22.428+00:00",[],"VNU-Journal-of-Science-Policy-and-Management-Studies",{"country":306,"issn":307,"eissn":309,"title":311,"gsId":314},{"VOID":15},{"VOID":308},"26159295",{"VOID":310},"25881116",{"EN":312,"VI":313},"VNU Journal of Science: Policy and Management Studies","Tạp chí Nghiên cứu Chính sách và Quản lý",{"VOID":315},"xKW2E_cAAAAJ","2023-08-01T03:23:46.688+00:00",[],[319],{"id":320,"createTime":321,"updateTime":322,"relativeEntities":323,"slug":324,"properties":325,"entityType":98,"verifyStatus":25,"verifyTime":335,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":336,"url":337,"parentIds":338,"statistic":339},"12466116-8f60-4b01-8faf-2411483a0977","2023-05-30T09:37:38.472+00:00","2026-06-19T02:14:28.352+00:00",[],"Vietnam-National-University",{"country":326,"title":327,"abbreviation":330,"address":332},{"VOID":15},{"EN":328,"VI":329},"Vietnam National University, Hanoi","Đại học Quốc gia Hà Nội",{"VOID":331},"VNU",{"VI":333,"EN":334},"Số 144 Xuân Thủy, Phường Dịch Vọng Hậu, Quận Cầu Giấy, Hà Nội, Việt Nam","No. 144 Xuan Thuy Street, Dich Vong Hau Ward, Cau Giay District, Hanoi, Vietnam","2023-08-02T13:58:17.029+00:00",16,"http:\u002F\u002Fwww.vnu.edu.vn\u002F",[],{"impactFactor":36,"impactFactorByYear":340,"i10Index":285,"i10IndexLast5Year":162,"totalPublication":344,"totalPublicationByYear":345,"totalCitation":354,"totalCitationByYear":355,"totalCitationPerPublication":368,"totalCitationPerPublicationByYear":369,"hindexLast5Year":336,"hindex":336},{"2014":109,"2015":231,"2016":231,"2017":206,"2018":341,"2019":110,"2020":342,"2021":343,"2022":171,"2023":231,"2024":110,"2025":39},0.06,0.18,0.35,1247,{"2003":115,"2004":115,"2005":114,"2006":59,"2007":111,"2008":162,"2009":59,"2010":50,"2011":124,"2012":336,"2013":260,"2014":244,"2015":250,"2016":281,"2017":346,"2018":347,"2019":348,"2020":349,"2021":350,"2022":351,"2023":352,"2024":353,"2025":255,"2026":50},94,88,83,67,176,185,187,93,1644,{"2004":111,"2005":115,"2006":52,"2007":298,"2008":356,"2009":298,"2010":286,"2011":357,"2012":244,"2013":358,"2014":359,"2015":360,"2016":361,"2017":362,"2018":363,"2019":364,"2020":365,"2021":366,"2022":367,"2023":367,"2024":162},13,81,48,70,151,115,109,259,174,181,121,101,1.32,{"2004":111,"2005":370,"2006":59,"2007":371,"2008":372,"2009":373,"2010":374,"2011":375,"2012":376,"2013":377,"2014":378,"2015":379,"2016":380,"2017":381,"2018":382,"2019":383,"2020":384,"2021":385,"2022":386,"2023":387,"2024":109},0.5,3.5,2.6,4.67,5.5,4.76,1.81,1.85,2.41,2.29,2.13,1.16,2.94,2.1,2.7,0.69,0.55,0.54,[],"https:\u002F\u002Fjs.vnu.edu.vn\u002FPaM","\u002Fapi\u002Fpublic\u002Ffile\u002Fpublisher\u002Fa7166325-6c9e-4db3-8a59-7c879701a372\u002Fecfe83f4bcc60c7023ae04d8900fe0ac.jpg",{"impactFactor":36,"impactFactorByYear":392,"i10Index":111,"i10IndexLast5Year":36,"totalPublication":394,"totalPublicationByYear":395,"totalCitation":399,"totalCitationByYear":400,"totalCitationPerPublication":293,"totalCitationPerPublicationByYear":403,"hindexLast5Year":158,"hindex":158},{"2018":109,"2019":171,"2020":393,"2021":108,"2022":54,"2023":206,"2024":54},0.23,320,{"2015":50,"2016":239,"2017":286,"2018":396,"2019":397,"2020":159,"2021":398,"2022":168,"2023":79,"2024":255},30,35,40,247,{"2015":115,"2016":242,"2017":401,"2018":222,"2019":402,"2020":79,"2021":239,"2022":50,"2023":116},77,50,{"2015":404,"2016":169,"2017":405,"2018":406,"2019":407,"2020":408,"2021":386,"2022":291,"2023":232},0.12,1.75,0.9,1.43,0.86,{"impactFactor":26,"impactFactorByYear":26,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":103,"totalPublicationByYear":410,"totalCitation":234,"totalCitationByYear":411,"totalCitationPerPublication":261,"totalCitationPerPublicationByYear":412,"hindexLast5Year":114,"hindex":59},{"2015":114,"2016":116},{"2016":115,"2017":114,"2018":114,"2019":59,"2020":114,"2021":59,"2022":114,"2023":114,"2024":115,"2026":115},{"2016":108},{"id":414,"createTime":415,"updateTime":416,"relativeEntities":417,"slug":418,"properties":419,"entityType":24,"verifyStatus":25,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":238,"subjectFields":428,"manageAffiliations":429,"indexDatabases":430,"url":431,"thumbnailPath":26,"statistic":432,"gsStatistic":438,"type":175,"analyzePriority":26},"16e65a3f-d274-47dd-8691-56d76eb58c3d","2023-05-30T09:10:06.062+00:00","2026-06-18T23:33:17.679+00:00",[],"Vietnam-Journal-of-Otorhinolaryngology-Head-and-Neck-Surgery",{"country":420,"issn":421,"title":423,"gsId":426},{"VOID":15},{"VOID":422},"18593704",{"EN":424,"VI":425},"Vietnam Journal of Otorhinolaryngology - Head and Neck Surgery","Tạp chí Tai Mũi Họng Việt Nam",{"VOID":427},"L78B_eIAAAAJ",[],[],[],"https:\u002F\u002Ftapchitaimuihong.vn\u002Findex.php\u002Ftmh",{"impactFactor":36,"impactFactorByYear":433,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":434,"totalPublicationByYear":435,"totalCitation":111,"totalCitationByYear":436,"totalCitationPerPublication":230,"totalCitationPerPublicationByYear":437,"hindexLast5Year":115,"hindex":115},{"2024":229},95,{"2022":52,"2023":286,"2024":255,"2025":53},{"2023":111},{"2023":231},{"impactFactor":26,"impactFactorByYear":26,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":240,"totalPublicationByYear":439,"totalCitation":234,"totalCitationByYear":440,"totalCitationPerPublication":441,"totalCitationPerPublicationByYear":442,"hindexLast5Year":114,"hindex":114},{"2023":53,"2024":116,"2025":135,"2026":115},{"2024":59,"2025":298,"2026":114},0.68,{"2024":443,"2025":444,"2026":114},0.3,2.33,{"id":446,"createTime":447,"updateTime":448,"relativeEntities":449,"slug":450,"properties":451,"entityType":24,"verifyStatus":25,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":396,"subjectFields":460,"manageAffiliations":461,"indexDatabases":462,"url":463,"thumbnailPath":464,"statistic":465,"gsStatistic":472,"type":175,"analyzePriority":26},"25988add-c322-4eda-afda-63b1559bb824","2023-04-07T03:49:55.817+00:00","2026-06-18T23:32:23.776+00:00",[],"T%E1%BA%A1p%20ch%C3%AD%20Y%20-%20D%C6%B0%E1%BB%A3c%20h%E1%BB%8Dc%20qu%C3%A2n%20s%E1%BB%B1",{"country":452,"issn":453,"title":455,"gsId":458},{"VOID":15},{"VOID":454},"18590748",{"EN":456,"VI":457},"Journal of Military Pharmaco-medicine","Tạp chí Y - Dược học quân sự",{"VOID":459},"_pmQ8IEAAAAJ",[],[],[],"https:\u002F\u002Fjmpm.vn\u002Findex.php\u002Fjmpm","\u002Fapi\u002Fpublic\u002Ffile\u002Fpublisher\u002F25988add-c322-4eda-afda-63b1559bb824\u002F09c6bc42157cf5ece95edc971ccddb52.jpg",{"impactFactor":36,"impactFactorByYear":466,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":467,"totalPublicationByYear":468,"totalCitation":135,"totalCitationByYear":470,"totalCitationPerPublication":38,"totalCitationPerPublicationByYear":471,"hindexLast5Year":115,"hindex":115},{"2023":229,"2024":38},475,{"2022":168,"2023":365,"2024":469,"2025":124},236,{"2022":114,"2023":111},{"2022":109,"2023":229},{"impactFactor":26,"impactFactorByYear":26,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":277,"totalPublicationByYear":473,"totalCitation":401,"totalCitationByYear":474,"totalCitationPerPublication":441,"totalCitationPerPublicationByYear":475,"hindexLast5Year":59,"hindex":59},{"2015":115,"2018":114,"2019":115,"2020":115,"2021":59,"2022":103,"2023":159,"2024":287,"2025":237},{"2020":115,"2021":115,"2022":115,"2023":52,"2024":237,"2025":79,"2026":116},{"2020":115,"2021":476,"2022":171,"2023":477,"2024":478,"2025":479},0.33,0.24,0.7,1.39,{"id":481,"createTime":482,"updateTime":483,"relativeEntities":484,"slug":485,"properties":486,"entityType":24,"verifyStatus":25,"verifyTime":26,"verifyNote":27,"syncStatus":28,"languages":496,"translateLanguages":26,"viewCount":45,"subjectFields":497,"manageAffiliations":498,"indexDatabases":525,"url":526,"thumbnailPath":527,"statistic":528,"gsStatistic":26,"type":26,"analyzePriority":26},"2b8d7b12-2d20-4777-be98-077f44f03c69","2023-09-07T07:40:58.286+00:00","2025-07-13T21:21:00.542+00:00",[],"VNU-Journal-of-Social-Sciences-and-Humanities",{"country":487,"issn":488,"introduce":490,"title":493},{"VOID":15},{"VOID":489},"23541172",{"EN":491,"VI":492},"{\"ops\":[{\"insert\":\"VNU Journal of Social Sciences and Humanities (ISSN 2354-1172) is a double-blind peer-reviewed journal published by University of Social Sciences and Humanities, Vietnam National University, Hanoi, Vietnam, under the publication permit no. 155\u002FGP-BTTTT, issued on 11\"},{\"attributes\":{\"script\":\"super\"},\"insert\":\"th \"},{\"insert\":\"May, 2015 by Ministry of Information and Communications. The journal publishes four Vietnamese issues and two English issues per year.\\nCurrently, there are 35 reputable professors in the editorial board. The main objectives of the journal include: providing an intellectual platform for Vietnamese and international scholars; promoting interdisciplinary studies in social sciences and humanities; becoming the leading journal in social sciences and humanities in Vietnam; being indexed by worldwide databases and having academic recognition internationally in the near future.\\nThe journal is currently indexed by Google Scholar, WorldCat, Open Archives, Cosmos Impact Factor, Advanced Sciences Index, Scientific Indexing Services, CrossRef, EBSCO Information Services and Vietnam National University’s digital archive.\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Journal of Social Sciences and Humanities-Vietnam\"},{\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"ISSN 2354-1172, email: tapchikhxhnv@gmail.com, tckhxhnv@vnu.edu.vn\"},{\"insert\":\"\\n\"}]}","{\"ops\":[{\"insert\":\"Được thành lập ngày 31\u002F8\u002F2015 (giấy phép hoạt động số 155\u002FGP-BVHTT ngày 11 tháng 5 năm 2015 của Bộ Thông tin và Truyền thông, mã số tiêu chuẩn quốc tế ISSN 2354-1172), Tạp chí Khoa học Xã hội và Nhân văn (Journal of Social Sciences and Humanities) là ấn phẩm khoa học chính thức, duy nhất của Trường Đại học Khoa học Xã hội và Nhân văn, ĐHQG Hà Nội, phát triển và kế thừa Chuyên san Khoa học Xã hội và Nhân văn, Tạp chí Khoa học, ĐHQG Hà Nội.\\nTạp chí xuất bản định kỳ (04 số tiếng Việt\u002Fnăm và 02 số tiếng Anh\u002Fnăm), có nhiệm vụ \"},{\"attributes\":{\"italic\":true},\"insert\":\"công bố, giới thiệu các công trình nghiên cứu khoa học khoa học xã hội và nhân văn của các tác giả là các nhà khoa học trong và ngoài nước, phục vụ giảng dạy, học tập và nghiên cứu khoa học\"},{\"insert\":\". Hội đồng biên tập của Tạp chí hiện bao gồm 33 nhà khoa học có uy tín trong nước và quốc tế. Tạp chí tập trung và ưu tiên đăng tải những bài báo theo định hướng của tinh thần cởi mở, sáng tạo, nhanh chóng vươn lên để tiếp cận và sánh ngang với các tạp chí có uy tín hàng đầu của khu vực và trên thế giới. Nội dung chính của Tạp chí bao gồm các Bài nghiên cứu (khoảng 6000 đến 15000 từ), các bài điểm sách, thông tin khoa học (khoảng 300 đến 1500 từ) được trình bày theo đúng cấu trúc và chuẩn mực của một tạp chí khoa học.\\nCác bài viết của Tạp chí hiện đang được trích dẫn bởi Google Scholar, WorldCat, Open Archives, Cosmos Impact Factor, Advanced Sciences Index, Scientific Indexing Services, CrossRef, EBSCO Information Services.\\nMọi thông tin xin liên hệ: \"},{\"attributes\":{\"italic\":true},\"insert\":\"Phòng Tạp chí, 701 - E, Trường Đại học Khoa học Xã hội và Nhân văn, 336 Nguyễn Trãi, Thanh Xuân, Hà Nội. ĐT: 024.35581984; email: tckhxhnv@vnu.edu.vn \"},{\"insert\":\"hoặc \"},{\"attributes\":{\"italic\":true},\"insert\":\"tapchikhxhnv@gmail.com \"},{\"insert\":\"\\n\"}]}",{"EN":494,"VI":495},"VNU Journal of Social Sciences and Humanities","Tạp chí Khoa học Xã hội và Nhân văn",[101,102],[],[499],{"id":500,"createTime":501,"updateTime":502,"relativeEntities":503,"slug":504,"properties":505,"entityType":98,"verifyStatus":25,"verifyTime":509,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":222,"url":26,"parentIds":510,"statistic":511},"8b6e349b-0daf-4895-9c3f-85f30f1bfd42","2023-07-31T12:55:58.430+00:00","2026-06-19T02:30:07.899+00:00",[],"Tr%C6%B0%E1%BB%9Dng-%C4%90%E1%BA%A1i-h%E1%BB%8Dc-Khoa-h%E1%BB%8Dc-X%C3%A3-h%E1%BB%99i-v%C3%A0-Nh%C3%A2n-v%C4%83n-%C4%90%E1%BA%A1i-h%E1%BB%8Dc-Qu%E1%BB%91c-gia-H%C3%A0-N%E1%BB%99i",{"title":506},{"EN":507,"VI":508},"VNU University of Social Sciences and Humanities","Trường Đại học Khoa học Xã hội và Nhân văn, Đại học Quốc gia Hà Nội","2023-08-02T15:28:49.057+00:00",[],{"impactFactor":36,"impactFactorByYear":512,"i10Index":59,"i10IndexLast5Year":115,"totalPublication":514,"totalPublicationByYear":515,"totalCitation":518,"totalCitationByYear":519,"totalCitationPerPublication":520,"totalCitationPerPublicationByYear":521,"hindexLast5Year":162,"hindex":162},{"2016":229,"2017":230,"2018":229,"2021":230,"2022":58,"2023":513,"2024":38},0.15,365,{"2013":115,"2014":158,"2015":125,"2016":252,"2017":44,"2018":516,"2019":286,"2020":396,"2021":259,"2022":517,"2023":396,"2024":115,"2025":59,"2026":115},21,42,169,{"2015":283,"2016":135,"2017":52,"2018":50,"2019":298,"2020":53,"2021":359,"2022":115,"2023":115},0.46,{"2015":266,"2016":57,"2017":57,"2018":522,"2019":523,"2020":524,"2021":368,"2022":229,"2023":39},0.38,0.32,0.37,[],"http:\u002F\u002Fjournal.ussh.vnu.edu.vn\u002Findex.php\u002Fvjossh","\u002Fapi\u002Fpublic\u002Ffile\u002Fpublisher\u002F2b8d7b12-2d20-4777-be98-077f44f03c69\u002F0bd0751202944a4b4165b482e6e623e4.png",{"impactFactor":36,"impactFactorByYear":529,"i10Index":162,"i10IndexLast5Year":115,"totalPublication":530,"totalPublicationByYear":531,"totalCitation":537,"totalCitationByYear":538,"totalCitationPerPublication":343,"totalCitationPerPublicationByYear":540,"hindexLast5Year":135,"hindex":135},{"2016":341,"2017":39,"2018":229,"2019":38,"2020":110,"2021":231,"2022":231,"2023":341,"2024":39},764,{"2015":255,"2016":245,"2017":532,"2018":259,"2019":533,"2020":534,"2021":535,"2022":536,"2023":534,"2024":254,"2025":50},111,106,68,92,89,265,{"2015":539,"2016":241,"2017":168,"2018":51,"2019":349,"2020":260,"2021":244,"2022":298,"2023":114},46,{"2015":541,"2016":523,"2017":524,"2018":290,"2019":542,"2020":522,"2021":523,"2022":57,"2023":39},1.48,0.63,{"id":544,"createTime":545,"updateTime":546,"relativeEntities":547,"slug":548,"properties":549,"entityType":24,"verifyStatus":25,"verifyTime":26,"verifyNote":558,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":50,"subjectFields":559,"manageAffiliations":560,"indexDatabases":561,"url":562,"thumbnailPath":563,"statistic":564,"gsStatistic":26,"type":26,"analyzePriority":26},"6ec01bd0-15c0-469a-86ac-41339076ae0a","2023-08-10T07:08:33.153+00:00","2026-01-31T21:19:06.362+00:00",[],"T%E1%BA%A1p-ch%C3%AD-Da-li%E1%BB%85u-h%E1%BB%8Dc-Vi%E1%BB%87t-Nam",{"country":550,"issn":551,"introduce":553,"title":555},{"VOID":15},{"VOID":552},"18594824",{"VI":554},"{\"ops\":[{\"insert\":\"Tạp chí “Da liễu học Việt Nam” (Tiếng Anh: Vietnamese Journal of Dermatology and Venereology) thuộc Hội Da liễu Việt Nam, xuất bản 4 số mỗi năm bằng tiếng Việt hoặc tiếng Anh.\\nTạp chí Da liễu học Việt Nam hoạt động với mục đích, tôn chỉ là phổ biến, trao đổi thông tin trong lĩnh vực chuyên ngành da liễu; đăng tải các công trình nghiên cứu khoa học; chuyển giao công nghệ - kinh tế và khoa học kỹ thuật liên quan đến lĩnh vực da liễu.\\nPhạm vi của tạp chí là tất cả các bài báo khoa học, bài tổng quan, giới thiệu ca lâm sàng, … có liên quan tới chuyên ngành da liễu trong và ngoài nước. Tạp chí công bố các công trình nghiên cứu liên quan đến mô hình bệnh tật, các phương pháp chẩn đoán, điều trị, dự phòng và phục hồi chức năng các bệnh thuộc chuyên ngành da liễu. Ngoài ra, tạp chí còn đăng tải các bài tổng quan, cập nhật thông tin, kiến thức, hướng dẫn chẩn đoán, điều trị trong chuyên ngành da liễu trong nước và quốc tế; đăng tải các bài ca lâm sàng đặc biệt trong chuyên ngành da liễu.\\nTạp chí Da liễu học Việt Nam được biết tới là một tạp chí chuyên ngành có uy tín trong lĩnh vực da liễu. Các bài báo về nghiên cứu khoa học đăng trong Tạp chí được bình duyệt một cách nghiêm ngặt bởi ít nhất 2 chuyên gia. Hội đồng biên tập tạp chí bao gồm các nhà khoa học có uy tín (Giáo sư, Phó Giáo sư, Tiến sĩ, Bác sĩ…) trong chuyên ngành da liễu nhằm đảm bảo chất lượng và tính khách quan, khoa học cho các bài viết đăng trên Tạp chí.\\n\"}]}",{"EN":556,"VI":557},"Vietnamese Journal of Dermatology and Venereology","Tạp chí Da liễu học Việt Nam","Admin Import",[],[],[],"https:\u002F\u002Fvjdv.vn\u002Findex.php\u002Fvjdv","\u002Fapi\u002Fpublic\u002Ffile\u002Fpublisher\u002F6ec01bd0-15c0-469a-86ac-41339076ae0a\u002F3cbc81720e58429dc7b1c4d7ab1935ca.jpg",{"impactFactor":36,"impactFactorByYear":565,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":566,"totalPublicationByYear":567,"totalCitation":116,"totalCitationByYear":570,"totalCitationPerPublication":109,"totalCitationPerPublicationByYear":571,"hindexLast5Year":115,"hindex":115},{"2023":38,"2024":230},182,{"2022":568,"2023":45,"2024":569},69,56,{"2022":52,"2023":115},{"2022":40,"2023":229},{"id":573,"createTime":574,"updateTime":575,"relativeEntities":576,"slug":577,"properties":578,"entityType":24,"verifyStatus":25,"verifyTime":26,"verifyNote":27,"syncStatus":28,"languages":587,"translateLanguages":26,"viewCount":283,"subjectFields":588,"manageAffiliations":589,"indexDatabases":647,"url":648,"thumbnailPath":649,"statistic":650,"gsStatistic":26,"type":26,"analyzePriority":26},"19221551-7519-47ff-a892-331d1139c64b","2023-09-12T07:03:05.744+00:00","2026-01-24T20:54:40.144+00:00",[],"T%E1%BA%A1p-ch%C3%AD-Khoa-h%E1%BB%8Dc-S%E1%BB%A9c-kho%E1%BA%BB-%C4%90%E1%BA%A1i-h%E1%BB%8Dc-Qu%E1%BB%91c-gia-Th%C3%A0nh-ph%E1%BB%91-H%E1%BB%93-Ch%C3%AD-Minh",{"country":579,"issn":580,"introduce":582,"title":584},{"VOID":15},{"VOID":581},"27349446",{"EN":583},"{\"ops\":[{\"attributes\":{\"bold\":true},\"insert\":\"1. History\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Science and Technology Development Journal\"},{\"insert\":\" (STDJ) (ISSN 2734-9446), Vietnam National University - Ho Chi Minh City (VNU-HCM) was established in 1997. And the first issue was published in January 1998 with ISSN 1859-0128. Since then, STDJ has become the most important scientific forum of scientists from VNU-HCM as well as other universities. The magazine has undergone 20 years of development and has become a bridge for scientific exchanges, as well as enriching reference materials for the faculty, doctoral students, students of VNU-HCM in particular and other universities, institutes...\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Science and Technology Development Journal - Health Sciences (STDJ-HS) is a subjournal of Science and Technology Development Journal since 2020.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\" \"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"2. Focus and Scope\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Publishing articles with contents on healthcare, research projects in the field of health, advanced directions in health education and management. Therefore, STDJ-HS will accept articles from doctors, administrators, teachers, researchers, graduate students and fellows. The authors will be responsible for the accuracy of the data, opinions, opinions and material cited in the article.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Facilitating the exchange of scientific and technological information and act as a bridge between theory and practice in the community of educators, scientists, managers, policy makers and enterprises in and out of the country.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"\\n\"}]}",{"EN":585,"VI":586},"VNUHCM JOURNAL OF HEALTH SCIENCES","Tạp chí Khoa học Sức khoẻ Đại học Quốc gia Thành phố Hồ Chí Minh",[101,102],[],[590],{"id":591,"createTime":592,"updateTime":593,"relativeEntities":594,"slug":595,"properties":596,"entityType":98,"verifyStatus":25,"verifyTime":606,"verifyNote":26,"syncStatus":28,"languages":607,"translateLanguages":26,"viewCount":608,"url":609,"parentIds":610,"statistic":611},"fc4c2560-868c-4677-acb1-8686bef88727","2023-06-26T04:48:23.774+00:00","2026-06-19T01:46:17.248+00:00",[],"%C4%90%E1%BA%A1i-h%E1%BB%8Dc-Qu%E1%BB%91c-gia-Th%C3%A0nh-ph%E1%BB%91-H%E1%BB%93-Ch%C3%AD-Minh",{"country":597,"title":598,"abbreviation":601,"address":603},{"VOID":15},{"EN":599,"VI":600},"Vietnam National University Ho Chi Minh City","Đại học Quốc gia Thành phố Hồ Chí Minh",{"VOID":602},"VNUHCM",{"VI":604,"EN":605},"khu phố 6, Phường Linh Trung, Thành phố Thủ Đức, Thành phố Hồ Chí Minh, Việt Nam","Quarter 6, Linh Trung Ward, Thu Duc City, Ho Chi Minh City, Vietnam","2023-08-16T14:13:07.134+00:00",[101,102],45,"https:\u002F\u002Fvnuhcm.edu.vn\u002F",[],{"impactFactor":36,"impactFactorByYear":612,"i10Index":285,"i10IndexLast5Year":51,"totalPublication":613,"totalPublicationByYear":614,"totalCitation":624,"totalCitationByYear":625,"totalCitationPerPublication":634,"totalCitationPerPublicationByYear":635,"hindexLast5Year":124,"hindex":124},{"2014":36,"2015":38,"2016":109,"2017":39,"2018":229,"2019":38,"2020":110,"2021":171,"2022":110,"2023":110,"2024":171,"2025":229},3708,{"2005":115,"2006":115,"2007":115,"2008":135,"2009":111,"2010":53,"2011":52,"2012":568,"2013":615,"2014":351,"2015":616,"2016":469,"2017":617,"2018":127,"2019":618,"2020":619,"2021":620,"2022":621,"2023":622,"2024":623,"2025":159,"2026":50},164,266,177,226,603,931,314,246,74,2399,{"2006":115,"2008":50,"2010":162,"2011":242,"2012":222,"2013":43,"2014":626,"2015":627,"2016":628,"2017":629,"2018":258,"2019":630,"2020":631,"2021":632,"2022":633,"2023":353,"2024":115},250,124,157,162,152,385,559,128,0.65,{"2006":115,"2008":636,"2010":637,"2011":638,"2012":639,"2013":522,"2014":640,"2015":641,"2016":642,"2017":643,"2018":644,"2019":642,"2020":645,"2021":292,"2022":646,"2023":522,"2024":38},1.33,0.45,2.22,0.39,1.35,0.47,0.67,0.92,0.73,0.64,0.41,[],"http:\u002F\u002Fstdjhs.scienceandtechnology.com.vn\u002Findex.php\u002Fstdjhs","\u002Fapi\u002Fpublic\u002Ffile\u002Fpublisher\u002F19221551-7519-47ff-a892-331d1139c64b\u002F2e10768b7d1e380c36a25ed0c714dd7e.png",{"impactFactor":36,"impactFactorByYear":651,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":652,"totalPublicationByYear":653,"totalCitation":516,"totalCitationByYear":654,"totalCitationPerPublication":151,"totalCitationPerPublicationByYear":655,"hindexLast5Year":59,"hindex":59},{"2022":57,"2023":108,"2024":39},79,{"2020":116,"2021":240,"2022":239,"2023":52,"2024":162,"2025":162},{"2020":59,"2021":51,"2022":59},{"2020":443,"2021":387,"2022":54},{"code":657,"data":658,"meta":26},"SUCCESS",{"id":659,"createTime":660,"updateTime":661,"relativeEntities":662,"slug":663,"properties":664,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":671,"manageAffiliations":672,"indexDatabases":673,"url":691,"thumbnailPath":26,"statistic":692,"gsStatistic":26,"type":175,"analyzePriority":26},"41150c9f-7cee-4971-84ac-6cec7a607266","2024-04-11T07:48:45.886+00:00","2025-11-21T09:58:05.862+00:00",[],"Current-Hepatitis-Reports",{"issn":665,"eissn":667,"title":669},{"VOID":666},"1541-0706",{"VOID":668},"1540-3416",{"EN":670},"Current Hepatitis Reports",[],[],[674],{"id":675,"indexDatabase":676,"url":688,"indexYears":689,"academicFieldIds":26,"indexDatabaseRanking":690},"1295d917-2b11-4213-8fe7-3aecb4ccad8d",{"id":677,"createTime":678,"updateTime":679,"relativeEntities":680,"label":681,"description":683,"key":685,"publicationTags":686,"standard":26},"3c7051d4-eb7d-4c57-a56b-36fc74c5d1e9","2023-05-22T09:57:18.509+00:00","2025-11-21T10:07:52.274+00:00",[],{"EN":682,"VI":682},"Scopus - Elsevier",{"EN":682,"VI":684},"Cơ sở dữ liệu Scopus thuộc Elsevier","scopus",[687],"SCOPUS","https:\u002F\u002Fwww.scopus.com\u002Fsourceid\u002F5000156905","2006-2015","SCOPUS__Q3","https:\u002F\u002Flink.springer.com\u002Fjournal\u002F11901",{"impactFactor":36,"impactFactorByYear":693,"i10Index":59,"i10IndexLast5Year":36,"totalPublication":694,"totalPublicationByYear":695,"totalCitation":536,"totalCitationByYear":696,"totalCitationPerPublication":132,"totalCitationPerPublicationByYear":697,"hindexLast5Year":162,"hindex":162},{"2012":231,"2013":229,"2014":39},209,{"2002":111,"2003":336,"2004":173,"2005":234,"2006":234,"2007":162,"2008":234,"2009":237,"2010":241,"2011":516,"2012":241,"2013":51},{"2003":114,"2004":114,"2005":59,"2006":53,"2007":50,"2008":234,"2009":115,"2010":285,"2011":114,"2012":135,"2013":115},{"2003":404,"2004":206,"2005":57,"2006":698,"2007":699,"2008":115,"2009":230,"2010":266,"2011":108,"2012":477,"2013":110},0.58,1.6,{"meta":701,"data":703},{"total":702},"209",[704,1001,1295,1346,1661,1856,2097,2364,2662,2881],{"id":705,"createTime":706,"updateTime":707,"relativeEntities":708,"slug":709,"properties":710,"entityType":725,"verifyStatus":25,"verifyTime":707,"verifyNote":726,"syncStatus":28,"languages":727,"translateLanguages":26,"viewCount":36,"primaryUrl":728,"fullTextUrl":26,"authors":729,"publicationType":768,"publisherRelationship":769,"citationCount":79,"citationInfo":797,"publishDate":799,"publishYear":800,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":801,"isForceReanalyzing":1000},"4f435f54-cad0-4b89-9b1f-4d26d90bb578","2024-04-18T05:38:25.269+00:00","2025-01-14T09:03:59.412+00:00",[],"A-Systematic-Review-of-Side-Effects-of-Nucleoside-and-Nucleotide-Drugs-Used-for-Treatment-of-Chronic-Hepatitis-B",{"mag":711,"keywords":713,"pmc":714,"openalex":716,"abstract":718,"title":719,"pm":721,"doi":723},{"VOID":712},"2018706343",{},{"VOID":715},"2861763",{"VOID":717},"W2018706343",{},{"EN":720},"A Systematic Review of Side Effects of Nucleoside and Nucleotide Drugs Used for Treatment of Chronic Hepatitis B",{"VOID":722},"20461127",{"VOID":724},"10.1007\u002Fs11901-010-0039-1","PUBLICATION","Auto Verify",[102],"http:\u002F\u002Flink.springer.com\u002F10.1007\u002Fs11901-010-0039-1",[730,751],{"id":731,"sortIndex":36,"researcher":26,"roles":732,"affiliations":733,"properties":744},"1a239dc5-918a-4266-b3b3-68dfad15ba0b",[],[734],{"id":735,"sortIndex":36,"affiliation":736,"properties":26},"22784beb-4f32-4481-a3e5-00d38258caab",{"id":737,"createTime":738,"updateTime":738,"relativeEntities":739,"slug":740,"properties":741,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"595c5c88-2cd9-4aad-904d-6317d2a6987a","2024-04-18T05:38:25.309+00:00",[],"Division-of-Digestive-Diseases-David-Geffen-School-of-Medicine-at-University-of-California-Los-Angeles-Los-Angeles-CA-USA",{"title":742},{"EN":743},"Division of Digestive Diseases, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, USA",{"openalex":745,"orcid":747,"title":749},{"VOID":746},"A5091511609",{"VOID":748},"https:\u002F\u002Forcid.org\u002F0000-0001-8720-533X",{"EN":750},"Vandana Khungar",{"id":752,"sortIndex":115,"researcher":26,"roles":753,"affiliations":754,"properties":761},"6d0e1707-8392-4ead-945f-588ab714b2be",[],[755],{"id":756,"sortIndex":36,"affiliation":757,"properties":26},"c9692609-0269-4cb6-8a60-2639d766b7a6",{"id":737,"createTime":738,"updateTime":738,"relativeEntities":758,"slug":740,"properties":759,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":760},{"EN":743},{"openalex":762,"orcid":764,"title":766},{"VOID":763},"A5070731084",{"VOID":765},"https:\u002F\u002Forcid.org\u002F0000-0003-1459-8763",{"EN":767},"Steven‐Huy Han","ARTICLE",{"url":26,"publisher":770,"properties":790},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":771,"slug":663,"properties":772,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":776,"manageAffiliations":777,"indexDatabases":778,"url":691,"thumbnailPath":26,"statistic":785,"gsStatistic":26,"type":175,"analyzePriority":26},[],{"issn":773,"eissn":774,"title":775},{"VOID":666},{"VOID":668},{"EN":670},[],[],[779],{"id":675,"indexDatabase":780,"url":688,"indexYears":689,"academicFieldIds":26,"indexDatabaseRanking":690},{"id":677,"createTime":678,"updateTime":679,"relativeEntities":781,"label":782,"description":783,"key":685,"publicationTags":784,"standard":26},[],{"EN":682,"VI":682},{"EN":682,"VI":684},[687],{"impactFactor":36,"impactFactorByYear":786,"i10Index":59,"i10IndexLast5Year":36,"totalPublication":694,"totalPublicationByYear":787,"totalCitation":536,"totalCitationByYear":788,"totalCitationPerPublication":132,"totalCitationPerPublicationByYear":789,"hindexLast5Year":162,"hindex":162},{"2012":231,"2013":229,"2014":39},{"2002":111,"2003":336,"2004":173,"2005":234,"2006":234,"2007":162,"2008":234,"2009":237,"2010":241,"2011":516,"2012":241,"2013":51},{"2003":114,"2004":114,"2005":59,"2006":53,"2007":50,"2008":234,"2009":115,"2010":285,"2011":114,"2012":135,"2013":115},{"2003":404,"2004":206,"2005":57,"2006":698,"2007":699,"2008":115,"2009":230,"2010":266,"2011":108,"2012":477,"2013":110},{"volume":791,"pages":793,"issue":795},{"VOID":792},"9",{"VOID":794},"75-90",{"VOID":796},"2",{"total":79,"publishYear":26,"statisticByYear":798},{"2012":114,"2013":59,"2014":114,"2015":162,"2016":59,"2017":59,"2018":114,"2019":114,"2020":59,"2021":59,"2022":115,"2023":115},"2010-05-01",2010,[802,805,808,812,816,820,824,828,831,834,837,840,843,847,851,855,859,863,867,871,875,879,883,886,890,894,898,902,906,910,914,917,921,925,929,933,937,941,945,949,953,957,961,965,969,973,976,980,984,988,992,996],{"id":26,"text":803,"url":26,"identifiers":804},"Kao JH, Chen DS: The natural history of hepatitis B virus infection. In Hepatitis B Virus. Edited by Lai CL, Locarnini S. London: International Medical Press; 2002:161–172.",{},{"id":26,"text":806,"url":26,"identifiers":807},"•• Lok ASF, McMahon BJ: Chronic hepatitis B: update 2009. Hepatology 2009, 50 (3): 1–36. This article presents the most up-to-date American guidelines for the treatment of chronic hepatitis B; these are the national standard of care.",{},{"id":26,"text":809,"url":26,"identifiers":810},"•• European Association for the Study of the Liver: EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009, 50:227–242. This article presents the most up-to-date European guidelines for the treatment of chronic hepatitis B, which help to put the American Association for the Study of Liver Diseases guidelines into perspective.",{"doi":811},"10.1016\u002Fj.jhep.2008.10.001",{"id":26,"text":813,"url":26,"identifiers":814},"•• Fontana RJ: Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 2009; 49: S185–S195. This article presents the most complete narrative review on the side effects of oral antiviral therapy for hepatitis B.",{"doi":815},"10.1002\u002Fhep.22885",{"id":26,"text":817,"url":26,"identifiers":818},"Birkus G, Hitchcock MJ, Cihlar T: Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemo 2002;46:716–723.",{"doi":819},"10.1128\u002FAAC.46.3.716-723.2002",{"id":26,"text":821,"url":26,"identifiers":822},"McKenzie R, Fried MW, Sallie R, et al.: Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analog for chronic hepatitis B. N Engl J Med 1995, 333:1099–1105.",{"doi":823},"10.1056\u002FNEJM199510263331702",{"id":26,"text":825,"url":26,"identifiers":826},"Lange CM, Bojunga J, Hofmann WP, et al.: Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009, 50:2001–2006.",{"doi":827},"10.1002\u002Fhep.23346",{"id":26,"text":829,"url":26,"identifiers":830},"Lamivudine [package insert]. Research Triangle Park, NC: Glaxo SmithKline; 2008.",{},{"id":26,"text":832,"url":26,"identifiers":833},"Adefovir [package insert]. Foster City, CA: Gilead Sciences, Inc.; 2008.",{},{"id":26,"text":835,"url":26,"identifiers":836},"Entecavir [package insert]. Princeton, NJ: Bristol-Meyers Squibb; 2009.",{},{"id":26,"text":838,"url":26,"identifiers":839},"Telbivudine [package insert]. Cambridge, MA: Idenix Pharmaceuticals; 2008.",{},{"id":26,"text":841,"url":26,"identifiers":842},"Tenofovir [package insert]. Foster City, CA: Gilead Sciences, Inc.; 2008.",{},{"id":26,"text":844,"url":26,"identifiers":845},"Lai CL, Chien RN, Leung NW, et al.: A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998, 339:61–68.",{"doi":846},"10.1056\u002FNEJM199807093390201",{"id":26,"text":848,"url":26,"identifiers":849},"Benhamou Y, Thibault V, Vig P, et al.: Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. J Hepatol 2006, 44:62–67.",{"doi":850},"10.1016\u002Fj.jhep.2005.08.020",{"id":26,"text":852,"url":26,"identifiers":853},"Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al.: Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006, 131:1743–1751.",{"doi":854},"10.1053\u002Fj.gastro.2006.09.020",{"id":26,"text":856,"url":26,"identifiers":857},"Schiff E, Ching-Lung L, Hadziyannis S, et al.: Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 2007, 13:349–360.",{"doi":858},"10.1002\u002Flt.20981",{"id":26,"text":860,"url":26,"identifiers":861},"Ha NB, Ha NB, Garcia RT, et al.: Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology 2009, 50: 727–734.",{"doi":862},"10.1002\u002Fhep.23044",{"id":26,"text":864,"url":26,"identifiers":865},"Izzedine H, Hulot JS, Launay-Vacher V, et al.: Renal Safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney Int 2004, 66: 1153–1158.",{"doi":866},"10.1111\u002Fj.1523-1755.2004.00866.x",{"id":26,"text":868,"url":26,"identifiers":869},"Lee YS, Dong JS, Young-Suk L, et al.: Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006, 43: 1385–1391.",{"doi":870},"10.1002\u002Fhep.21189",{"id":26,"text":872,"url":26,"identifiers":873},"Marcellin P, Chang TT, Lim SGL, et al.: Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008, 48:750–758.",{"doi":874},"10.1002\u002Fhep.22414",{"id":26,"text":876,"url":26,"identifiers":877},"Zeng M, Mao Y, Yao G, et al.: A double-blind randomized trial of adefovir dipivoxil in chinese subjects with HBeAg-positive chronic hepatitis B. Hepatology 2006, 44: 108–116.",{"doi":878},"10.1002\u002Fhep.21225",{"id":26,"text":880,"url":26,"identifiers":881},"Gish RG, Lok AS, Chang TT, et al.: Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007, 133: 1437–1444.",{"doi":882},"10.1053\u002Fj.gastro.2007.08.025",{"id":26,"text":884,"url":26,"identifiers":885},"Han SB, Chang TT, Chao YC, et al.: Five years of continuous entecavir for nucleoside-naïve HBeAg+ chronic hepatitis B: results from study ETV-901. Hepatology 2008, 48: 705A.",{},{"id":26,"text":887,"url":26,"identifiers":888},"Tenney DJ, Rose RE, Baldick CJ, et al.: Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 2009, 49: 1503–1514.",{"doi":889},"10.1002\u002Fhep.22841",{"id":26,"text":891,"url":26,"identifiers":892},"Tenney DJ, Pokorowski KA, Rose RE, et al.: Entecavir maintains a high genetic barrier to HBV resistance through 6 years in naïve patients. Presented at Digestive Disease Week. Chicago, IL; May 30–June 4, 2009.",{"doi":893},"10.1016\u002FS0016-5085(09)63991-3",{"id":26,"text":895,"url":26,"identifiers":896},"Schiff E, Simsek H, Lee WM, et al.: Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am J Gastroenterol 2008, 103: 2776–2783.",{"doi":897},"10.1111\u002Fj.1572-0241.2008.02086.x",{"id":26,"text":899,"url":26,"identifiers":900},"Lai CL, Leung N, Teo EK, et al.: A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005, 129: 528–536.",{"doi":901},"10.1016\u002Fj.gastro.2005.05.053",{"id":26,"text":903,"url":26,"identifiers":904},"Lai CL, Gane E, Liaw YF, et al.: Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007, 357:2576–2588.",{"doi":905},"10.1056\u002FNEJMoa066422",{"id":26,"text":907,"url":26,"identifiers":908},"Liaw YF, Gane E, Leung N, et al.: 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009, 136:486–495.",{"doi":909},"10.1053\u002Fj.gastro.2008.10.026",{"id":26,"text":911,"url":26,"identifiers":912},"Zhang XS, Jin R, Zhang SB, et al.: Clinical features of adverse reactions associated with telbivudine. World J Gastroenterol 2008, 14: 3549–3553.",{"doi":913},"10.3748\u002Fwjg.14.3549",{"id":26,"text":915,"url":26,"identifiers":916},"US Food and Drug Administration: Potential signals of serious risks\u002Fnew safety information identified from the adverse event reporting system (AERS) between January–March 2008. Available at http:\u002F\u002Fwww.fda.gov\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FSurveillance\u002FAdverseDrugEffects\u002Fucm082196.htm . Accessed November 2009.",{},{"id":26,"text":918,"url":26,"identifiers":919},"Leemans WF, Janssen HLA, Niesters HGM, et al.: Switching patients with lamivudine resistant chronic hepatitis B virus from tenofovir to adefovir results in less potent HBV-DNA suppression. J Viral Hepat 2008, 15:108–114.",{"doi":920},"10.1111\u002Fj.1365-2893.2007.00906.x",{"id":26,"text":922,"url":26,"identifiers":923},"Marcellin P, Heathcoate EJ, Buti M, et al.: Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008, 359:2442–2455.",{"doi":924},"10.1056\u002FNEJMoa0802878",{"id":26,"text":926,"url":26,"identifiers":927},"Tan LKK, Gilleece Y, Mandalia S: Reduced glomerular filtration rate but sustained virologic response in HIV\u002Fhepatitis B co-infected individuals on long-term tenofovir. Journal of Viral Hepatitis 2009, 16: 471–478.",{"doi":928},"10.1111\u002Fj.1365-2893.2009.01084.x",{"id":26,"text":930,"url":26,"identifiers":931},"Sung JJY, Lai JK, Zeuzem S, et al.: Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol 2008: 728–735.",{"doi":932},"10.1016\u002Fj.jhep.2007.12.026",{"id":26,"text":934,"url":26,"identifiers":935},"Hannon H, Bagnis CI, Benhamou Y, et al.: The renal tolerance of low-dose adefovir dipivoxil by lamivudine-resistant individuals co-infected with hepatitis B and HIV. Nephrol Dial Transplant, 19: 386–390.",{"doi":936},"10.1093\u002Fndt\u002Fgfg505",{"id":26,"text":938,"url":26,"identifiers":939},"Pellicelli AM, Barbaro G, Francavilla R, et al.: Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study. Clin Ther 2008, 30:317–323.",{"doi":940},"10.1016\u002Fj.clinthera.2008.02.012",{"id":26,"text":942,"url":26,"identifiers":943},"Jonas MM, Kelly D, Pollack K, et al.: Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to \u003C18 years) with chronic hepatitis B. Hepatology 2008, 47: 1863–1871.",{"doi":944},"10.1002\u002Fhep.22250",{"id":26,"text":946,"url":26,"identifiers":947},"Chang TT, Gish RG, Hadziyannis SJ, et al.: A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005, 129: 1198–1209.",{"doi":948},"10.1053\u002Fj.gastro.2005.06.055",{"id":26,"text":950,"url":26,"identifiers":951},"Sherman M, Yurdaydin C, Simsek H, et al.: Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 2008, 48: 99–108.",{"doi":952},"10.1002\u002Fhep.22323",{"id":26,"text":954,"url":26,"identifiers":955},"Suzuki F, Toyoda J, Katano Y, et al.: Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients. J Gastroenterol Hepatol 2008, 23: 1320–1326.",{"doi":956},"10.1111\u002Fj.1440-1746.2008.05455.x",{"id":26,"text":958,"url":26,"identifiers":959},"Kobashi H, Takaguchi K, Ikeda H, et al.: Efficacy and safety of entecavir in nucleoside-naïve, chronic hepatitis b patients: phase II clinical study in Japan. J Gastroenterol Hepatol 2009, 24: 255–261.",{"doi":960},"10.1111\u002Fj.1440-1746.2008.05593.x",{"id":26,"text":962,"url":26,"identifiers":963},"Leung N, Peng CY, Hann HW, et al.: Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir. Hepatology 2009, 49: 72–79.",{"doi":964},"10.1002\u002Fhep.22658",{"id":26,"text":966,"url":26,"identifiers":967},"Pessoa MG, Gazzard B, Huang AK, et al.: Efficacy and safety of entecavir for chronic HBV in HIV\u002FHBV coinfected patients receiving lamivudine as part of antiretroviral therapy. AIDS 2008, 22: 1779–1787.",{"doi":968},"10.1097\u002FQAD.0b013e32830b3ab5",{"id":26,"text":970,"url":26,"identifiers":971},"Sherman M, Yurdaydin C, Sollano J, et al.: Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006, 130:2039–2049.",{"doi":972},"10.1053\u002Fj.gastro.2006.04.007",{"id":26,"text":974,"url":26,"identifiers":975},"Chang TT, Gish RG, Hadziyannis SJ, et al.: A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005, 129:1198–1209.",{"doi":948},{"id":26,"text":977,"url":26,"identifiers":978},"Chang TT, Gish RG, de Man R, et al.: A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006, 354:1001–1010.",{"doi":979},"10.1056\u002FNEJMoa051285",{"id":26,"text":981,"url":26,"identifiers":982},"Hou J, Yin YK, Xu D, et al.: Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial. Hepatology 2008, 47: 447–454.",{"doi":983},"10.1002\u002Fhep.22075",{"id":26,"text":985,"url":26,"identifiers":986},"Chan HLY, Heathcote J, Marcellin P, et al.: Treatment of hepatitis B e antigen-positive chronic hepatitis with telbivudine or adefovir. Ann Intern Med. 2007, 147: 745–754.",{"doi":987},"10.7326\u002F0003-4819-147-11-200712040-00183",{"id":26,"text":989,"url":26,"identifiers":990},"Peters MG, Andersen J, Lynch P, et al.: Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology 2006, 44: 1110–1116.",{"doi":991},"10.1002\u002Fhep.21388",{"id":26,"text":993,"url":26,"identifiers":994},"Bommel FV, Zollner B, Sarrazin C, et al.: Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 2006, 44:318–325.",{"doi":995},"10.1002\u002Fhep.21253",{"id":26,"text":997,"url":26,"identifiers":998},"Santos SA, Uriel AJ, Park JS, et al.: Effect of switching to tenofovir with emtricitabine in patients with chronic hepatitis B failing to respond to an adefovir-containing regimen. Eur J Gastroenterol Hepatol 2006, 18:1247–1253.",{"doi":999},"10.1097\u002F01.meg.0000243877.17444.5e",false,{"id":1002,"createTime":1003,"updateTime":1004,"relativeEntities":1005,"slug":1006,"properties":1007,"entityType":725,"verifyStatus":28,"verifyTime":1004,"verifyNote":1022,"syncStatus":28,"languages":1023,"translateLanguages":26,"viewCount":36,"primaryUrl":1024,"fullTextUrl":26,"authors":1025,"publicationType":768,"publisherRelationship":1075,"citationCount":103,"citationInfo":1096,"publishDate":1098,"publishYear":1099,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":1100,"isForceReanalyzing":1000},"5e850dfe-7fe2-40ae-b0d7-13d4f7832369","2024-04-15T01:25:11.185+00:00","2025-02-19T14:02:24.926+00:00",[],"Hepatitis-C-viral-kinetics-in-special-populations",{"mag":1008,"keywords":1010,"pmc":1011,"openalex":1013,"abstract":1015,"title":1016,"pm":1018,"doi":1020},{"VOID":1009},"2002916699",{},{"VOID":1012},"2626272",{"VOID":1014},"W2002916699",{},{"EN":1017},"Hepatitis C viral kinetics in special populations",{"VOID":1019},"19148305",{"VOID":1021},"10.1007\u002Fs11901-008-0022-2","Author affiliation is blank",[102],"http:\u002F\u002Flink.springer.com\u002F10.1007\u002Fs11901-008-0022-2",[1026,1035,1044,1055],{"id":1027,"sortIndex":115,"researcher":26,"roles":1028,"affiliations":1029,"properties":1030},"9c17e4ee-1bff-4536-b48d-71265035c762",[],[],{"openalex":1031,"title":1033},{"VOID":1032},"A5056032432",{"EN":1034},"Jennifer E. Layden‐Almer",{"id":1036,"sortIndex":59,"researcher":26,"roles":1037,"affiliations":1038,"properties":1039},"e47fd65e-3089-48c8-836d-4bec86ecf5cf",[],[],{"openalex":1040,"title":1042},{"VOID":1041},"A5033640233",{"EN":1043},"Thomas J. Layden",{"id":1045,"sortIndex":114,"researcher":26,"roles":1046,"affiliations":1047,"properties":1048},"f18ac699-bbf5-41c3-8c20-68abbabdd4da",[],[],{"openalex":1049,"orcid":1051,"title":1053},{"VOID":1050},"A5058338534",{"VOID":1052},"https:\u002F\u002Forcid.org\u002F0000-0002-2455-0002",{"EN":1054},"Alan S. Perelson",{"id":1056,"sortIndex":36,"researcher":26,"roles":1057,"affiliations":1058,"properties":1068},"a5a7210c-f5e3-4c01-8467-36a22564275c",[],[1059],{"id":26,"sortIndex":36,"affiliation":1060,"properties":26},{"id":1061,"createTime":1062,"updateTime":1062,"relativeEntities":1063,"slug":1064,"properties":1065,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"f717aa72-9fc9-4ca0-97fe-2e53af19e98f","2024-04-15T01:25:11.195+00:00",[],"Department-of-Medicine-Section-of-Hepatology-The-University-of-Illinois-at-Chicago-Chicago-USA",{"title":1066},{"EN":1067},"Department of Medicine, Section of Hepatology, The University of Illinois at Chicago, Chicago, USA",{"openalex":1069,"orcid":1071,"title":1073},{"VOID":1070},"A5042241497",{"VOID":1072},"https:\u002F\u002Forcid.org\u002F0000-0002-3357-1817",{"EN":1074},"Harel Dahari",{"url":26,"publisher":1076,"properties":26},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":1077,"slug":663,"properties":1078,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":1082,"manageAffiliations":1083,"indexDatabases":1084,"url":691,"thumbnailPath":26,"statistic":1091,"gsStatistic":26,"type":175,"analyzePriority":26},[],{"issn":1079,"eissn":1080,"title":1081},{"VOID":666},{"VOID":668},{"EN":670},[],[],[1085],{"id":675,"indexDatabase":1086,"url":688,"indexYears":689,"academicFieldIds":26,"indexDatabaseRanking":690},{"id":677,"createTime":678,"updateTime":679,"relativeEntities":1087,"label":1088,"description":1089,"key":685,"publicationTags":1090,"standard":26},[],{"EN":682,"VI":682},{"EN":682,"VI":684},[687],{"impactFactor":36,"impactFactorByYear":1092,"i10Index":59,"i10IndexLast5Year":36,"totalPublication":694,"totalPublicationByYear":1093,"totalCitation":536,"totalCitationByYear":1094,"totalCitationPerPublication":132,"totalCitationPerPublicationByYear":1095,"hindexLast5Year":162,"hindex":162},{"2012":231,"2013":229,"2014":39},{"2002":111,"2003":336,"2004":173,"2005":234,"2006":234,"2007":162,"2008":234,"2009":237,"2010":241,"2011":516,"2012":241,"2013":51},{"2003":114,"2004":114,"2005":59,"2006":53,"2007":50,"2008":234,"2009":115,"2010":285,"2011":114,"2012":135,"2013":115},{"2003":404,"2004":206,"2005":57,"2006":698,"2007":699,"2008":115,"2009":230,"2010":266,"2011":108,"2012":477,"2013":110},{"total":103,"publishYear":26,"statisticByYear":1097},{"2012":114,"2013":115,"2020":115},"2008-08-01",2008,[1101,1104,1108,1112,1116,1119,1123,1127,1131,1135,1139,1143,1147,1151,1155,1158,1162,1166,1170,1174,1178,1182,1186,1189,1193,1197,1201,1205,1208,1212,1216,1220,1224,1228,1232,1236,1240,1244,1248,1252,1256,1260,1263,1267,1271,1275,1279,1283,1287,1291],{"id":26,"text":1102,"url":26,"identifiers":1103},"National Institutes of Health: National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. Hepatology 2002, 36:S3–S20.",{},{"id":26,"text":1105,"url":26,"identifiers":1106},"Nguyen TT, Sedghi-Vaziri A, Wilkes LB, et al.: Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection. J Viral Hepat 1996, 3:75–78.",{"doi":1107},"10.1111\u002Fj.1365-2893.1996.tb00084.x",{"id":26,"text":1109,"url":26,"identifiers":1110},"Neumann AU, Lam NP, Dahari H, et al.: Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998, 282:103–107.",{"doi":1111},"10.1126\u002Fscience.282.5386.103",{"id":26,"text":1113,"url":26,"identifiers":1114},"Neumann AU, Lam NP, Dahari H, et al.: Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 2000, 182:28–35.",{"doi":1115},"10.1086\u002F315661",{"id":26,"text":1117,"url":26,"identifiers":1118},"Bergmann CC, Layden JE, Levy-Drummer RS, et al.: Clinical implications of a new tri-phasic model for hepatitis C viral kinetics during IFN-alpha therapy [abstract]. Hepatology 2001, 34:345A.",{},{"id":26,"text":1120,"url":26,"identifiers":1121},"Herrmann E, Lee JH, Marinos G, et al.: Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 2003, 37:1351–1358.",{"doi":1122},"10.1053\u002Fjhep.2003.50218",{"id":26,"text":1124,"url":26,"identifiers":1125},"Kieffer TL, Sarrazin C, Miller JS, et al.: Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007, 46:631–639.",{"doi":1126},"10.1002\u002Fhep.21781",{"id":26,"text":1128,"url":26,"identifiers":1129},"Garcia-Retortillo M, Forns X, Feliu A, et al.: Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002, 35:680–687.",{"doi":1130},"10.1053\u002Fjhep.2002.31773",{"id":26,"text":1132,"url":26,"identifiers":1133},"Dahari H, Feliu A, Garcia-Retortillo M, et al.: Second hepatitis C replication compartment indicated by viral dynamics during liver transplantation. J Hepatol 2005, 42:491–498.",{"doi":1134},"10.1016\u002Fj.jhep.2004.12.017",{"id":26,"text":1136,"url":26,"identifiers":1137},"Powers KA, Ribeiro RM, Patel K, et al.: KInetics of hepatitis C virus reinfection after liver transplantation. Liver Transpl 2006, 12:207–216.",{"doi":1138},"10.1002\u002Flt.20572",{"id":26,"text":1140,"url":26,"identifiers":1141},"Schiano TD, Gutierrez JA, Walewski JL, et al.: Accelerated hepatitis C virus kinetics but similar survival rates in recipients of liver grafts from living versus deceased donors. Hepatology 2005, 42:1420–1428.",{"doi":1142},"10.1002\u002Fhep.20947",{"id":26,"text":1144,"url":26,"identifiers":1145},"Ho DD, Neumann AU, Perelson AS, et al.: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123–126.",{"doi":1146},"10.1038\u002F373123a0",{"id":26,"text":1148,"url":26,"identifiers":1149},"Wei X, Ghosh SK, Taylor ME, et al.: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373:117–122.",{"doi":1150},"10.1038\u002F373117a0",{"id":26,"text":1152,"url":26,"identifiers":1153},"Dahari H, Major M, Zhang X, et al.: Mathematical modeling of primary hepatitis C infection: noncytolytic clearance and early blockage of virion production. Gastroenterology 2005, 128:1056–1066.",{"doi":1154},"10.1053\u002Fj.gastro.2005.01.049",{"id":26,"text":1156,"url":26,"identifiers":1157},"Powers KA, Dixit NM, Ribeiro RM, et al.: Modeling viral and drug kinetics: hepatitis C virus treatment with pegylated interferon alfa-2b. Semin Liver Dis 2003, 23(Suppl 1):13–18.",{},{"id":26,"text":1159,"url":26,"identifiers":1160},"Talal AH, Ribeiro RM, Powers KA, et al.: Pharmacodynamics of PEG-IFN alpha differentiate HIV\u002FHCV coinfected sustained virological responders from nonresponders. Hepatology 2006, 43:943–953.",{"doi":1161},"10.1002\u002Fhep.21136",{"id":26,"text":1163,"url":26,"identifiers":1164},"Ribeiro RM, Layden-Almer J, Powers KA, et al.: Dynamics of alanine aminotransferase during hepatitis C virus treatment. Hepatology 2003, 38:509–517.",{"doi":1165},"10.1053\u002Fjhep.2003.50344",{"id":26,"text":1167,"url":26,"identifiers":1168},"Colombatto P, Civitano L, Oliveri F, et al.: Sustained response to interferon-ribavirin combination therapy predicted by a model of hepatitis C virus dynamics using both HCV RNA and alanine aminotransferase. Antivir Ther 2003, 8:519–530.",{"doi":1169},"10.1177\u002F135965350300800602",{"id":26,"text":1171,"url":26,"identifiers":1172},"Lam NP, Neumann AU, Gretch DR, et al.: Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997, 26:226–231.",{"doi":1173},"10.1002\u002Fhep.510260130",{"id":26,"text":1175,"url":26,"identifiers":1176},"Blight KJ, Kolykhalov AA, Rice CM: Efficient initiation of HCV RNA replication in cell culture. Science 2000, 290:1972–1974.",{"doi":1177},"10.1126\u002Fscience.290.5498.1972",{"id":26,"text":1179,"url":26,"identifiers":1180},"Dixit NM, Layden-Almer JE, Layden TJ, Perelson AS: Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 2004, 432:922–924.",{"doi":1181},"10.1038\u002Fnature03153",{"id":26,"text":1183,"url":26,"identifiers":1184},"Layden-Almer JE, Ribeiro RM, Wiley T, et al.: Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology 2003, 37:1343–1350.",{"doi":1185},"10.1053\u002Fjhep.2003.50217",{"id":26,"text":1187,"url":26,"identifiers":1188},"Bortoletto G, Realdon S, Dal Pero F, et al.: Insulin resistance (IR) defined by the homeostasis model of assessment insulin resistance (HOMA-IR) index has a direct effect on early viral kinetics during pegylated-interferon therapy for chronic hepatitis C [abstract]. Hepatology 2007, 46:361A.",{},{"id":26,"text":1190,"url":26,"identifiers":1191},"Lam NP, Pitrak D, Speralakis R, et al.: Effect of obesity on pharmacokinetics and biologic effect of interferon-alpha in hepatitis C. Dig Dis Sci 1997, 42:178–185.",{"doi":1192},"10.1023\u002FA:1018865928308",{"id":26,"text":1194,"url":26,"identifiers":1195},"Westin J, Lagging M, Dhillon AP, et al.: Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection. J Viral Hepat 2007, 14:29–35.",{"doi":1196},"10.1111\u002Fj.1365-2893.2006.00777.x",{"id":26,"text":1198,"url":26,"identifiers":1199},"Medeiros-Filho JE, de Carvalho Mello IM, Pinho JR, et al.: Differences in viral kinetics between genotypes 1 and 3 of hepatitis C virus and between cirrhotic and non-cirrhotic patients during antiviral therapy. World J Gastroenterol 2006, 12:7271–7277.",{"doi":1200},"10.3748\u002Fwjg.v12.i45.7271",{"id":26,"text":1202,"url":26,"identifiers":1203},"Cotler SJ, Layden JE, Neumann AU, Jensen DM: First phase hepatitis c viral kinetics in previous nonresponders patients. J Viral Hepat 2003, 10:43–49.",{"doi":1204},"10.1046\u002Fj.1365-2893.2003.00401.x",{"id":26,"text":1206,"url":26,"identifiers":1207},"Neumann AU, Mohan P, Lutchman G, et al.: Hepatitis C viral kinetics in children treated with PEGIFN alfa-2a [abstract]. Hepatology 2004, 40(Suppl 1):473A.",{},{"id":26,"text":1209,"url":26,"identifiers":1210},"Torriani FJ, Ribeiro RM, Gilbert TL, et al.: Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV\u002FHIV coinfection. J Infect Dis 2003, 188:1498–1507.",{"doi":1211},"10.1086\u002F379255",{"id":26,"text":1213,"url":26,"identifiers":1214},"Layden JE, Layden TJ, Reddy KR, et al.: First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline. J Viral Hepat 2002, 9:340–345.",{"doi":1215},"10.1046\u002Fj.1365-2893.2002.00377.x",{"id":26,"text":1217,"url":26,"identifiers":1218},"Jessner W, Gschwantler M, Steindl-Munda P, et al.: Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study. Lancet 2001, 358:1241–1242.",{"doi":1219},"10.1016\u002FS0140-6736(01)06356-5",{"id":26,"text":1221,"url":26,"identifiers":1222},"Dahari H, Markatou M, Zeremski M, et al.: Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV\u002FHCV co-infected patients during treatment with pegylated interferon and ribavirin. J Hepatol 2007, 47:23–30.",{"doi":1223},"10.1016\u002Fj.jhep.2007.01.027",{"id":26,"text":1225,"url":26,"identifiers":1226},"Sherman KE, Shire NJ, Rouster SD, et al.: Viral kinetics in hepatitis C or hepatitis C\u002Fhuman immunodeficiency virus-infected patients. Gastroenterology 2005, 128:313–327.",{"doi":1227},"10.1053\u002Fj.gastro.2004.11.059",{"id":26,"text":1229,"url":26,"identifiers":1230},"Sarrazin C, Kieffer TL, Bartels D, et al.: Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007, 132:1767–1777.",{"doi":1231},"10.1053\u002Fj.gastro.2007.02.037",{"id":26,"text":1233,"url":26,"identifiers":1234},"Pawlotsky JM, Dahari H, Neumann AU, et al.: Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 2004, 126:703–714.",{"doi":1235},"10.1053\u002Fj.gastro.2003.12.002",{"id":26,"text":1237,"url":26,"identifiers":1238},"Zeuzem S, Herrmann E, Lee JH, et al.: Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology 2001, 120:1438–1447.",{"doi":1239},"10.1053\u002Fgast.2001.24006",{"id":26,"text":1241,"url":26,"identifiers":1242},"Pilli M, Zerbini A, Penna A, et al.: HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project). Gastroenterology 2007, 133:1132–1143.",{"doi":1243},"10.1053\u002Fj.gastro.2007.06.059",{"id":26,"text":1245,"url":26,"identifiers":1246},"Inoue K, Umehara T, Ruegg UT, et al.: Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo. Hepatology 2007, 45:921–928.",{"doi":1247},"10.1002\u002Fhep.21587",{"id":26,"text":1249,"url":26,"identifiers":1250},"Dahari H, Perelson AS: Hepatitis C virus kinetics in chimeric mice during antiviral therapy. Hepatology 2007, 46:2048–2049.",{"doi":1251},"10.1002\u002Fhep.21798",{"id":26,"text":1253,"url":26,"identifiers":1254},"Lindh M, Alestig E, Arnholm B, et al.: Response prediction and treatment tailoring for chronic hepatitis C virus genotype 1 infection. J Clin Microbiol 2007, 45:2439–2445.",{"doi":1255},"10.1128\u002FJCM.00577-07",{"id":26,"text":1257,"url":26,"identifiers":1258},"Dahari H, Perelson AS: Hepatitis C virus RNA kinetics: drug efficacy and the rate of HCV-infected cells loss. World J Gastroenterol 2007, 13:3020–3021.",{"doi":1259},"10.3748\u002Fwjg.v13.i21.3020",{"id":26,"text":1261,"url":26,"identifiers":1262},"Levy-Drummer RS, Haagmans BL, Soulier A, et al.: Pharmacodynamic modeling of HCV kinetics during peg-interferon-alfa-2a (40KD) and ribavirin treatment of chronic hepatitis C genotype 1 patients in the DITTO-HCV study [abstract]. Hepatology 2004, 40:390A.",{},{"id":26,"text":1264,"url":26,"identifiers":1265},"Bekkering FC, Neumann AU, Brouwer JT, et al.: Changes in anti-viral effectiveness of interferon after dose reduction in chronic hepatitis C patients: a case control study. BMC Gastroenterol 2001, 1:14.",{"doi":1266},"10.1186\u002F1471-230X-1-14",{"id":26,"text":1268,"url":26,"identifiers":1269},"Dahari H, Lo A, Ribeiro RM, Perelson AS: Modeling hepatitis C virus dynamics: liver regeneration and critical drug efficacy. J Theor Biol 2007, 247:371–381.",{"doi":1270},"10.1016\u002Fj.jtbi.2007.03.006",{"id":26,"text":1272,"url":26,"identifiers":1273},"Wein LM, D’Amato RM, Perelson AS: Mathematical analysis of antiretroviral therapy aimed at HIV-1 eradication or maintenance of low viral loads. J Theor Biol 1998, 192:81–98.",{"doi":1274},"10.1006\u002Fjtbi.1997.0622",{"id":26,"text":1276,"url":26,"identifiers":1277},"Callaway DS, Perelson AS: HIV-1 infection and low steady state viral loads. Bull Math Biol 2002, 64:29–64.",{"doi":1278},"10.1006\u002Fbulm.2001.0266",{"id":26,"text":1280,"url":26,"identifiers":1281},"Pal S, Shuhart MC, Thomassen L, et al.: Intrahepatic hepatitis C virus replication correlates with chronic hepatitis C disease severity in vivo. J Virol 2006, 80:2280–2290.",{"doi":1282},"10.1128\u002FJVI.80.5.2280-2290.2006",{"id":26,"text":1284,"url":26,"identifiers":1285},"Everson GT, Hoefs JC, Seeff LB, et al.: Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: lessons from the HALT-C trial. Hepatology 2006, 44:1675–1684.",{"doi":1286},"10.1002\u002Fhep.21440",{"id":26,"text":1288,"url":26,"identifiers":1289},"Iacobellis A, Siciliano M, Perri F, et al.: Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol 2007, 46:206–212.",{"doi":1290},"10.1016\u002Fj.jhep.2006.08.020",{"id":26,"text":1292,"url":26,"identifiers":1293},"Dahari H, Ribeiro RM, Perelson AS: Triphasic decline of hepatitis C virus RNA during antiviral therapy. Hepatology 2007, 46:16–21.",{"doi":1294},"10.1002\u002Fhep.21657",{"id":1296,"createTime":1297,"updateTime":1298,"relativeEntities":1299,"slug":1300,"properties":1301,"entityType":725,"verifyStatus":28,"verifyTime":1298,"verifyNote":1310,"syncStatus":28,"languages":1311,"translateLanguages":26,"viewCount":36,"primaryUrl":1312,"fullTextUrl":26,"authors":1313,"publicationType":768,"publisherRelationship":1314,"citationCount":116,"citationInfo":1341,"publishDate":1343,"publishYear":1344,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":1345,"isForceReanalyzing":1000},"1df624a3-4152-4355-9016-6ba1f0c9d5be","2024-04-16T21:38:21.751+00:00","2024-12-26T18:52:00.294+00:00",[],"Web-alert",{"keywords":1302,"openalex":1303,"abstract":1305,"title":1306,"doi":1308},{},{"VOID":1304},"W4251155103",{},{"EN":1307},"Web alert",{"VOID":1309},"10.1007\u002Fs11901-006-0001-4","Author title is blank",[102],"http:\u002F\u002Flink.springer.com\u002F10.1007\u002Fs11901-006-0001-4",[],{"url":26,"publisher":1315,"properties":1335},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":1316,"slug":663,"properties":1317,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":1321,"manageAffiliations":1322,"indexDatabases":1323,"url":691,"thumbnailPath":26,"statistic":1330,"gsStatistic":26,"type":175,"analyzePriority":26},[],{"issn":1318,"eissn":1319,"title":1320},{"VOID":666},{"VOID":668},{"EN":670},[],[],[1324],{"id":675,"indexDatabase":1325,"url":688,"indexYears":689,"academicFieldIds":26,"indexDatabaseRanking":690},{"id":677,"createTime":678,"updateTime":679,"relativeEntities":1326,"label":1327,"description":1328,"key":685,"publicationTags":1329,"standard":26},[],{"EN":682,"VI":682},{"EN":682,"VI":684},[687],{"impactFactor":36,"impactFactorByYear":1331,"i10Index":59,"i10IndexLast5Year":36,"totalPublication":694,"totalPublicationByYear":1332,"totalCitation":536,"totalCitationByYear":1333,"totalCitationPerPublication":132,"totalCitationPerPublicationByYear":1334,"hindexLast5Year":162,"hindex":162},{"2012":231,"2013":229,"2014":39},{"2002":111,"2003":336,"2004":173,"2005":234,"2006":234,"2007":162,"2008":234,"2009":237,"2010":241,"2011":516,"2012":241,"2013":51},{"2003":114,"2004":114,"2005":59,"2006":53,"2007":50,"2008":234,"2009":115,"2010":285,"2011":114,"2012":135,"2013":115},{"2003":404,"2004":206,"2005":57,"2006":698,"2007":699,"2008":115,"2009":230,"2010":266,"2011":108,"2012":477,"2013":110},{"volume":1336,"pages":1338,"issue":1340},{"VOID":1337},"5",{"VOID":1339},"41-42",{"VOID":796},{"total":116,"publishYear":26,"statisticByYear":1342},{"2012":115,"2013":115,"2020":115},"2006-05-01",2006,[],{"id":1347,"createTime":1348,"updateTime":1349,"relativeEntities":1350,"slug":1351,"properties":1352,"entityType":725,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":1363,"translateLanguages":26,"viewCount":36,"primaryUrl":1364,"fullTextUrl":26,"authors":1365,"publicationType":768,"publisherRelationship":1397,"citationCount":158,"citationInfo":1418,"publishDate":1420,"publishYear":1421,"citationAnalyzeStatus":1422,"lastCitationAnalyze":1423,"indexDatabases":26,"openAccess":26,"references":1424,"isForceReanalyzing":1000},"3ea4b3ff-4f3f-4704-bec5-682a4d4218ee","2024-04-11T18:57:17.152+00:00","2024-04-11T22:30:48.391+00:00",[],"Hepatitis-B-virus-genotype-What-should-the-clinician-know-",{"mag":1353,"keywords":1355,"openalex":1356,"abstract":1358,"title":1359,"doi":1361},{"VOID":1354},"2069143436",{},{"VOID":1357},"W2069143436",{},{"EN":1360},"Hepatitis B virus genotype: What should the clinician know?",{"VOID":1362},"10.1007\u002Fbf02942174",[102],"http:\u002F\u002Flink.springer.com\u002F10.1007\u002FBF02942174",[1366,1377],{"id":1367,"sortIndex":36,"researcher":26,"roles":1368,"affiliations":1369,"properties":1370},"ec1a2611-b720-4236-9d64-3dd792f15dc8",[],[],{"openalex":1371,"orcid":1373,"title":1375},{"VOID":1372},"A5072593323",{"VOID":1374},"https:\u002F\u002Forcid.org\u002F0000-0002-6202-0993",{"EN":1376},"Chun–Jen Liu",{"id":1378,"sortIndex":115,"researcher":26,"roles":1379,"affiliations":1380,"properties":1390},"1f774d50-2004-40ec-9b58-25f4fb61a7fa",[],[1381],{"id":26,"sortIndex":36,"affiliation":1382,"properties":26},{"id":1383,"createTime":1384,"updateTime":1384,"relativeEntities":1385,"slug":1386,"properties":1387,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"19d2f097-4197-4d23-b50e-eedf0193d6de","2023-11-27T04:41:31.602+00:00",[],"Hepatitis-Research-Center-National-Taiwan-University-Hospital-Taipei-100-Taiwan",{"title":1388},{"VI":1389},"Hepatitis Research Center, National Taiwan University Hospital, Taipei 100, Taiwan",{"openalex":1391,"orcid":1393,"title":1395},{"VOID":1392},"A5063550464",{"VOID":1394},"https:\u002F\u002Forcid.org\u002F0000-0002-2442-7952",{"EN":1396},"Jia‐Horng Kao",{"url":26,"publisher":1398,"properties":26},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":1399,"slug":663,"properties":1400,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":1404,"manageAffiliations":1405,"indexDatabases":1406,"url":691,"thumbnailPath":26,"statistic":1413,"gsStatistic":26,"type":175,"analyzePriority":26},[],{"issn":1401,"eissn":1402,"title":1403},{"VOID":666},{"VOID":668},{"EN":670},[],[],[1407],{"id":675,"indexDatabase":1408,"url":688,"indexYears":689,"academicFieldIds":26,"indexDatabaseRanking":690},{"id":677,"createTime":678,"updateTime":679,"relativeEntities":1409,"label":1410,"description":1411,"key":685,"publicationTags":1412,"standard":26},[],{"EN":682,"VI":682},{"EN":682,"VI":684},[687],{"impactFactor":36,"impactFactorByYear":1414,"i10Index":59,"i10IndexLast5Year":36,"totalPublication":694,"totalPublicationByYear":1415,"totalCitation":536,"totalCitationByYear":1416,"totalCitationPerPublication":132,"totalCitationPerPublicationByYear":1417,"hindexLast5Year":162,"hindex":162},{"2012":231,"2013":229,"2014":39},{"2002":111,"2003":336,"2004":173,"2005":234,"2006":234,"2007":162,"2008":234,"2009":237,"2010":241,"2011":516,"2012":241,"2013":51},{"2003":114,"2004":114,"2005":59,"2006":53,"2007":50,"2008":234,"2009":115,"2010":285,"2011":114,"2012":135,"2013":115},{"2003":404,"2004":206,"2005":57,"2006":698,"2007":699,"2008":115,"2009":230,"2010":266,"2011":108,"2012":477,"2013":110},{"total":158,"publishYear":26,"statisticByYear":1419},{"2022":115},"2007-02-01",2007,"ERROR_IN_ANALYZE_CITATION","2024-04-11T22:30:48.390+00:00",[1425,1429,1433,1437,1441,1445,1449,1453,1457,1461,1465,1469,1473,1477,1481,1485,1489,1493,1497,1501,1505,1509,1513,1517,1521,1525,1529,1533,1537,1541,1544,1548,1552,1556,1560,1564,1568,1571,1574,1578,1582,1586,1590,1594,1598,1602,1606,1610,1614,1618,1621,1625,1629,1633,1637,1641,1645,1649,1653,1657],{"id":26,"text":1426,"url":26,"identifiers":1427},"Kao JH, Chen DS:Global control of hepatitis B virus.Lancet Infect Dis 2002,2:395–403.",{"doi":1428},"10.1016\u002FS1473-3099(02)00315-8",{"id":26,"text":1430,"url":26,"identifiers":1431},"Fung SK, Lok ASF:Hepatitis B virus genotypes: Do they play a role in the outcome of HBV infection? Hepatology 2004,40:790–792.",{"doi":1432},"10.1002\u002Fhep.20455",{"id":26,"text":1434,"url":26,"identifiers":1435},"Liu CJ, Kao JH, Chen DS:Therapeutic implications of hepatitis B virus genotypes.Liver Int 2005,25:1097–1107.",{"doi":1436},"10.1111\u002Fj.1478-3231.2005.01177.x",{"id":26,"text":1438,"url":26,"identifiers":1439},"Kao JH, Chen DS:HBV genotypes: epidemiology and implications regarding natural history [review].Curr Hepatitis Rep 2006,5:5–13.",{"doi":1440},"10.1007\u002Fs11901-006-0017-9",{"id":26,"text":1442,"url":26,"identifiers":1443},"Okamoto H, Tsuda F, Sakugawa H, et al.:Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes.J Gen Virol 1988,69:2575–2583.",{"doi":1444},"10.1099\u002F0022-1317-69-10-2575",{"id":26,"text":1446,"url":26,"identifiers":1447},"Norder H, Courouce AM, Magnius LO:Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes.Virology 1994,198:489–503.",{"doi":1448},"10.1006\u002Fviro.1994.1060",{"id":26,"text":1450,"url":26,"identifiers":1451},"Norder H, Courouce AM, Coursaget P, et al.:Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes.Intervirology 2004,47:289–309.",{"doi":1452},"10.1159\u002F000080872",{"id":26,"text":1454,"url":26,"identifiers":1455},"Sugauchi F, Orito E, Ichida T, et al.:Hepatitis B virus of genotype B with or without recombination with genotype C over the precore region plus the core gene.J Virol 2002,76:5985–5992.",{"doi":1456},"10.1128\u002FJVI.76.12.5985-5992.2002",{"id":26,"text":1458,"url":26,"identifiers":1459},"Kramvis A, Weitzmann L, Owiredu WK, Kew MC:Analysis of the complete genome of subgroup A′, hepatitis B virus isolates from South Africa.J Gen Virol 2002,83:835–839.",{"doi":1460},"10.1099\u002F0022-1317-83-4-835",{"id":26,"text":1462,"url":26,"identifiers":1463},"Chan HL, Tsui SK, Tse CH, et al.:Epidemiological and virological characteristics of 2 subgroups of hepatitis B virus genotype C.J Infect Dis 2005,191:2022–2032.",{"doi":1464},"10.1086\u002F430324",{"id":26,"text":1466,"url":26,"identifiers":1467},"Liu CJ, Kao JH:Subgenotypes of hepatitis B virus genotype C in Taiwan.J Infect Dis 2005,192:1308–1309.",{"doi":1468},"10.1086\u002F444470",{"id":26,"text":1470,"url":26,"identifiers":1471},"Liu CJ, Chen BF, Chen PJ, et al.:Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers.J Infect Dis 2006,193:1258–1265.",{"doi":1472},"10.1086\u002F502978",{"id":26,"text":1474,"url":26,"identifiers":1475},"Yang HI, Chen PJ, Yeh SH, et al.:Risk of hepatocellular carcinoma associated with genotypes and mutants of hepatitis B virus: a community-based prospective cohort study.J Hepatol 2006,44(suppl 2):27A.",{"doi":1476},"10.1016\u002FS0168-8278(06)80028-0",{"id":26,"text":1478,"url":26,"identifiers":1479},"Kao JH, Chen PJ, Lai MY, Chen DS:Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B.Gastroenterology 2000,118:554–559.",{"doi":1480},"10.1016\u002FS0016-5085(00)70261-7",{"id":26,"text":1482,"url":26,"identifiers":1483},"Ni YH, Chang MH, Wang KJ, et al.:Clinical relevance of hepatitis B virus genotype in children with chronic infection and hepatocellular carcinoma.Gastroenterology 2004,127:1733–1738.",{"doi":1484},"10.1053\u002Fj.gastro.2004.09.048",{"id":26,"text":1486,"url":26,"identifiers":1487},"Orito E, Ichida T, Sakugawa H, et al.:Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan.Hepatology 2001,34:590–594.",{"doi":1488},"10.1053\u002Fjhep.2001.27221",{"id":26,"text":1490,"url":26,"identifiers":1491},"Ding X, Mizokami M, Yao G, et al.:Hepatitis B virus genotype distribution among chronic hepatitis B virus carriers in Shanghai, China.Intervirology 2001,44:43–47.",{"doi":1492},"10.1159\u002F000050029",{"id":26,"text":1494,"url":26,"identifiers":1495},"Chu CM, Liaw YF:Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline.J Hepatol 2005,43:411–417.",{"doi":1496},"10.1016\u002Fj.jhep.2005.03.018",{"id":26,"text":1498,"url":26,"identifiers":1499},"Kao JH, Chen PJ, Lai MY, Chen DS:Acute exacerbations of chronic hepatitis B are rarely associated with superinfection of hepatitis B virus.Hepatology 2001,34:817–823.",{"doi":1500},"10.1053\u002Fjhep.2001.28188",{"id":26,"text":1502,"url":26,"identifiers":1503},"Kao JH, Chen PJ, Lai MY, Chen DS:Hepatitis B virus genotypes and spontaneous hepatitis B e antigen seroconversion in Taiwanese hepatitis B carriers.J Med Virol 2004,72:363–369.",{"doi":1504},"10.1002\u002Fjmv.10534",{"id":26,"text":1506,"url":26,"identifiers":1507},"Chen CH, Lee CM, Lu SN, et al.:Clinical significance of hepatitis B virus (HBV) genotypes and precore and core promoter mutations affecting HBV e antigen expression in Taiwan.J Clin Microbiol 2005,43:6000–6006.",{"doi":1508},"10.1128\u002FJCM.43.12.6000-6006.2005",{"id":26,"text":1510,"url":26,"identifiers":1511},"Mayerat C, Mantegani A, Frei PC:Does hepatitis B virus (HBV) genotype influence the clinical outcome of HBV infection? J Viral Hepat 1999,6:299–304.",{"doi":1512},"10.1046\u002Fj.1365-2893.1999.00174.x",{"id":26,"text":1514,"url":26,"identifiers":1515},"Thakur V, Guptan RC, Kazim SN, et al.:Profile, spectrum and significance of HBV genotypes in chronic liver disease patients in the Indian subcontinent.J Gastroenterol Hepatol 2002,17:165–170.",{"doi":1516},"10.1046\u002Fj.1440-1746.2002.02605.x",{"id":26,"text":1518,"url":26,"identifiers":1519},"Sanchez-Tapias JM, Costa J, Mas A, et al.:Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients.Gastroenterology 2002,123:1848–1856.",{"doi":1520},"10.1053\u002Fgast.2002.37041",{"id":26,"text":1522,"url":26,"identifiers":1523},"Rodriguez-Frias F, Jardi R, Buti M, et al.:Hepatitis B virus genotypes and G1896A precore mutation in 486 Spanish patients with acute and chronic HBV infection.J Viral Hepat 2006,13:343–350.",{"doi":1524},"10.1111\u002Fj.1365-2893.2005.00691.x",{"id":26,"text":1526,"url":26,"identifiers":1527},"Wai CT, Fontana RJ, Polson J, et al.:Clinical outcome and virological characteristics of hepatitis B-related acute liver failure in the United States.J Viral Hepat 2005,12:192–198.",{"doi":1528},"10.1111\u002Fj.1365-2893.2005.00581.x",{"id":26,"text":1530,"url":26,"identifiers":1531},"Ozasa A, Tanaka Y, Orito E, et al.:Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection.Hepatology 2006,44:326–334.",{"doi":1532},"10.1002\u002Fhep.21249",{"id":26,"text":1534,"url":26,"identifiers":1535},"Liaw YF, Leung N, Guan R, et al.:Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update.Liver Int 2005,25:472–489.",{"doi":1536},"10.1111\u002Fj.1478-3231.2005.01134.x",{"id":26,"text":1538,"url":26,"identifiers":1539},"Kao JH, Wu NH, Chen PJ, et al.:Hepatitis B genotypes and the response to interferon therapy.J Hepatol 2000,33:998–1002.",{"doi":1540},"10.1016\u002FS0168-8278(00)80135-X",{"id":26,"text":1542,"url":26,"identifiers":1543},"Wai CT, Chu CJ, Hussain M, Lok AS:HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C.Hepatology 2002,36:1425–1430.",{},{"id":26,"text":1545,"url":26,"identifiers":1546},"Liu CJ, Lai MY, Chao YC, et al.:Interferon alpha-2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B: a randomized study.Hepatology 2006,43:742–749.",{"doi":1547},"10.1002\u002Fhep.21100",{"id":26,"text":1549,"url":26,"identifiers":1550},"Hou J, Schilling R, Janssen HL:Molecular characteristics of hepatitis B virus genotype A confer a higher response to interferon treatment.J Hepatol 2001,34(suppl 1):15.",{"doi":1551},"10.1016\u002FS0168-8278(01)80922-3",{"id":26,"text":1553,"url":26,"identifiers":1554},"Erhardt A, Blondin D, Hauck K, et al.:Response to interferon alfa is hepatitis B virus genotype dependent: Genotype A is more sensitive to interferon than genotype D.Gut 2005,54:1009–1013.",{"doi":1555},"10.1136\u002Fgut.2004.060327",{"id":26,"text":1557,"url":26,"identifiers":1558},"Cooksley WG, Piratvisuth T, Lee SD, et al.:Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.J Viral Hepat 2003,10:298–305.",{"doi":1559},"10.1046\u002Fj.1365-2893.2003.00450.x",{"id":26,"text":1561,"url":26,"identifiers":1562},"Janssen HL, van Zonneveld M, Senturk H, et al.:Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomized trial.Lancet 2005,365:123–129.",{"doi":1563},"10.1016\u002FS0140-6736(05)17701-0",{"id":26,"text":1565,"url":26,"identifiers":1566},"Flink HJ, Zonneveld M, Hansen BE, et al.:Treatment with peg-interferon alfa-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype.Am J Gastroenterol 2006,101:297–303.",{"doi":1567},"10.1111\u002Fj.1572-0241.2006.00418.x",{"id":26,"text":1569,"url":26,"identifiers":1570},"Cooksley G, Manns M, Lau GKK, et al.:Effect of genotype and other baseline factors on response to peginterferon alfa-2a (40KD) (Pegasys) in HBeAg-positive chronic hepatitis B: results from a large, randomized study.J Hepatol 2005,42(suppl 2):30.",{},{"id":26,"text":1572,"url":26,"identifiers":1573},"Hadziyannis S, Lau GKK, Marcellin P, et al.:Sustained HBsAg seroconversion in patients with chronic hepatitis B treated with peginterferon alfa-2a (40 kDa) (Pegasys).J Hepatol 2005,42(suppl 2):178.",{},{"id":26,"text":1575,"url":26,"identifiers":1576},"Kao JH, Liu CJ, Chen DS:Hepatitis B viral genotypes and lamivudine resistance [letter].J Hepatol 2002,36:303–304.",{"doi":1577},"10.1016\u002FS0168-8278(01)00246-X",{"id":26,"text":1579,"url":26,"identifiers":1580},"Yuen MF, Wong DK, Sablon E, et al.:Hepatitis B virus genotypes B and C do not affect the antiviral response to lamivudine.Antivir Ther 2003,8:531–534.",{"doi":1581},"10.1177\u002F135965350300800610",{"id":26,"text":1583,"url":26,"identifiers":1584},"Chan HL, Wong ML, Hui AY, et al.:Hepatitis B virus genotype has no impact on hepatitis B e antigen seroconversion after lamivudine treatment.World J Gastroenterol 2003,9:2695–2697.",{"doi":1585},"10.3748\u002Fwjg.v9.i12.2695",{"id":26,"text":1587,"url":26,"identifiers":1588},"Buti M, Cotrina M, Valdes A, et al.:Is hepatitis B virus subtype testing useful in predicting virological response and resistance to lamivudine? J Hepatol 2002,36:445–446.",{"doi":1589},"10.1016\u002FS0168-8278(01)00283-5",{"id":26,"text":1591,"url":26,"identifiers":1592},"Chien RN, Yeh CT, Tsai SL, et al.:Determinants for sustained HBeAg response to lamivudine therapy.Hepatology 2003,38:1267–1273.",{"doi":1593},"10.1053\u002Fjhep.2003.50458",{"id":26,"text":1595,"url":26,"identifiers":1596},"Zollner B, Petersen J, Schroter M, et al.:20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw.Lancet 2001,357:934–935.",{"doi":1597},"10.1016\u002FS0140-6736(00)04219-7",{"id":26,"text":1599,"url":26,"identifiers":1600},"Zollner B, Petersen J, Puchhammer-Stockl E, et al.:Viral features of lamivudine resistant hepatitis B genotypes A and D.Hepatology 2004,39:42–50.",{"doi":1601},"10.1002\u002Fhep.20016",{"id":26,"text":1603,"url":26,"identifiers":1604},"Akuta N, Suzuki F, Kobayashi M, et al.:The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment.J Hepatol 2003,38:315–321.",{"doi":1605},"10.1016\u002FS0168-8278(02)00410-5",{"id":26,"text":1607,"url":26,"identifiers":1608},"Orito E, Fujiwara K, Tanaka Y, et al.:A case-control study of response to lamivudine therapy for 2 years in Japanese and Chinese patients chronically infected with hepatitis B virus of genotypes Bj, Ba and C.Hepatol Res 2006,35:127–134.",{"doi":1609},"10.1016\u002Fj.hepres.2006.03.005",{"id":26,"text":1611,"url":26,"identifiers":1612},"Westland C, Delaney W 4th, Yang H, et al.:Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil.Gastroenterology 2003,125:107–116.",{"doi":1613},"10.1016\u002FS0016-5085(03)00700-5",{"id":26,"text":1615,"url":26,"identifiers":1616},"Fung SK, Chae HB, Fontana RJ, et al.:Virologic response and resistance to adefovir in patients with chronic hepatitis B.J Hepatol 2006,44:283–290.",{"doi":1617},"10.1016\u002Fj.jhep.2005.10.018",{"id":26,"text":1619,"url":26,"identifiers":1620},"Lurie Y, Manns MP, Gish RG, et al.:The efficacy of entecavir is similar regardless of disease-related baseline subgroups in treatment of nucleoside-naïve HBeAg(+) and HBeAg(−) patients with chronic hepatitis B.J Hepatol 2005,42(suppl 2):184.",{},{"id":26,"text":1622,"url":26,"identifiers":1623},"Liu CJ, Kao JH, Chen DS:Mixed hepatitis B virus genotype infections: the more, the worse? [letter].Hepatology 2006,44:770.",{"doi":1624},"10.1002\u002Fhep.21342",{"id":26,"text":1626,"url":26,"identifiers":1627},"Chen BF, Chen PJ, Jow GM, et al.:High prevalence of mixed genotype infections in hepatitis B virus infected intravenous drug users.J Med Virol 2004,74:536–542.",{"doi":1628},"10.1002\u002Fjmv.20211",{"id":26,"text":1630,"url":26,"identifiers":1631},"Chen BF, Kao JH, Liu CJ, et al.:Genotypic dominance and novel recombinations in HBV genotype B and C co-infected intravenous drug users.J Med Virol 2004,73:13–22.",{"doi":1632},"10.1002\u002Fjmv.20051",{"id":26,"text":1634,"url":26,"identifiers":1635},"Chen BF, Liu CJ, Jow GM, et al.:Evolution of hepatitis B virus in an acute hepatitis B patient co-infected with genotypes B and C.J Gen Virol 2006,87:39–49.",{"doi":1636},"10.1099\u002Fvir.0.81357-0",{"id":26,"text":1638,"url":26,"identifiers":1639},"Toan NL, Song LH, Kremsner PG, et al.:Impact of the hepatitis B virus genotype and genotype mixtures on the course of liver disease in Vietnam.Hepatology 2006,43:1375–1384.",{"doi":1640},"10.1002\u002Fhep.21188",{"id":26,"text":1642,"url":26,"identifiers":1643},"Liu CJ, Chen PJ, Wang HY, et al.:Lack of interferon sensitivity-determining region in the genome of hepatitis B virus genotype Ba.Antivir Ther 2004,9:895–903.",{"doi":1644},"10.1177\u002F135965350400900603",{"id":26,"text":1646,"url":26,"identifiers":1647},"Jazayeri MS, Basuni AA, Cooksley G, et al.:Hepatitis B virus genotypes, core gene variability and ethnicity in the Pacific region.J Hepatol 2004,41:139–146.",{"doi":1648},"10.1016\u002Fj.jhep.2004.03.025",{"id":26,"text":1650,"url":26,"identifiers":1651},"Lin CL, Kao JH, Chen BF, et al.:Application of hepatitis B virus genotyping and phylogenetic analysis in intrafamilial transmission of hepatitis B virus.Clin Infect Dis 2005,41:1576–1581.",{"doi":1652},"10.1086\u002F497837",{"id":26,"text":1654,"url":26,"identifiers":1655},"Lobato C, Tavares-Neto J, Rios-Leite M, et al.:Intrafamilial prevalence of hepatitis B virus in Western Brazilian Amazon region: epidemiologic and biomolecular study.J Gastroenterol Hepatol 2006,21:863–868.",{"doi":1656},"10.1111\u002Fj.1440-1746.2006.04298.x",{"id":26,"text":1658,"url":26,"identifiers":1659},"Keeffe EB, Dieterich DT, Han SB, et al.:A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update.Clin Gastroenterol Hepatol 2006,4:936–962.",{"doi":1660},"10.1016\u002Fj.cgh.2006.05.016",{"id":1662,"createTime":1663,"updateTime":1664,"relativeEntities":1665,"slug":1666,"properties":1667,"entityType":725,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":1678,"translateLanguages":26,"viewCount":36,"primaryUrl":1679,"fullTextUrl":26,"authors":1680,"publicationType":768,"publisherRelationship":1735,"citationCount":162,"citationInfo":1756,"publishDate":1758,"publishYear":1759,"citationAnalyzeStatus":1422,"lastCitationAnalyze":1664,"indexDatabases":26,"openAccess":26,"references":1760,"isForceReanalyzing":1000},"e1410380-0a6e-46a9-b56a-d35b884908a9","2024-04-14T12:31:20.317+00:00","2024-04-15T01:53:12.789+00:00",[],"Partial-Response-to-Entecavir-and-Tenofovir-in-Na%C3%AFve-Patients-with-Chronic-Hepatitis-B-Clinical-Relevance-and-Management",{"mag":1668,"keywords":1670,"openalex":1671,"abstract":1673,"title":1674,"doi":1676},{"VOID":1669},"2041655759",{},{"VOID":1672},"W2041655759",{},{"EN":1675},"Partial Response to Entecavir and Tenofovir in Naïve Patients with Chronic Hepatitis B: Clinical Relevance and Management",{"VOID":1677},"10.1007\u002Fs11901-012-0127-5",[102],"http:\u002F\u002Flink.springer.com\u002F10.1007\u002Fs11901-012-0127-5",[1681,1701,1719],{"id":1682,"sortIndex":115,"researcher":26,"roles":1683,"affiliations":1684,"properties":1694},"d11c4fcf-b23c-4036-af2e-ce9529ce33ae",[],[1685],{"id":26,"sortIndex":36,"affiliation":1686,"properties":26},{"id":1687,"createTime":1688,"updateTime":1688,"relativeEntities":1689,"slug":1690,"properties":1691,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"aa5c3cba-26a2-45e7-b5b7-7b5ab33dff62","2024-04-14T12:31:20.341+00:00",[],"Hepatology-Unit-Ospedale-San-Giuseppe-Universit%C3%A0-degli-Studi-di-Milano-Milan-Italy",{"title":1692},{"EN":1693},"Hepatology Unit, Ospedale San Giuseppe, Università degli Studi di Milano, Milan, Italy",{"openalex":1695,"orcid":1697,"title":1699},{"VOID":1696},"A5016061964",{"VOID":1698},"https:\u002F\u002Forcid.org\u002F0000-0003-0769-1767",{"EN":1700},"M. Viganò",{"id":1702,"sortIndex":114,"researcher":26,"roles":1703,"affiliations":1704,"properties":1714},"13aa9f70-bfbf-4725-94bb-b87e0ca55628",[],[1705],{"id":26,"sortIndex":36,"affiliation":1706,"properties":26},{"id":1707,"createTime":1708,"updateTime":1708,"relativeEntities":1709,"slug":1710,"properties":1711,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"1a592f0b-6666-4564-9ed8-819bd9644742","2024-04-14T12:31:20.328+00:00",[],"1st-Division-of-Gastroenterology-Fondazione-IRCCS-Ca-Granda-Ospedale-Maggiore-Policlinico-Universit%C3%A0-di-Milano-Via-Francesco-Sforza-35-20122-Milan-Italy",{"title":1712},{"EN":1713},"1st Division of Gastroenterology, Fondazione IRCCS Ca’ Granda—Ospedale Maggiore Policlinico, Università di Milano, Via Francesco Sforza 35, 20122, Milan, Italy",{"openalex":1715,"title":1717},{"VOID":1716},"A5063864088",{"EN":1718},"Massimo Colombo",{"id":1720,"sortIndex":36,"researcher":26,"roles":1721,"affiliations":1722,"properties":1728},"5854efc4-8936-4433-86d9-e93328c48590",[],[1723],{"id":26,"sortIndex":36,"affiliation":1724,"properties":26},{"id":1707,"createTime":1708,"updateTime":1708,"relativeEntities":1725,"slug":1710,"properties":1726,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1727},{"EN":1713},{"openalex":1729,"orcid":1731,"title":1733},{"VOID":1730},"A5074836130",{"VOID":1732},"https:\u002F\u002Forcid.org\u002F0000-0002-1026-7476",{"EN":1734},"Pietro Lampertico",{"url":26,"publisher":1736,"properties":26},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":1737,"slug":663,"properties":1738,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":1742,"manageAffiliations":1743,"indexDatabases":1744,"url":691,"thumbnailPath":26,"statistic":1751,"gsStatistic":26,"type":175,"analyzePriority":26},[],{"issn":1739,"eissn":1740,"title":1741},{"VOID":666},{"VOID":668},{"EN":670},[],[],[1745],{"id":675,"indexDatabase":1746,"url":688,"indexYears":689,"academicFieldIds":26,"indexDatabaseRanking":690},{"id":677,"createTime":678,"updateTime":679,"relativeEntities":1747,"label":1748,"description":1749,"key":685,"publicationTags":1750,"standard":26},[],{"EN":682,"VI":682},{"EN":682,"VI":684},[687],{"impactFactor":36,"impactFactorByYear":1752,"i10Index":59,"i10IndexLast5Year":36,"totalPublication":694,"totalPublicationByYear":1753,"totalCitation":536,"totalCitationByYear":1754,"totalCitationPerPublication":132,"totalCitationPerPublicationByYear":1755,"hindexLast5Year":162,"hindex":162},{"2012":231,"2013":229,"2014":39},{"2002":111,"2003":336,"2004":173,"2005":234,"2006":234,"2007":162,"2008":234,"2009":237,"2010":241,"2011":516,"2012":241,"2013":51},{"2003":114,"2004":114,"2005":59,"2006":53,"2007":50,"2008":234,"2009":115,"2010":285,"2011":114,"2012":135,"2013":115},{"2003":404,"2004":206,"2005":57,"2006":698,"2007":699,"2008":115,"2009":230,"2010":266,"2011":108,"2012":477,"2013":110},{"total":162,"publishYear":26,"statisticByYear":1757},{"2013":115,"2014":115,"2015":114,"2016":115},"2012-06-01",2012,[1761,1764,1768,1772,1776,1779,1783,1786,1789,1793,1796,1800,1804,1807,1811,1815,1819,1823,1827,1831,1834,1837,1841,1845,1848,1852],{"id":26,"text":1762,"url":26,"identifiers":1763},"•• European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227–42. The most recent and update international practice guidelines in the management of patients with chronic hepatitis B.",{"doi":811},{"id":26,"text":1765,"url":26,"identifiers":1766},"Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661–2.",{"doi":1767},"10.1002\u002Fhep.23190",{"id":26,"text":1769,"url":26,"identifiers":1770},"Lampertico P. Partial virological response to nucleos(t)ide analogues in naïve patients with chronic hepatitis B: from guidelines to field practice. J Hepatol. 2009;50:644–7.",{"doi":1771},"10.1016\u002Fj.jhep.2009.01.007",{"id":26,"text":1773,"url":26,"identifiers":1774},"Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology. 2009;137:1593–608.",{"doi":1775},"10.1053\u002Fj.gastro.2009.08.063",{"id":26,"text":1777,"url":26,"identifiers":1778},"Chang TT, Gish RG, de Man R, et al. BEHoLD AI463022 study group. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354:1001–10.",{"doi":979},{"id":26,"text":1780,"url":26,"identifiers":1781},"Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354:1011–20.",{"doi":1782},"10.1056\u002FNEJMoa051287",{"id":26,"text":1784,"url":26,"identifiers":1785},"• Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology. 2009;49:1503–14. In this long-term study in NUCs-naïve patients treated with ETV, the 5-year cumulative probability of genotypic ETV-resistance was 1.2%.",{"doi":889},{"id":26,"text":1787,"url":26,"identifiers":1788},"Leung N, Peng CY, Hann HW, et al. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir. Hepatology. 2009;49:72–9.",{"doi":964},{"id":26,"text":1790,"url":26,"identifiers":1791},"• Liaw YF, Raptopoulou-Gigi M, Cheinquer H, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology. 2011;54:91–100. This randomized, open-label comparative study in subjects with CHB and hepatic decompensation showed that patients treated with ETV had a higher rate of undetectable serum HBV DNA at weeks 48 compared to those treated with ADV.",{"doi":1792},"10.1002\u002Fhep.24361",{"id":26,"text":1794,"url":26,"identifiers":1795},"Lampertico P, Viganò M, Facchetti F, et al. Effectiveness and safety of entecavir treatment of nucleos(t)ide-naïve chronic hepatitis B patients: a 4-year multicenter field practice study of 418 patients in Italy. (submitted)",{},{"id":26,"text":1797,"url":26,"identifiers":1798},"•• Zoutendijk R, Reijnders JG, Brown A, et al. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response. Hepatology. 2011;54:443–51. This study showed that ETV monotherapy can be continued in NUCs-naïve patients with detectable HBV DNA at week 48, particularly in those with a viral load \u003C1,000 IU\u002FmL because long-term ETV leads to a virological response in the vast majority of those patients.",{"doi":1799},"10.1002\u002Fhep.24406",{"id":26,"text":1801,"url":26,"identifiers":1802},"Chon YE, Kim SU, Lee CK, et al. Partial virological response to entecavir in treatment-naive patients with chronic hepatitis B. Antivir Ther. 2011;16:469–77.",{"doi":1803},"10.3851\u002FIMP1772",{"id":26,"text":1805,"url":26,"identifiers":1806},"Lok AS, Trinh HN, Carosi G, et al. Entecavir (ETV) monotherapy for 96 weeks is comparable to combination therapy with ETV plus tenofovir (TDF) in nucleos(t)ide-naive patients with chronic hepatitis B (CHB): the below study. Hepatology. 2011;54:471A.",{},{"id":26,"text":1808,"url":26,"identifiers":1809},"Lee JM, Ahn SH, Kim HS, et al. Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. Hepatology. 2011;53:1486–93.",{"doi":1810},"10.1002\u002Fhep.24221",{"id":26,"text":1812,"url":26,"identifiers":1813},"Ha NB, Ha NB, Garcia RT, et al. Medication nonadherence with long-term management of patients with hepatitis B e antigen-negative chronic hepatitis B. Dig Dis Sci. 2011;56:2423–31.",{"doi":1814},"10.1007\u002Fs10620-011-1610-5",{"id":26,"text":1816,"url":26,"identifiers":1817},"Suzuki F, Akuta N, Suzuki Y, et al. Selection of a virus strain resistant to entecavir in a nucleoside-naıve patient with hepatitis B of genotype H. J Clin Virol. 2007;39:149–52.",{"doi":1818},"10.1016\u002Fj.jcv.2007.03.004",{"id":26,"text":1820,"url":26,"identifiers":1821},"Guo JJ, Li QL, Shic XF, et al. Dynamics of hepatitis B virus resistance to entecavir in a nucleoside\u002Fnucleotide-naıve patient. Antiviral Res. 2009;81:180–3.",{"doi":1822},"10.1016\u002Fj.antiviral.2008.09.004",{"id":26,"text":1824,"url":26,"identifiers":1825},"Kobashi H, Fujioka S, Kawaguchi M, et al. Two cases of development of entecavir resistance during entecavir treatment for nucleoside-naive chronic hepatitis B. Hepatol Int. 2009;3:403–10.",{"doi":1826},"10.1007\u002Fs12072-008-9108-8",{"id":26,"text":1828,"url":26,"identifiers":1829},"Yuen MF, Seto WK, Fung J, et al. Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: viral suppression, viral resistance, and clinical safety. Am J Gastroenterol. 2011;106:1264–71.",{"doi":1830},"10.1038\u002Fajg.2011.45",{"id":26,"text":1832,"url":26,"identifiers":1833},"•• Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359:2442–55. In this large multinational trial in chronic hepatitis B patients, TDF at a daily dose of 300 mg had superior antiviral efficacy with a similar safety profile as compared with ADV at a daily dose of 10 mg through week 48.",{"doi":924},{"id":26,"text":1835,"url":26,"identifiers":1836},"Marcellin P, Heathcote EJ, Corsa A, et al. No detectable resistance to tenofovir disoproxil fumarate (TDF) following 240 weeks of treatment in patients with HBeAg + and HBeAg- chronic hepatitis B virus infection. Hepatology. 2011;54:480A.",{},{"id":26,"text":1838,"url":26,"identifiers":1839},"Liaw YF, Sheen IS, Lee CM, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine\u002FTDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology. 2011;53:62–72.",{"doi":1840},"10.1002\u002Fhep.23952",{"id":26,"text":1842,"url":26,"identifiers":1843},"Lampertico P, Soffredini R, Viganò M, et al. 2-year effectiveness and safety of tenofovir in 302 NUC-naïve patients with chronic hepatitis B: a multicenter European study in clinical practice. Hepatology. 2011;54:1041A.",{"doi":1844},"10.1016\u002Fj.jhep.2010.12.001",{"id":26,"text":1846,"url":26,"identifiers":1847},"Carey I, Nguyen HL, Joe D, et al. De-novo antiviral therapy with nucleos(t)ide analogues in “real-life” patients with chronic hepatitis B infection: comparison of virological response between lamivudine + adefovir vs entecavir vs tenofovir therapy. Hepatology. 2011;54:1022A.",{},{"id":26,"text":1849,"url":26,"identifiers":1850},"Pan C, Hu K, Yu AS, et al. Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir. J Viral Hep 2011, in press",{"doi":1851},"10.1111\u002Fj.1365-2893.2011.01533.x",{"id":26,"text":1853,"url":26,"identifiers":1854},"Sarrecchia C, Svicher V, Volpi A, et al. Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance. Infection. 2011;39:367–70.",{"doi":1855},"10.1007\u002Fs15010-011-0127-3",{"id":1857,"createTime":1858,"updateTime":1859,"relativeEntities":1860,"slug":1861,"properties":1862,"entityType":725,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":1873,"translateLanguages":26,"viewCount":36,"primaryUrl":1874,"fullTextUrl":26,"authors":1875,"publicationType":768,"publisherRelationship":1908,"citationCount":59,"citationInfo":1929,"publishDate":1931,"publishYear":1932,"citationAnalyzeStatus":1422,"lastCitationAnalyze":1859,"indexDatabases":26,"openAccess":26,"references":1933,"isForceReanalyzing":1000},"be5cd4b7-7a1f-49ef-b600-52ee19f64abd","2024-04-14T19:19:23.434+00:00","2024-04-15T10:15:11.891+00:00",[],"Treatment-of-HCV-infection-with-pegylated-interferons",{"mag":1863,"keywords":1865,"openalex":1866,"abstract":1868,"title":1869,"doi":1871},{"VOID":1864},"2035976944",{},{"VOID":1867},"W2035976944",{},{"EN":1870},"Treatment of HCV infection with pegylated interferons",{"VOID":1872},"10.1007\u002Fs11901-005-0014-4",[102],"http:\u002F\u002Flink.springer.com\u002F10.1007\u002Fs11901-005-0014-4",[1876,1894],{"id":1877,"sortIndex":36,"researcher":26,"roles":1878,"affiliations":1879,"properties":1889},"d957f5c1-bd18-4883-8d60-7302d4854f2f",[],[1880],{"id":26,"sortIndex":36,"affiliation":1881,"properties":26},{"id":1882,"createTime":1883,"updateTime":1883,"relativeEntities":1884,"slug":1885,"properties":1886,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"18cf237f-0efd-4ffa-b96f-7ecc9d53d551","2024-04-14T19:19:23.457+00:00",[],"Hepatobiliary-Group-Centre-for-Adult-and-Paediatric-Gastroenterology-Barts-The-London-Queen-Mary-s-School-of-Medicine-and-Dentistry-London-UK",{"title":1887},{"EN":1888},"Hepatobiliary Group, Centre for Adult and Paediatric Gastroenterology, Barts & The London Queen Mary’s School of Medicine and Dentistry, London, UK",{"openalex":1890,"title":1892},{"VOID":1891},"A5071679284",{"EN":1893},"Graham Foster",{"id":1895,"sortIndex":115,"researcher":26,"roles":1896,"affiliations":1897,"properties":1903},"e36b17da-b083-4f2b-9fd8-823c791bd7d8",[],[1898],{"id":26,"sortIndex":36,"affiliation":1899,"properties":26},{"id":1882,"createTime":1883,"updateTime":1883,"relativeEntities":1900,"slug":1885,"properties":1901,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1902},{"EN":1888},{"openalex":1904,"title":1906},{"VOID":1905},"A5024273391",{"EN":1907},"Abid Suddle",{"url":26,"publisher":1909,"properties":26},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":1910,"slug":663,"properties":1911,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":1915,"manageAffiliations":1916,"indexDatabases":1917,"url":691,"thumbnailPath":26,"statistic":1924,"gsStatistic":26,"type":175,"analyzePriority":26},[],{"issn":1912,"eissn":1913,"title":1914},{"VOID":666},{"VOID":668},{"EN":670},[],[],[1918],{"id":675,"indexDatabase":1919,"url":688,"indexYears":689,"academicFieldIds":26,"indexDatabaseRanking":690},{"id":677,"createTime":678,"updateTime":679,"relativeEntities":1920,"label":1921,"description":1922,"key":685,"publicationTags":1923,"standard":26},[],{"EN":682,"VI":682},{"EN":682,"VI":684},[687],{"impactFactor":36,"impactFactorByYear":1925,"i10Index":59,"i10IndexLast5Year":36,"totalPublication":694,"totalPublicationByYear":1926,"totalCitation":536,"totalCitationByYear":1927,"totalCitationPerPublication":132,"totalCitationPerPublicationByYear":1928,"hindexLast5Year":162,"hindex":162},{"2012":231,"2013":229,"2014":39},{"2002":111,"2003":336,"2004":173,"2005":234,"2006":234,"2007":162,"2008":234,"2009":237,"2010":241,"2011":516,"2012":241,"2013":51},{"2003":114,"2004":114,"2005":59,"2006":53,"2007":50,"2008":234,"2009":115,"2010":285,"2011":114,"2012":135,"2013":115},{"2003":404,"2004":206,"2005":57,"2006":698,"2007":699,"2008":115,"2009":230,"2010":266,"2011":108,"2012":477,"2013":110},{"total":59,"publishYear":26,"statisticByYear":1930},{"2019":115,"2020":114},"2005-05-01",2005,[1934,1938,1942,1946,1950,1954,1958,1962,1966,1970,1974,1978,1982,1985,1988,1992,1996,2000,2004,2008,2012,2016,2020,2024,2028,2031,2035,2039,2042,2046,2050,2054,2058,2062,2066,2069,2073,2077,2081,2085,2089,2093],{"id":26,"text":1935,"url":26,"identifiers":1936},"National Institute of Health Consensus Development Conference Panel statement: management of hepatitis C [no authors listed]. Hepatology 1997, 26:2S–10S.",{"doi":1937},"10.1002\u002Fhep.510260701",{"id":26,"text":1939,"url":26,"identifiers":1940},"Seeff LB, Buskell-Bates Z, Wright EC, et al.: Long-term mortality after transfusion-associated non-A non-B hepatitis. N Engl J Med. 1992, 327:1906–1911.",{"doi":1941},"10.1056\u002FNEJM199212313272703",{"id":26,"text":1943,"url":26,"identifiers":1944},"Seeff LB: Natural history of hepatitis C. Hepatology. 1997, 26:21S-28S.",{"doi":1945},"10.1002\u002Fhep.510260704",{"id":26,"text":1947,"url":26,"identifiers":1948},"Hoofnagle JH: Hepatitis C: the clinical spectrum of disease. Hepatology. 1997, 26:15S-20S.",{"doi":1949},"10.1002\u002Fhep.510260703",{"id":26,"text":1951,"url":26,"identifiers":1952},"Di Bisceglie AM: Natural history of hepatitis C: its impact on clinical management. Hepatology. 2000, 31:1014–1018.",{"doi":1953},"10.1053\u002Fhe.2000.5762",{"id":26,"text":1955,"url":26,"identifiers":1956},"Seeff LB, Hollinger B, Alter AJ, et al.: Long-term morbidity of post transfusion hepatitis C. Hepatology. 1998, 28:407A.",{"doi":1957},"10.1002\u002Fhep.510280636",{"id":26,"text":1959,"url":26,"identifiers":1960},"Fattovich G, Guistina G, Degos F, et al.: Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997, 112:463–472.",{"doi":1961},"10.1053\u002Fgast.1997.v112.pm9024300",{"id":26,"text":1963,"url":26,"identifiers":1964},"Serfaty L, Aumaitre H, Chazouileres O, et al.: Determinants of outcome of compensated hepatitis C virus related cirrhosis. Hepatology. 1998, 27:1435–1440.",{"doi":1965},"10.1002\u002Fhep.510270535",{"id":26,"text":1967,"url":26,"identifiers":1968},"Yano M, Kumada H, Kage M, et al.: The long-term pathological evolution of chronic hepatitis C. Hepatology. 1996, 23:1334–1340.",{"doi":1969},"10.1002\u002Fhep.510230607",{"id":26,"text":1971,"url":26,"identifiers":1972},"Poynard T, Bedossa P, Opolon P: Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet. 1997, 349:825–832.",{"doi":1973},"10.1016\u002FS0140-6736(96)07642-8",{"id":26,"text":1975,"url":26,"identifiers":1976},"Lindsay KL: Therapy of chronic hepatitis C: overview. Hepatology. 1997, 26(suppl):71S-77S.",{"doi":1977},"10.1002\u002Fhep.510260713",{"id":26,"text":1979,"url":26,"identifiers":1980},"Craxi A, Almasio P, Schalm S: Evaluation of efficacy of antiviral therapy for chronic hepatitis C: a EUROHEP Consensus Report on response criteria. J Viral Hepat. 1996, 3:273–276.",{"doi":1981},"10.1111\u002Fj.1365-2893.1996.tb00055.x",{"id":26,"text":1983,"url":26,"identifiers":1984},"Craxi A, Camma C, Guinta M: Definition of response. Paper presented at the EASL International Consensus Conference on Hepatitis C (suppl). Paris, France; February 26–28, 1999.",{},{"id":26,"text":1986,"url":26,"identifiers":1987},"Booth JCL: Current clinical practise guidelines on the management of HCV. In The Effective Management of Hepatitis C Infection, edn 2. Edited by Bossendine M, et al. London: Aesculapius Press; 2003:55–74.",{},{"id":26,"text":1989,"url":26,"identifiers":1990},"Angelini G, Sgarbi D, Colombari R, et al.: Alpha-interferon treatment of chronic hepatitis C: a controlled, multi-centre, prospective study. Digestion. 1995, 56:199–203.",{"doi":1991},"10.1159\u002F000201243",{"id":26,"text":1993,"url":26,"identifiers":1994},"Poynard T, Bedossa P, Chevallier M, et al.: A comparison of three interferon alpha 2b regimens for long term treatment of chronic non-A, non-B hepatitis. N Engl J Med. 1995, 332:1457–1462.",{"doi":1995},"10.1056\u002FNEJM199506013322201",{"id":26,"text":1997,"url":26,"identifiers":1998},"Reichard O, Foberg U, Fryden A, et al.: High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon alpha 2b for 60 weeks. Hepatology. 1994, 19:280–285.",{"doi":1999},"10.1002\u002Fhep.1840190204",{"id":26,"text":2001,"url":26,"identifiers":2002},"Tsubota A, Chayama K, Ikeda K, et al.: Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology. 1994, 19:1088–1094.",{"doi":2003},"10.1002\u002Fhep.1840190505",{"id":26,"text":2005,"url":26,"identifiers":2006},"Martinot-Peignoux M, Marcellin P, Pouteau M, et al.: Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alpha therapy in chronic hepatitis C. Hepatology. 1995, 22:1050–1056.",{"doi":2007},"10.1002\u002Fhep.1840220406",{"id":26,"text":2009,"url":26,"identifiers":2010},"McHutchinson JG, Gordon ST, Schiff ER, et al.: Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. The Hepatitis Interventional Therapy Group. N Engl J Med. 1998, 339:1485–1492.",{"doi":2011},"10.1056\u002FNEJM199811193392101",{"id":26,"text":2013,"url":26,"identifiers":2014},"Poynard T, Marcellin P, Lee S, et al.: Randomised trial of interferon alpha-2b plus ribavirin for 48 weeks or 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet. 1998, 352:1426–1432.",{"doi":2015},"10.1016\u002FS0140-6736(98)07124-4",{"id":26,"text":2017,"url":26,"identifiers":2018},"Brillianti S, Garson J, Foli M, et al.: A pilot study of combination therapy with ribavirin plus interferon alpha for interferon alpha resistant chronic hepatitis C. Gastroenterology 1994, 107:812–817.",{"doi":2019},"10.1016\u002F0016-5085(94)90131-7",{"id":26,"text":2021,"url":26,"identifiers":2022},"Davis GL, Mur RE, Rustgi V, et al.: Interferon alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. The Hepatitis Interventional Therapy Group. N Engl J Med. 1998, 339:1493–1499.",{"doi":2023},"10.1056\u002FNEJM199811193392102",{"id":26,"text":2025,"url":26,"identifiers":2026},"Wills RJ: Clinical pharmacokinetics of interferons. Clin Pharmacokinet. 1990, 19:390–399.",{"doi":2027},"10.2165\u002F00003088-199019050-00003",{"id":26,"text":2029,"url":26,"identifiers":2030},"Xu ZX, Patel I, Joubert P: Single dose safety\u002Ftolerability and pharmacokinetics\u002Fpharmacodynamics following ascending subcutaneous doses of pegylated-interferon (PEG-IFN) and interferon alpha-2a (IFN alpha-2a) to healthy subjects [abstract]. Hepatology. 1998, 28(suppl):702.",{},{"id":26,"text":2032,"url":26,"identifiers":2033},"Reddy KR: Controlled-release, pegylation, liposomal formulations: new mechanisms in the delivery of injectable drugs. Ann Pharmacother. 2000, 34:915–923.",{"doi":2034},"10.1345\u002Faph.10054",{"id":26,"text":2036,"url":26,"identifiers":2037},"Glue P, Fang JW, Rouzier-Panis R, et al.: Pegylated interferon alpha-2b: pharmacokinetics, pharmacokinetics, pharmacodynamics, safety and preliminary efficacy. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther. 2000, 68:556–567.",{"doi":2038},"10.1067\u002Fmcp.2000.110973",{"id":26,"text":2040,"url":26,"identifiers":2041},"Modi M, Fried M, Reindollar R, et al.: The pharmacokinetics behaviour of pegylated (40 kDa) interferon alfa 2a (PEGASYS) in chronic hepatitis C infection after multiple dosing. Paper presented at the 51st Annual Meeting of the American Association for the Study of Liver Diseases. Dallas, TX; October 27–31, 2000.",{},{"id":26,"text":2043,"url":26,"identifiers":2044},"Lindsay K, Trepo C, Heintges T, et al.: Randomised, doubleblind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 2001, 34:395–403.",{"doi":2045},"10.1053\u002Fjhep.2001.26371",{"id":26,"text":2047,"url":26,"identifiers":2048},"Zeuzem S, Feinman SV, Rasenack J, et al.: Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000, 343:1666–1672.",{"doi":2049},"10.1056\u002FNEJM200012073432301",{"id":26,"text":2051,"url":26,"identifiers":2052},"Heathcote EJ, Shiffman ML, Cooksley WG, et al.: Peginterferon alpha-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med. 2000, 343:1673–1680.",{"doi":2053},"10.1056\u002FNEJM200012073432302",{"id":26,"text":2055,"url":26,"identifiers":2056},"Manns MP, McHutchinson J, Gordon SC, et al.: Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b as initial treatment for chronic hepatitis C: a randomised trial. Lancet. 2001, 358:958–965. Pivotal trial of peginterferon alfa-2b.",{"doi":2057},"10.1016\u002FS0140-6736(01)06102-5",{"id":26,"text":2059,"url":26,"identifiers":2060},"Fried MW, Shiffman ML, Reddy KR, et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C infection. N Engl J Med 2002, 347:975–982. Pivotal trial of peginterferon alfa-2a.",{"doi":2061},"10.1056\u002FNEJMoa020047",{"id":26,"text":2063,"url":26,"identifiers":2064},"Hadziyannis SJ, Sette H, Morgan TR, et al.: Peginterferon alpha-2a (40 kilodaltons) and ribavirin combination therapy in chronic hepatitis C: randomised study of the effect of treatment duration and ribavirin dosage. Ann Intern Med 2004, 140:346–355. Randomised trial examining different dosing regimens for peginterferon alfa-2a and ribavirin.",{"doi":2065},"10.7326\u002F0003-4819-140-5-200403020-00010",{"id":26,"text":2067,"url":26,"identifiers":2068},"Davis GL: Monitoring of viral levels during therapy of hepatitis C. Hepatology. 2002, 36(suppl):S145-S151.",{},{"id":26,"text":2070,"url":26,"identifiers":2071},"Hoofnagle JH, Di Bisceglie AM: The treatment of chronic viral hepatitis. N Engl J Med. 1997, 336:347–356.",{"doi":2072},"10.1056\u002FNEJM199701303360507",{"id":26,"text":2074,"url":26,"identifiers":2075},"EASL International Consensus Conference on Hepatitis C. Consensus statement [no authors listed]. J Hepatol 1999, 30:956–961.",{"doi":2076},"10.1016\u002FS0168-8278(99)80154-8",{"id":26,"text":2078,"url":26,"identifiers":2079},"Booth JCL, O’Grady J, Neuberger J: Clinical guidelines on the management of hepatitis C. Gut. 2001, 49(suppl):1–21.",{"doi":2080},"10.1136\u002Fgut.49.suppl_1.I1",{"id":26,"text":2082,"url":26,"identifiers":2083},"Stradler DB, Wright T, Thomas DL, Seeff LB: Diagnosis, management, and treatment of hepatitis C. AASLD Practice Guidelines. Hepatology. 2004, 39:1147–1171. Up-to-date evidence-based guidelines.",{"doi":2084},"10.1002\u002Fhep.20119",{"id":26,"text":2086,"url":26,"identifiers":2087},"Zeuzem S, Diago M, Gane E, et al.: Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with hepatitis C and normal aminotransferase levels. Gastroenterology. 2004, 127:1724–1732.",{"doi":2088},"10.1053\u002Fj.gastro.2004.09.050",{"id":26,"text":2090,"url":26,"identifiers":2091},"Jaekel E, Cornberg M, Wedemeyer H, et al.: Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med. 2001, 345:1452–1457.",{"doi":2092},"10.1056\u002FNEJMoa011232",{"id":26,"text":2094,"url":26,"identifiers":2095},"Gerlach JT, Diepolder HM, Zachoval R, et al.: Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology. 2003, 125:80–88.",{"doi":2096},"10.1016\u002FS0016-5085(03)00668-1",{"id":2098,"createTime":2099,"updateTime":2100,"relativeEntities":2101,"slug":2102,"properties":2103,"entityType":725,"verifyStatus":28,"verifyTime":2100,"verifyNote":1022,"syncStatus":28,"languages":2114,"translateLanguages":26,"viewCount":36,"primaryUrl":2115,"fullTextUrl":26,"authors":2116,"publicationType":768,"publisherRelationship":2145,"citationCount":59,"citationInfo":2172,"publishDate":2174,"publishYear":1099,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":2175,"isForceReanalyzing":1000},"8659ea28-a06a-4e22-8de9-bfa28df1c3b4","2024-04-18T06:58:30.945+00:00","2024-12-23T11:39:53.517+00:00",[],"Hepatitis-C-in-liver-transplant-patients",{"mag":2104,"keywords":2106,"openalex":2107,"abstract":2109,"title":2110,"doi":2112},{"VOID":2105},"2021330516",{},{"VOID":2108},"W2021330516",{},{"EN":2111},"Hepatitis C in liver transplant patients",{"VOID":2113},"10.1007\u002Fs11901-008-0012-4",[102],"http:\u002F\u002Flink.springer.com\u002F10.1007\u002Fs11901-008-0012-4",[2117,2136],{"id":2118,"sortIndex":115,"researcher":26,"roles":2119,"affiliations":2120,"properties":2131},"1e92cf37-aafd-4ebe-9a48-6dc3f8ea5ee5",[],[2121],{"id":2122,"sortIndex":36,"affiliation":2123,"properties":26},"46cd73c3-b857-4a84-a008-a28a58c3c85c",{"id":2124,"createTime":2125,"updateTime":2125,"relativeEntities":2126,"slug":2127,"properties":2128,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"3fc0dd5a-ce50-4395-bad6-44122b63122b","2024-04-18T06:58:30.970+00:00",[],"Albert-Einstein-College-of-Medicine-Montefiore-Einstein-Liver-Center-Bronx-USA",{"title":2129},{"EN":2130},"Albert Einstein College of Medicine, Montefiore-Einstein Liver Center, Bronx, USA",{"openalex":2132,"title":2134},{"VOID":2133},"A5056889276",{"EN":2135},"Paul J. Gaglio",{"id":2137,"sortIndex":36,"researcher":26,"roles":2138,"affiliations":2139,"properties":2140},"e00ce1b3-2236-41b9-97ef-63eb2227051e",[],[],{"openalex":2141,"title":2143},{"VOID":2142},"A5060499305",{"EN":2144},"Scott Fink",{"url":26,"publisher":2146,"properties":2166},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":2147,"slug":663,"properties":2148,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":2152,"manageAffiliations":2153,"indexDatabases":2154,"url":691,"thumbnailPath":26,"statistic":2161,"gsStatistic":26,"type":175,"analyzePriority":26},[],{"issn":2149,"eissn":2150,"title":2151},{"VOID":666},{"VOID":668},{"EN":670},[],[],[2155],{"id":675,"indexDatabase":2156,"url":688,"indexYears":689,"academicFieldIds":26,"indexDatabaseRanking":690},{"id":677,"createTime":678,"updateTime":679,"relativeEntities":2157,"label":2158,"description":2159,"key":685,"publicationTags":2160,"standard":26},[],{"EN":682,"VI":682},{"EN":682,"VI":684},[687],{"impactFactor":36,"impactFactorByYear":2162,"i10Index":59,"i10IndexLast5Year":36,"totalPublication":694,"totalPublicationByYear":2163,"totalCitation":536,"totalCitationByYear":2164,"totalCitationPerPublication":132,"totalCitationPerPublicationByYear":2165,"hindexLast5Year":162,"hindex":162},{"2012":231,"2013":229,"2014":39},{"2002":111,"2003":336,"2004":173,"2005":234,"2006":234,"2007":162,"2008":234,"2009":237,"2010":241,"2011":516,"2012":241,"2013":51},{"2003":114,"2004":114,"2005":59,"2006":53,"2007":50,"2008":234,"2009":115,"2010":285,"2011":114,"2012":135,"2013":115},{"2003":404,"2004":206,"2005":57,"2006":698,"2007":699,"2008":115,"2009":230,"2010":266,"2011":108,"2012":477,"2013":110},{"volume":2167,"pages":2169,"issue":2171},{"VOID":2168},"7",{"VOID":2170},"81-87",{"VOID":796},{"total":59,"publishYear":26,"statisticByYear":2173},{},"2008-06-01",[2176,2180,2184,2188,2192,2196,2200,2204,2208,2210,2214,2217,2221,2225,2229,2233,2236,2240,2244,2248,2252,2256,2260,2264,2268,2272,2276,2280,2284,2288,2292,2296,2300,2304,2308,2312,2316,2320,2324,2328,2332,2336,2340,2344,2348,2352,2356,2360],{"id":26,"text":2177,"url":26,"identifiers":2178},"Gane EJ, Portmann BC, Naoumov NV, et al.: Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996, 334:815–820.",{"doi":2179},"10.1056\u002FNEJM199603283341302",{"id":26,"text":2181,"url":26,"identifiers":2182},"Berenguer M, Ferrell L, Watson J, et al.: HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000, 32:673–684.",{"doi":2183},"10.1016\u002FS0168-8278(00)80231-7",{"id":26,"text":2185,"url":26,"identifiers":2186},"Berenguer M, Prieto M, Rayon JM, et al.: Natural history of clinically compensated HCV-related graft cirrhosis after liver transplantation. Hepatology 2000, 32:852–858.",{"doi":2187},"10.1053\u002Fjhep.2000.17924",{"id":26,"text":2189,"url":26,"identifiers":2190},"Forman LM, Lewis JD, Berlin JA, et al.: The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002, 122:889–896.",{"doi":2191},"10.1053\u002Fgast.2002.32418",{"id":26,"text":2193,"url":26,"identifiers":2194},"Kemmer N, Kaiser TE, Zacharias V, et al.: Revisiting posttransplant survival for hepatitis C virus recipients. Transplantation 2007, 84:932–933.",{"doi":2195},"10.1097\u002F01.tp.0000282790.66889.a5",{"id":26,"text":2197,"url":26,"identifiers":2198},"Cammà C, Di Bona D, Schepis F, et al.: Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology 2004, 39:333–340.",{"doi":2199},"10.1002\u002Fhep.20073",{"id":26,"text":2201,"url":26,"identifiers":2202},"Poynard T, McHutchison J, Manns M, et al.: Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002, 122:1303–1313.",{"doi":2203},"10.1053\u002Fgast.2002.33023",{"id":26,"text":2205,"url":26,"identifiers":2206},"Veldt BJ, Heathcote EJ, Wedemeyer H, et al.: Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007, 147:677–684.",{"doi":2207},"10.7326\u002F0003-4819-147-10-200711200-00003",{"id":26,"text":1288,"url":26,"identifiers":2209},{"doi":1290},{"id":26,"text":2211,"url":26,"identifiers":2212},"Weksler BB: Review article: the pathophysiology of thrombocytopenia in hepatitis C virus infection and chronic liver disease. Aliment Pharmacol Ther 2007, 26:13–19.",{"doi":2213},"10.1111\u002Fj.1365-2036.2007.03512.x",{"id":26,"text":2215,"url":26,"identifiers":2216},"Di Bisceglie AM, Shiffman ML, Everson GT, et al.: Prolonged antiviral therapy with peginterferon to prevent complications of advanced liver disease associated with hepatitis C: results of the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial. Hepatology 2007, 46(Suppl 1):290A.",{},{"id":26,"text":2218,"url":26,"identifiers":2219},"Everson GT, Trotter J, Forman L, et al.: Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005, 42:255–262.",{"doi":2220},"10.1002\u002Fhep.20793",{"id":26,"text":2222,"url":26,"identifiers":2223},"Sherman M: Optimizing management strategies in special patient populations. Am J Gastroenterol 2006, 101(Suppl 1):S26–S31.",{"doi":2224},"10.1111\u002Fj.1572-0241.2006.00369.x",{"id":26,"text":2226,"url":26,"identifiers":2227},"Lee LP, Dai CY, Chuang WL, et al.: Comparison of liver histopathology between chronic hepatitis C patients and chronic hepatitis B and C-coinfected patients. J Gastroenterol Hepatol 2007, 22:515–517.",{"doi":2228},"10.1111\u002Fj.1440-1746.2006.04547.x",{"id":26,"text":2230,"url":26,"identifiers":2231},"Cheruvu S, Marks K, Talal AH: Understanding the pathogenesis and management of hepatitis B\u002FHIV and hepatitis B\u002Fhepatitis C virus coinfection. Clin Liver Dis 2007, 11:917–943.",{"doi":2232},"10.1016\u002Fj.cld.2007.08.007",{"id":26,"text":2234,"url":26,"identifiers":2235},"Merchante N, Jiménez-Saenz M, Pineda JA: Management of HCV-related end-stage liver disease in HIV-coinfected patients. AIDS Rev 2007, 9:131–139.",{},{"id":26,"text":2237,"url":26,"identifiers":2238},"McGovern BH: Hepatitis C in the HIV-infected patient. J Acquir Immune Defic Syndr 2007, 45:S47–S45.",{"doi":2239},"10.1097\u002FQAI.0b013e318068d190",{"id":26,"text":2241,"url":26,"identifiers":2242},"Bonacini M: Diagnosis and management of cirrhosis in coinfected patients. J Acquir Immune Defic Syndr 2007, 45:S38–S44.",{"doi":2243},"10.1097\u002FQAI.0b013e318068d151",{"id":26,"text":2245,"url":26,"identifiers":2246},"Morra R, Munteanu M, Imbert-Bismut F, et al.: FibroMAX: towards a new universal biomarker of liver disease? Expert Rev Mol Diagn 2007, 7:481–489.",{"doi":2247},"10.1586\u002F14737159.7.5.481",{"id":26,"text":2249,"url":26,"identifiers":2250},"Halfon P, Bourliere M, Deydier R, et al.: Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study. Am J Gastroenterol 2006, 101:547–555.",{"doi":2251},"10.1111\u002Fj.1572-0241.2006.00411.x",{"id":26,"text":2253,"url":26,"identifiers":2254},"Huwart L, Sempoux C, Salameh N, et al.: Liver fibrosis: noninvasive assessment with MR elastography versus aspartate aminotransferase-to-platelet ratio index. Radiology 2007, 245:458–460.",{"doi":2255},"10.1148\u002Fradiol.2452061673",{"id":26,"text":2257,"url":26,"identifiers":2258},"Talwalkar JA, Kurtz DM, Schoenleber SJ, et al.: Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2007, 5:1214–1220.",{"doi":2259},"10.1016\u002Fj.cgh.2007.07.020",{"id":26,"text":2261,"url":26,"identifiers":2262},"Roche B, Samuel D: Risk factors for hepatitis C recurrence after liver transplantation. J Viral Hepat 2007, 14:89–96.",{"doi":2263},"10.1111\u002Fj.1365-2893.2007.00920.x",{"id":26,"text":2265,"url":26,"identifiers":2266},"Cameron AM, Ghobrial RM, Hiatt JR, et al.: Effect of nonviral factors on hepatitis C recurrence after liver transplantation. Ann Surg 2006, 244:563–571.",{"doi":2267},"10.1097\u002F01.sla.0000217673.04165.ea",{"id":26,"text":2269,"url":26,"identifiers":2270},"Onaca NN, Levy MF, Netto GJ, et al.: Pretransplant MELD score as a predictor of outcome after liver transplantation for chronic hepatitis C. Am J Transplant 2003, 3:626–630.",{"doi":2271},"10.1034\u002Fj.1600-6143.2003.00092.x",{"id":26,"text":2273,"url":26,"identifiers":2274},"Briceño J, Ciria R, Pleguezuelo M, et al.: Contribution of marginal donors to liver transplantation for hepatitis C virus infection. Transplant Proc 2007, 39:2297–2299.",{"doi":2275},"10.1016\u002Fj.transproceed.2007.07.069",{"id":26,"text":2277,"url":26,"identifiers":2278},"Botha JF, Thompson E, Gilroy R, et al.: Mild donor liver steatosis has no impact on hepatitis C virus fibrosis progression following liver transplantation. Liver Int 2007, 27:758–763.",{"doi":2279},"10.1111\u002Fj.1478-3231.2007.01490.x",{"id":26,"text":2281,"url":26,"identifiers":2282},"Rayhill SC, Wu YM, Katz DA, et al.: Older donor livers show early severe histological activity, fibrosis, and graft failure after liver transplantation for hepatitis C. Transplantation 2007, 84:331–339.",{"doi":2283},"10.1097\u002F01.tp.0000270313.31328.63",{"id":26,"text":2285,"url":26,"identifiers":2286},"Belli LS, Burroughs AK, Burra P, et al.: Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study. Liver Transpl 2007, 13:733–740.",{"doi":2287},"10.1002\u002Flt.21093",{"id":26,"text":2289,"url":26,"identifiers":2290},"Gaglio PJ, Malireddy S, Levitt BS, et al.: Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donors. Liver Transpl 2003, 9:1028–1035.",{"doi":2291},"10.1053\u002Fjlts.2003.50211",{"id":26,"text":2293,"url":26,"identifiers":2294},"Terrault NA, Shiffman ML, Lok AS, et al.: A2ALL Study Group: Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl 2007, 13:122–129.",{"doi":2295},"10.1002\u002Flt.20995",{"id":26,"text":2297,"url":26,"identifiers":2298},"Lee KW, Simpkins CE, Montgomery RA, et al.: Factors affecting graft survival after liver transplantation from donation after cardiac death donors. Transplantation 2006, 82:1683–1688.",{"doi":2299},"10.1097\u002F01.tp.0000250936.73034.98",{"id":26,"text":2301,"url":26,"identifiers":2302},"Dezza MC, Berrevoet F, Sainz-Barriga M, et al.: The choice of recipient does not have a bearing on early outcome in liver transplant patients receiving grafts from non-heart-beating donors: a reappraisal? Transplant Proc 2007, 39:2675–2677.",{"doi":2303},"10.1016\u002Fj.transproceed.2007.08.008",{"id":26,"text":2305,"url":26,"identifiers":2306},"Katz LH, Mor E, Brown M, et al.: Recurrent hepatitis C virus disease after liver transplantation and concurrent biliary tract complications: poor outcome. Clin Transplant 2006, 20:465–470.",{"doi":2307},"10.1111\u002Fj.1399-0012.2006.00507.x",{"id":26,"text":2309,"url":26,"identifiers":2310},"Klintmalm GB, Washburn WK, Rudich SM, et al.: Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study. Liver Transpl 2007, 13:1521–1531.",{"doi":2311},"10.1002\u002Flt.21182",{"id":26,"text":2313,"url":26,"identifiers":2314},"Vivarelli M, Burra P, Barba GL, et al.: Influence of steroids on HCV recurrence after liver transplantation: a prospective study. J Hepatol 2007, 47:793–798.",{"doi":2315},"10.1016\u002Fj.jhep.2007.07.023",{"id":26,"text":2317,"url":26,"identifiers":2318},"Berenguer M, Royuela A, Zamora J: Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl 2007, 13:21–29.",{"doi":2319},"10.1002\u002Flt.21035",{"id":26,"text":2321,"url":26,"identifiers":2322},"Guitard J, Sandres-Sauné K, Kamar N: Hepatitis C virus viral load after conversion from tacrolimus to cyclosporine in liver transplant patients. Transplant Proc 2007, 39:2603–2605.",{"doi":2323},"10.1016\u002Fj.transproceed.2007.08.086",{"id":26,"text":2325,"url":26,"identifiers":2326},"Bahra M, Neumann UP, Jacob D, et al.: Repeated steroid pulse therapies in HCV-positive liver recipients. Transplant Proc 2005, 37:1700–1702.",{"doi":2327},"10.1016\u002Fj.transproceed.2005.03.081",{"id":26,"text":2329,"url":26,"identifiers":2330},"Wiesner RH, Shorr JS, Steffen BJ, et al.: Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C. Liver Transpl 2005, 11:750–759.",{"doi":2331},"10.1002\u002Flt.20453",{"id":26,"text":2333,"url":26,"identifiers":2334},"Kwo PY, Saxena R, Cummings OW, et al.: Intravenous interferon during the anhepatic phase of liver retransplantation and prevention of recurrence of cholestatic hepatitis C virus. Liver Transpl 2007, 13:1710–1713.",{"doi":2335},"10.1002\u002Flt.21295",{"id":26,"text":2337,"url":26,"identifiers":2338},"Arjal RR, Burton JR Jr, Villamil F, et al.: Review article: the treatment of hepatitis C virus recurrence after liver transplantation. Aliment Pharmacol Ther 2007, 26:127–140.",{"doi":2339},"10.1111\u002Fj.1365-2036.2007.03364.x",{"id":26,"text":2341,"url":26,"identifiers":2342},"Wiesner RH, Sorrell M, Villamil F, et al.: Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003, 9:S1–S9.",{"doi":2343},"10.1053\u002Fjlts.2003.50268",{"id":26,"text":2345,"url":26,"identifiers":2346},"Saab S, Oh MK, Ibrahim AB, et al.: Anemia in liver transplant recipients undergoing antiviral treatment for recurrent hepatitis C. Liver Transpl 2007, 13:1032–1038.",{"doi":2347},"10.1002\u002Flt.21184",{"id":26,"text":2349,"url":26,"identifiers":2350},"Schecter JM, Mears JG, Alobeid B, et al.: Anti-erythropoietin antibody-mediated pure red cell alpasia in a living donor liver transplant recipient treated for hepatitis C virus. Liver Transpl 2007, 13:1589–1592.",{"doi":2351},"10.1002\u002Flt.21332",{"id":26,"text":2353,"url":26,"identifiers":2354},"Picciotto FP, Tritto G, Lanza AG, et al.: Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 2007, 46:459–465.",{"doi":2355},"10.1016\u002Fj.jhep.2006.10.017",{"id":26,"text":2357,"url":26,"identifiers":2358},"Kornberg A, Küpper B, Tannapfel A, et al.: Antiviral maintenance treatment with interferon and ribavirin for recurrent hepatitis C after liver transplantation: pilot study. J Gastroenterol Hepatol 2007, 22:2135–2142.",{"doi":2359},"10.1111\u002Fj.1440-1746.2006.04516.x",{"id":26,"text":2361,"url":26,"identifiers":2362},"McCashland T, Watt K, Lyden E, et al.: Retransplantation for heaptitis C: results of a U.S. multicenter retransplant study. Liver Transpl 2007, 13:1246–1253.",{"doi":2363},"10.1002\u002Flt.21322",{"id":2365,"createTime":2366,"updateTime":2367,"relativeEntities":2368,"slug":2369,"properties":2370,"entityType":725,"verifyStatus":25,"verifyTime":2367,"verifyNote":726,"syncStatus":28,"languages":2381,"translateLanguages":26,"viewCount":36,"primaryUrl":2382,"fullTextUrl":26,"authors":2383,"publicationType":768,"publisherRelationship":2402,"citationCount":114,"citationInfo":2423,"publishDate":2425,"publishYear":2426,"citationAnalyzeStatus":1422,"lastCitationAnalyze":2427,"indexDatabases":26,"openAccess":26,"references":2428,"isForceReanalyzing":1000},"4b1c6aa2-d8ff-4826-a44f-8d4e139ebd06","2024-04-11T11:53:36.386+00:00","2025-01-29T18:13:58.139+00:00",[],"Treatment-of-chronic-hepatitis-C-Improved-combination-therapy",{"mag":2371,"keywords":2373,"openalex":2374,"abstract":2376,"title":2377,"doi":2379},{"VOID":2372},"2066505686",{},{"VOID":2375},"W2066505686",{},{"EN":2378},"Treatment of chronic hepatitis C: Improved combination therapy",{"VOID":2380},"10.1007\u002Fs11901-003-0013-2",[102],"http:\u002F\u002Flink.springer.com\u002F10.1007\u002Fs11901-003-0013-2",[2384],{"id":2385,"sortIndex":36,"researcher":26,"roles":2386,"affiliations":2387,"properties":2397},"6e827e9b-4f11-44a9-bd92-765d11c5a1a3",[],[2388],{"id":26,"sortIndex":36,"affiliation":2389,"properties":26},{"id":2390,"createTime":2391,"updateTime":2391,"relativeEntities":2392,"slug":2393,"properties":2394,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"b154ef34-c06d-4084-8b0d-f321b5111135","2024-04-11T11:53:36.394+00:00",[],"Division-of-Hepatology-Liver-Transplantation-Baylor-University-Medical-Center-Baylor-Regional-Transplant-Institute-Dallas-USA",{"title":2395},{"EN":2396},"Division of Hepatology, Liver Transplantation, Baylor University Medical Center, Baylor Regional Transplant Institute, Dallas, USA",{"openalex":2398,"title":2400},{"VOID":2399},"A5067953805",{"EN":2401},"Gary L. Davis",{"url":26,"publisher":2403,"properties":26},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":2404,"slug":663,"properties":2405,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":2409,"manageAffiliations":2410,"indexDatabases":2411,"url":691,"thumbnailPath":26,"statistic":2418,"gsStatistic":26,"type":175,"analyzePriority":26},[],{"issn":2406,"eissn":2407,"title":2408},{"VOID":666},{"VOID":668},{"EN":670},[],[],[2412],{"id":675,"indexDatabase":2413,"url":688,"indexYears":689,"academicFieldIds":26,"indexDatabaseRanking":690},{"id":677,"createTime":678,"updateTime":679,"relativeEntities":2414,"label":2415,"description":2416,"key":685,"publicationTags":2417,"standard":26},[],{"EN":682,"VI":682},{"EN":682,"VI":684},[687],{"impactFactor":36,"impactFactorByYear":2419,"i10Index":59,"i10IndexLast5Year":36,"totalPublication":694,"totalPublicationByYear":2420,"totalCitation":536,"totalCitationByYear":2421,"totalCitationPerPublication":132,"totalCitationPerPublicationByYear":2422,"hindexLast5Year":162,"hindex":162},{"2012":231,"2013":229,"2014":39},{"2002":111,"2003":336,"2004":173,"2005":234,"2006":234,"2007":162,"2008":234,"2009":237,"2010":241,"2011":516,"2012":241,"2013":51},{"2003":114,"2004":114,"2005":59,"2006":53,"2007":50,"2008":234,"2009":115,"2010":285,"2011":114,"2012":135,"2013":115},{"2003":404,"2004":206,"2005":57,"2006":698,"2007":699,"2008":115,"2009":230,"2010":266,"2011":108,"2012":477,"2013":110},{"total":114,"publishYear":26,"statisticByYear":2424},{"2021":114},"2003-03-01",2003,"2024-04-11T12:50:32.282+00:00",[2429,2433,2437,2441,2444,2448,2451,2454,2458,2461,2464,2468,2472,2476,2480,2483,2486,2489,2492,2496,2500,2504,2508,2512,2516,2519,2523,2527,2531,2535,2539,2543,2546,2549,2552,2555,2558,2562,2565,2568,2572,2576,2579,2582,2586,2590,2594,2598,2602,2606,2609,2612,2616,2620,2623,2627,2631,2635,2639,2643,2645,2647,2651,2655,2659],{"id":26,"text":2430,"url":26,"identifiers":2431},"Alter MJ: The epidemiology of acute and chronic hepatitis C. Clin Liver Dis 1997, 1:559–568.",{"doi":2432},"10.1016\u002FS1089-3261(05)70321-4",{"id":26,"text":2434,"url":26,"identifiers":2435},"Alter M, Kruszon-Moran D, Nainan OV, et al.: The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999, 341:556–562.",{"doi":2436},"10.1056\u002FNEJM199908193410802",{"id":26,"text":2438,"url":26,"identifiers":2439},"Alter MJ, Hadler SC, Judson FN, et al.: Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. JAMA 1990, 264:2231–2235.",{"doi":2440},"10.1001\u002Fjama.1990.03450170079026",{"id":26,"text":2442,"url":26,"identifiers":2443},"Davis GL, Albright JE, Cook SF, Rosenberg DM: Projecting the future healthcare burden from hepatitis C in the United States. Liver Transpl 2002, in press. The paper uses a validated mathematical model of the natural history of hepatitis C to project the course of infection in the US population in coming decades. A dramatic increase in cases of hepatic decompensation and hepatocellular carcinoma is estimated.",{},{"id":26,"text":2445,"url":26,"identifiers":2446},"Sànchez-Tapias JM, Barrera JM, Costa J, et al.: Hepatitis C virus infection in patients with nonalcoholic chronic liver disease. Ann Intern Med 1990, 112:921–924.",{"doi":2447},"10.7326\u002F0003-4819-112-12-921",{"id":26,"text":2449,"url":26,"identifiers":2450},"Meyer RA, Gordon SC: Epidemiology of hepatitis C virus infection in a suburban Detroit community. Am J Gastroenterol 1991, 86:1224–1226.",{},{"id":26,"text":2452,"url":26,"identifiers":2453},"Seeff LB, Buskell-Bales Z, Wright EC, et al.: Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 1992, 327:1906–1911.",{"doi":1941},{"id":26,"text":2455,"url":26,"identifiers":2456},"El-Serag HB, Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999, 340:745–750.",{"doi":2457},"10.1056\u002FNEJM199903113401001",{"id":26,"text":2459,"url":26,"identifiers":2460},"Primary Liver Disease of Liver Transplant Recipients 1991 and 1992. The UNOS Scientific Registry [no authors listed]. UNOS Update 1993, 9:27.",{},{"id":26,"text":2462,"url":26,"identifiers":2463},"Peters M, Davis GL, Dooley JS, et al. The IFN system in acute and chronic viral hepatitis. In Progress in Liver Diseases, vol 8. Edited by Popper H, Schaffner F. New York: Grune and Stratton; 1986:453–467.",{},{"id":26,"text":2465,"url":26,"identifiers":2466},"Hoofnagle JH, Mullen KD, Jones DB, et al.: Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: a preliminary report. New Engl J Med 1986, 315:1575–1578.",{"doi":2467},"10.1056\u002FNEJM198612183152503",{"id":26,"text":2469,"url":26,"identifiers":2470},"Davis GL, Balart LA, Schiff ER, et al.: Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized controlled study. N Engl J Med 1989, 321:1501–1506.",{"doi":2471},"10.1056\u002FNEJM198911303212203",{"id":26,"text":2473,"url":26,"identifiers":2474},"DiBisceglie AM, Martin P, Kassianides C, et al.: Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-bind, placebo-controlled trial. N Engl J Med 1989, 321:1506–1510.",{"doi":2475},"10.1056\u002FNEJM198911303212204",{"id":26,"text":2477,"url":26,"identifiers":2478},"Poynard T, Leroy V, Cohard M, et al.: Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996, 24:778–789.",{"doi":2479},"10.1002\u002Fhep.510240405",{"id":26,"text":2481,"url":26,"identifiers":2482},"McHutchison JG, Gordon S, Schiff ER, et al.: Interferon alfa-2b monotherapy versus interferon alfa-2b plus ribavirin as initial treatment for chronic hepatitis C: results of a U.S. multicenter randomized controlled study. N Engl J Med 1998, 339:1485–1492.",{"doi":2011},{"id":26,"text":2484,"url":26,"identifiers":2485},"Poynard T, Marcellin P, Lee S, et al.: Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998, 352:1426–1432.",{"doi":2015},{"id":26,"text":2487,"url":26,"identifiers":2488},"Patterson JL, Fernandez-Larson R: Molecular action of ribavirin. Rev Infect Dis 1990, 12:1132–1146.",{},{"id":26,"text":2490,"url":26,"identifiers":2491},"Crumpacker CS: Overview of ribavirin treatment of infection caused by RNA viruses. In Clinical Applications of Ribavirin. Edited by RA Smith et al. Orlando, FL: Academic Press; 1984:33–38.",{},{"id":26,"text":2493,"url":26,"identifiers":2494},"Martin J, Navas S, Quiroga JA, et al.: Effects of the ribavirininterferon alpha combination on cultured peripheral blood mononuclear cells from chronic hepatitis C patients. Cytokine 1998, 10:635–644.",{"doi":2495},"10.1006\u002Fcyto.1997.0333",{"id":26,"text":2497,"url":26,"identifiers":2498},"Ning Q, Brown D, Parodo J, et al.: Ribavirin inhibits viral induced macrophage production of tumor necrosis factor, interleukin 1, and procoagulant activity and preserves TH1 cytokine production, but inhibits TH2 cytokine response. J Immunol 1998, 160:3487–3493.",{"doi":2499},"10.4049\u002Fjimmunol.160.7.3487",{"id":26,"text":2501,"url":26,"identifiers":2502},"Cramp ME, Rossol S, Chokshi S, et al.: Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 2000, 118:346–355.",{"doi":2503},"10.1016\u002FS0016-5085(00)70217-4",{"id":26,"text":2505,"url":26,"identifiers":2506},"Reichard O, Andersson J, Schvarcz R, et al.: Ribavirin treatment for chronic hepatitis C. Lancet 1991, 337:1058–1061.",{"doi":2507},"10.1016\u002F0140-6736(91)91707-2",{"id":26,"text":2509,"url":26,"identifiers":2510},"Bodenheimer HC, Lindsay KL, Davis GL, et al.: Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1997, 26:473–477.",{"doi":2511},"10.1002\u002Fhep.510260231",{"id":26,"text":2513,"url":26,"identifiers":2514},"Reichard O, Norkrans G, Fryden A, et al.: Alfa-interferon and ribavirin versus alfa-interferon alone as therapy for chronic hepatitis C-a randomized, double-blind, placebo-controlled study. Lancet 1998, 351:83–87.",{"doi":2515},"10.1016\u002FS0140-6736(97)06088-1",{"id":26,"text":2517,"url":26,"identifiers":2518},"McHutchison JG, Poynard T: Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin Liver Dis 1999, 19:57–65.",{},{"id":26,"text":2520,"url":26,"identifiers":2521},"Schalm SW, Weiland O, Hansen BE, et al.: Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled studies. Gastroenterology 1999, 117:408–413.",{"doi":2522},"10.1053\u002Fgast.1999.0029900408",{"id":26,"text":2524,"url":26,"identifiers":2525},"Shiratori Y, Imazeki F, Moriyama M, et al.: Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000, 132:517–524.",{"doi":2526},"10.7326\u002F0003-4819-132-7-200004040-00002",{"id":26,"text":2528,"url":26,"identifiers":2529},"Marcellin P, Boyer N, Gervais A, et al.: Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997, 127:875–881.",{"doi":2530},"10.7326\u002F0003-4819-127-10-199711150-00003",{"id":26,"text":2532,"url":26,"identifiers":2533},"Poynard T, McHutchison J, Goodman Z, et al.: Is an \"a la carte\" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? Hepatology 2000, 3:211–218.",{"doi":2534},"10.1002\u002Fhep.510310131",{"id":26,"text":2536,"url":26,"identifiers":2537},"Davis GL, Lau JYN: Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997, 26(suppl):122–127.",{"doi":2538},"10.1002\u002Fhep.510260721",{"id":26,"text":2540,"url":26,"identifiers":2541},"Wang YS, Youngster S, Bausch J, et al.: Identification of the major positional isomer of pegylated interferon alpha-2b. Biochemistry 2000, 39:10634–10640.",{"doi":2542},"10.1021\u002Fbi000617t",{"id":26,"text":2544,"url":26,"identifiers":2545},"Glue P, Fang JW, Rouzier-Panis R, et al.: Pegylated interferonalpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther 2000, 68:556–567.",{"doi":2038},{"id":26,"text":2547,"url":26,"identifiers":2548},"Xu ZX, Hoffman J, Patel I, Joubert P: Single dose safety\u002Ftolerability and pharmacokinetic\u002Fpharmacodynamics following administration of ascending doses of pegylated interferon and interferon alfa 2a to healthy subjects [abstract]. Hepatology 1998, 28:702A.",{},{"id":26,"text":2550,"url":26,"identifiers":2551},"Modi MW, Fulton JS, Buckmann DK, et al.: Clearance of pegylated (40 kDa) interferon alfa-2a is primarily hepatic [abstract]. Hepatology 2000, 32:371A.",{},{"id":26,"text":2553,"url":26,"identifiers":2554},"Heathcote EJ, Shiffman ML, Cooksley WG, et al.: Peg-interferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000, 343:1673–1680.",{"doi":2053},{"id":26,"text":2556,"url":26,"identifiers":2557},"Zeuzem S, Feinman SV, Rasenack J, et al.: Peg-interferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000, 343:1666–1672.",{"doi":2049},{"id":26,"text":2559,"url":26,"identifiers":2560},"Trepo C, Lindsay K, Niederau C, et al.: Pegylated interferon alfa-2b monotherapy is superior to interferon alfa-2b (Intron A) for the treatment of chronic hepatitis C [abstract]. J Hepatol 2000, 32(suppl_2):29A.",{"doi":2561},"10.1016\u002FS0168-8278(00)80446-8",{"id":26,"text":2563,"url":26,"identifiers":2564},"Manns MP, McHutchison JG, Gordon S, et al.: Peg-interferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C: a randomized trial. Lancet 2001, 358:958–965.",{"doi":2057},{"id":26,"text":2566,"url":26,"identifiers":2567},"Fried MW, Shiffman ML, Reddy R, et al.: Peg-interferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975–982. Describes the results of treatment with peginterferons in combination with oral ribavirin. This regimens represents the current gold standard for treatment of chronic hepatitis C.",{"doi":2061},{"id":26,"text":2569,"url":26,"identifiers":2570},"Hadziyannis SJ, Cheinquer H, Morgan T, et al.: Peg-interferon alfa-2a (40KD)(Pegasys) in combination with ribavirin: Efficacy and safety results from a phase III, randomized, doubleblind, multicentre study examining the effect of duration of treatment and ribavirin dose [abstract]. J Hepatol 2002, 37:536A. An important study that demonstrates the impact of treatment duration and ribavirin dose on SVRs. This study clearly demonstrates that 12 months of treatment with peginterferon plus 1000 to 1200 mg of ribavirin per day is optimal for genotype 1 patients, whereas 6 months of peginterferon with only 800 mg\u002Fd of ribavirin is sufficient for genotypes 2 and 3.",{"doi":2571},"10.1016\u002FS0168-8278(02)00240-4",{"id":26,"text":2573,"url":26,"identifiers":2574},"Layden JE, Layden TJ: How can mathematics help us understand HCV? Gastroenterology 2001, 120:1546–1549.",{"doi":2575},"10.1053\u002Fgast.2001.24401",{"id":26,"text":2577,"url":26,"identifiers":2578},"Zeuzem S, Herrmann E, Lee JH, et al.: Viral kinetics in patients with chronic hepatitis treated with standard and peg-interferon alfa-2a. Hepatology 2001, 120:1438–1447.",{},{"id":26,"text":2580,"url":26,"identifiers":2581},"Davis GL: Utilization of virologic testing in the treatment of chronic hepatitis C. Hepatology 2002, 36:S145-S151.",{},{"id":26,"text":2583,"url":26,"identifiers":2584},"Ferenci P, Shiffman ML, Fried MW, et al.: Early prediction of response to 40 KDa peg-interferon alfa-2a (Pegasys) plus ribavirin in patients with chronic hepatitis C [abstract]. Hepatology 2001, 34:351A.",{"doi":2585},"10.1053\u002Fjhep.2001.28706",{"id":26,"text":2587,"url":26,"identifiers":2588},"Davis GL, Lau JYN, Urdea MS, et al.: Quantitative detection of hepatitis C virus (HCV) RNA by a solid-phase signal amplification method: definition of optimal conditions for specimen collection and clinical application in interferon-treated patients. Hepatology 1994, 19:1337–1341.",{"doi":2589},"10.1002\u002Fhep.1840190603",{"id":26,"text":2591,"url":26,"identifiers":2592},"Pradat P, Chossegros P, Bailly F, et al.: Comparison between three quantitative assays in patients with chronic hepatitis C and their relevance in the prediction of response to therapy. J Viral Hepat 2000, 7:203–210.",{"doi":2593},"10.1046\u002Fj.1365-2893.2000.00224.x",{"id":26,"text":2595,"url":26,"identifiers":2596},"Martinot-Peignoux M, Le Breton V, Fritsch S, et al.: Assessment of viral loads in patients with chronic hepatitis C with Amplicor HCV Monitor version 1.0, Cobas HCV Monitor version 2.0, and Quantiplex HCV RNA version 2.0 assays. J Clin Microbiol 2000, 38:2722–2725.",{"doi":2597},"10.1128\u002FJCM.38.7.2722-2725.2000",{"id":26,"text":2599,"url":26,"identifiers":2600},"Pawlotsky JM, Bouvier-Alias M, Hezode C, et al.: Standardization of hepatitis C virus RNA quantification. Hepatology 2000, 32:654–659.",{"doi":2601},"10.1053\u002Fjhep.2000.16603",{"id":26,"text":2603,"url":26,"identifiers":2604},"McHutchison JG, Manns M, Patel K, et al.: Adherence to combination therapy enhances sustained response in genotype-1 infected patients with chronic hepatitis C. Gastroenterology 2002, 123:1061–1069.",{"doi":2605},"10.1053\u002Fgast.2002.35950",{"id":26,"text":2607,"url":26,"identifiers":2608},"McHutchison J, Davis GL, Esteban-Mur R, et al.: Durability of sustained virologic response in patients with chronic hepatitis C after treatment with interferon alfa-2b alone or in combination with ribavirin [abstract]. Hepatology 2001, 34:244A.",{},{"id":26,"text":2610,"url":26,"identifiers":2611},"Davis GL, Balart LA, Schiff ER, et al.: Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized controlled study. New Engl J Med 1989, 321:1501–1506.",{"doi":2471},{"id":26,"text":2613,"url":26,"identifiers":2614},"Cammà C, Giunta M, Chemello L, et al.: Chronic hepatitis C: interferon retreatment of relapsers. A meta-analysis of individual patient data. Hepatology 1999, 30:801–807.",{"doi":2615},"10.1002\u002Fhep.510300329",{"id":26,"text":2617,"url":26,"identifiers":2618},"Alberti A, Chemello L, Noventa F, et al.: Therapy of hepatitis C: retreatment with alpha interferon. Hepatology 1997, 26(suppl):137–142.",{"doi":2619},"10.1002\u002Fhep.510260724",{"id":26,"text":2621,"url":26,"identifiers":2622},"Davis GL, Esteban-Mur R, Rustgi V, et al.: Recombinant interferon alfa-2b (Intron A) alone or in combination with ribavirin (Rebetol) for retreatment of interferon relapse in chronic hepatitis C. New Engl J Med 1998, 339:1493–1499.",{"doi":2023},{"id":26,"text":2624,"url":26,"identifiers":2625},"Bellobouno A, Mondazzi L, Tempini S, et al.: Ribavirin and interferon-alpha combination therapy vs interferon-alpha alone in the retreatment of chronic hepatitis C: a randomized clinical trial. J Viral Hepat 1997, 4:185–191.",{"doi":2626},"10.1046\u002Fj.1365-2893.1997.00142.x",{"id":26,"text":2628,"url":26,"identifiers":2629},"Poynard T, McHutchison J, Davis GL, et al.: Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000, 32:1131–1137.",{"doi":2630},"10.1053\u002Fjhep.2000.19347",{"id":26,"text":2632,"url":26,"identifiers":2633},"Poynard T, Moussali J, Ratziu V, et al.: Effects of interferon therapy in \"non-responder\" patients with chronic hepatitis C. J Hepatol 1999, 31:178–183.",{"doi":2634},"10.1016\u002FS0168-8278(99)80397-3",{"id":26,"text":2636,"url":26,"identifiers":2637},"Shiffman ML, Hofmann CM, Contos MJ, et al.: A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999, 117:1164–1172.",{"doi":2638},"10.1016\u002FS0016-5085(99)70402-6",{"id":26,"text":2640,"url":26,"identifiers":2641},"Everson G: Maintenance interferon for chronic hepatitis C: more issues than answers. Hepatology 2000, 32:436–438.",{"doi":2642},"10.1053\u002Fjhep.2000.16216",{"id":26,"text":2524,"url":26,"identifiers":2644},{"doi":2526},{"id":26,"text":2528,"url":26,"identifiers":2646},{"doi":2530},{"id":26,"text":2648,"url":26,"identifiers":2649},"Wong JB, McQuillan GM, McHutchison JG, Poynard T: Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000, 90:1562–1569.",{"doi":2650},"10.2105\u002FAJPH.90.10.1562",{"id":26,"text":2652,"url":26,"identifiers":2653},"Bonkovsky HL, Woolley JM: Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology 1999, 29:264–270.",{"doi":2654},"10.1002\u002Fhep.510290124",{"id":26,"text":2656,"url":26,"identifiers":2657},"Ware JE, Bayliss MS, Mannocchia M, Davis GL: Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The International Hepatitis Interventional Therapy Group. Hepatology 1999, 30:550–555.",{"doi":2658},"10.1002\u002Fhep.510300203",{"id":26,"text":2660,"url":26,"identifiers":2661},"Davis GL, Nelson DR, Reyes G: Future options for the management of hepatitis C. Semin Liver Dis 1999, 19(suppl 1):103–112.",{},{"id":2663,"createTime":2664,"updateTime":2665,"relativeEntities":2666,"slug":2667,"properties":2668,"entityType":725,"verifyStatus":25,"verifyTime":2665,"verifyNote":726,"syncStatus":28,"languages":2679,"translateLanguages":26,"viewCount":36,"primaryUrl":2680,"fullTextUrl":26,"authors":2681,"publicationType":768,"publisherRelationship":2715,"citationCount":114,"citationInfo":2736,"publishDate":2738,"publishYear":800,"citationAnalyzeStatus":1422,"lastCitationAnalyze":2739,"indexDatabases":26,"openAccess":26,"references":2740,"isForceReanalyzing":1000},"c130b7e0-23de-486d-89ee-b29fd8855559","2024-04-12T01:45:37.465+00:00","2024-12-17T00:49:57.811+00:00",[],"HIV-and-HCV-Coinfection-Where-Are-We-in-2010-",{"mag":2669,"keywords":2671,"openalex":2672,"abstract":2674,"title":2675,"doi":2677},{"VOID":2670},"2065448358",{},{"VOID":2673},"W2065448358",{},{"EN":2676},"HIV and HCV Coinfection: Where Are We in 2010?",{"VOID":2678},"10.1007\u002Fs11901-010-0045-3",[102],"http:\u002F\u002Flink.springer.com\u002F10.1007\u002Fs11901-010-0045-3",[2682,2699],{"id":2683,"sortIndex":36,"researcher":26,"roles":2684,"affiliations":2685,"properties":2694},"a361c9c9-edc7-43ac-8cc9-e4d6b489de95",[],[2686],{"id":26,"sortIndex":36,"affiliation":2687,"properties":26},{"id":2688,"createTime":2689,"updateTime":2689,"relativeEntities":2690,"slug":26,"properties":2691,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"4721acd4-3c2e-47b9-bac3-2b7545dc03fb","2024-01-11T19:08:37.380+00:00",[],{"title":2692},{"VI":2693},"Gastrointestinal Unit, Massachusetts General Hospital, Boston, USA",{"openalex":2695,"title":2697},{"VOID":2696},"A5068030415",{"EN":2698},"Esperance A. Schaefer",{"id":2700,"sortIndex":115,"researcher":26,"roles":2701,"affiliations":2702,"properties":2708},"9d3e9b64-e3b6-4862-8535-0d2fa382c7ab",[],[2703],{"id":26,"sortIndex":36,"affiliation":2704,"properties":26},{"id":2688,"createTime":2689,"updateTime":2689,"relativeEntities":2705,"slug":26,"properties":2706,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":2707},{"VI":2693},{"openalex":2709,"orcid":2711,"title":2713},{"VOID":2710},"A5020069661",{"VOID":2712},"https:\u002F\u002Forcid.org\u002F0000-0001-7587-718X",{"EN":2714},"Raymond T. Chung",{"url":26,"publisher":2716,"properties":26},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":2717,"slug":663,"properties":2718,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":2722,"manageAffiliations":2723,"indexDatabases":2724,"url":691,"thumbnailPath":26,"statistic":2731,"gsStatistic":26,"type":175,"analyzePriority":26},[],{"issn":2719,"eissn":2720,"title":2721},{"VOID":666},{"VOID":668},{"EN":670},[],[],[2725],{"id":675,"indexDatabase":2726,"url":688,"indexYears":689,"academicFieldIds":26,"indexDatabaseRanking":690},{"id":677,"createTime":678,"updateTime":679,"relativeEntities":2727,"label":2728,"description":2729,"key":685,"publicationTags":2730,"standard":26},[],{"EN":682,"VI":682},{"EN":682,"VI":684},[687],{"impactFactor":36,"impactFactorByYear":2732,"i10Index":59,"i10IndexLast5Year":36,"totalPublication":694,"totalPublicationByYear":2733,"totalCitation":536,"totalCitationByYear":2734,"totalCitationPerPublication":132,"totalCitationPerPublicationByYear":2735,"hindexLast5Year":162,"hindex":162},{"2012":231,"2013":229,"2014":39},{"2002":111,"2003":336,"2004":173,"2005":234,"2006":234,"2007":162,"2008":234,"2009":237,"2010":241,"2011":516,"2012":241,"2013":51},{"2003":114,"2004":114,"2005":59,"2006":53,"2007":50,"2008":234,"2009":115,"2010":285,"2011":114,"2012":135,"2013":115},{"2003":404,"2004":206,"2005":57,"2006":698,"2007":699,"2008":115,"2009":230,"2010":266,"2011":108,"2012":477,"2013":110},{"total":114,"publishYear":26,"statisticByYear":2737},{"2012":115},"2010-08-01","2024-04-13T09:03:02.694+00:00",[2741,2744,2748,2752,2756,2760,2763,2767,2771,2775,2779,2783,2787,2791,2795,2799,2803,2807,2811,2815,2819,2823,2827,2831,2835,2838,2842,2846,2850,2854,2858,2862,2866,2869,2873,2877],{"id":26,"text":2742,"url":26,"identifiers":2743},"UNAIDS: 2008 Report on the Global AIDS Epidemic. Available at http:\u002F\u002Fdata.unaids.org\u002Fpub\u002FGlobalReport\u002F2008\u002Fjc1510_2008globalreport_en.pdf . Accessed February 2010.",{},{"id":26,"text":2745,"url":26,"identifiers":2746},"Mohsen AH, Easterbrook P, Taylor CB, Norris S: Hepatitis C and HIV-1 coinfection. Gut 2002, 51:601–608.",{"doi":2747},"10.1136\u002Fgut.51.4.601",{"id":26,"text":2749,"url":26,"identifiers":2750},"Sulkowski MS, Thomas DL: Hepatitis C in the HIV-infected person. Ann Intern Med 2003, 138:197–207.",{"doi":2751},"10.7326\u002F0003-4819-138-3-200302040-00012",{"id":26,"text":2753,"url":26,"identifiers":2754},"Weber R, Sabin CA, Friis-Moller N, et al.: Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006, 166:1632–1641.",{"doi":2755},"10.1001\u002Farchinte.166.15.1632",{"id":26,"text":2757,"url":26,"identifiers":2758},"Chen TY, Ding EL, Seage III GR, Kim AY: Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clin Infect Dis 2009, 49:1605–1615.",{"doi":2759},"10.1086\u002F644771",{"id":26,"text":2761,"url":26,"identifiers":2762},"US Public Health Service: Updated US Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR Reccomm Rep 2001, 50:1–52.",{},{"id":26,"text":2764,"url":26,"identifiers":2765},"Hahn JA: Sex, drugs, and hepatitis C virus. J Infect Dis 2007, 195:1556–1559.",{"doi":2766},"10.1086\u002F516792",{"id":26,"text":2768,"url":26,"identifiers":2769},"van de Laar T, Pybus O, Bruisten S, et al.: Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. Gastroenterology 2009, 136:1609–1617.",{"doi":2770},"10.1053\u002Fj.gastro.2009.02.006",{"id":26,"text":2772,"url":26,"identifiers":2773},"England K, Thorne C, Newell ML: Vertically acquired paediatric coinfection with HIV and hepatitis C virus. Lancet Infect Dis 2006, 6:83–90.",{"doi":2774},"10.1016\u002FS1473-3099(06)70381-4",{"id":26,"text":2776,"url":26,"identifiers":2777},"Lauer GM, Walker BD: Hepatitis C virus infection. N Engl J Med 2001, 345:41–52.",{"doi":2778},"10.1056\u002FNEJM200107053450107",{"id":26,"text":2780,"url":26,"identifiers":2781},"Fierer DS, Uriel AJ, Carriero DC, et al.: Liver Fibrosis During an Outbreak of Acute Hepatitis C Virus Infection in HIV-Infected Men: A Prospective Cohort Study. Journal of Infect Dis 2008, 198:683–686.",{"doi":2782},"10.1086\u002F590430",{"id":26,"text":2784,"url":26,"identifiers":2785},"Puoti M, Bonacini M, Spinetti A, et al.: Liver fibrosis progression is related to CD4+ cell depletion in patients coifected with hepatitis C virus and human immunodeficiency virus. J Infect Dis 2001, 183:134–137.",{"doi":2786},"10.1086\u002F317644",{"id":26,"text":2788,"url":26,"identifiers":2789},"Kim AY, Chung RT: Coinfection with HIV-1 and HCV—a one-two punch. Gastroenterology 2009, 137:795–814.",{"doi":2790},"10.1053\u002Fj.gastro.2009.06.040",{"id":26,"text":2792,"url":26,"identifiers":2793},"Lin W, Weinberg EM, Tai AW, et al.: HIV increases HCV replication in a TGF-beta1-dependent manner. Gastroenterology 2008, 134:803–811.",{"doi":2794},"10.1053\u002Fj.gastro.2008.01.005",{"id":26,"text":2796,"url":26,"identifiers":2797},"Bruno R, Galastri S, Sacchi P, et al.: gp120 modulates the biology of human hepatic stellate cells: a link between HIV infection and liver fibrogenesis. Gut 2010, 59:513–520.",{"doi":2798},"10.1136\u002Fgut.2008.163287",{"id":26,"text":2800,"url":26,"identifiers":2801},"Thomas DL, Astemborski J, Raj RM, et al.: The Natural History of Hepatitis C Virus Infection: host, viral and environmental factors. JAMA 2000, 284:450–456.",{"doi":2802},"10.1001\u002Fjama.284.4.450",{"id":26,"text":2804,"url":26,"identifiers":2805},"Gilleece YC, Browne RE, Asboe D, et al.: Transmission of Hepatitis C Virus among HIV positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin. J Acquir Immune Defic Syndr 2005, 40:41–46.",{"doi":2806},"10.1097\u002F01.qai.0000174930.64145.a9",{"id":26,"text":2808,"url":26,"identifiers":2809},"Greub G, Ledergerber B, Battegay M, et al.: Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000, 356:1800–1805. (Published erratum appears in Lancet 2001, 357:1536.)",{"doi":2810},"10.1016\u002FS0140-6736(00)03232-3",{"id":26,"text":2812,"url":26,"identifiers":2813},"Weis N, Lindhardt BO, Kronborg G, et al.: Impact of hepatitis C virus coinfection on response to highly active antiretroviral therapy and outcome in HIV infected individuals: a nationwide cohort study. Clin Infect Dis 2006, 42:1481–1487.",{"doi":2814},"10.1086\u002F503569",{"id":26,"text":2816,"url":26,"identifiers":2817},"Braitstein P, Justice A, Bangsberg DR, et al.: Hepatitis C coinfection is independently associated with decreased adherence to antiretroviral therapy in a population based HIV cohort. AIDS 2006, 20:323–331.",{"doi":2818},"10.1097\u002F01.aids.0000198091.70325.f4",{"id":26,"text":2820,"url":26,"identifiers":2821},"Chung RT, Andersen J, Volberding P, et al.: Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV coinfected persons. N Engl J Med 2004, 351:451–459.",{"doi":2822},"10.1056\u002FNEJMoa032653",{"id":26,"text":2824,"url":26,"identifiers":2825},"Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatiti C infection in HIV infected patients. N Engl J Med 2004, 351:438–450.",{"doi":2826},"10.1056\u002FNEJMoa040842",{"id":26,"text":2828,"url":26,"identifiers":2829},"Carrat F, Bani-Sadr F, Pol S, et al.: Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV infected patients: a randomized controlled trial. JAMA 2004, 292:2839–2848.",{"doi":2830},"10.1001\u002Fjama.292.23.2839",{"id":26,"text":2832,"url":26,"identifiers":2833},"Núñez M, Mariño A, Miralles C, et al.: Baseline serum hepatitis C virus (HCV) RNA level and response at week 4 are best predictors of relapse after treatment with pegylated interferon plus ribavirin in HIV\u002FHCV coinfected patients. J Acquir Immune Defic Syndr 2007, 45:439–444. (Published erratum appears in J Acquir Immune Defic Syndr 2008, 47:528.)",{"doi":2834},"10.1097\u002FQAI.0b013e318061b5d9",{"id":26,"text":2836,"url":26,"identifiers":2837},"Chung RC, Umbleja T, Butt A, et al.: SLAM-C (ACTG A5178): Role of early virologic response in extended therapy with PEG-interferon and weight-based ribavirin in HIV\u002FHCV coinfection. Presented at the 16th Conference on Retroviruses and Opportunistic Infections 2009. Montreal, Canada; February 8–11, 2009.",{},{"id":26,"text":2839,"url":26,"identifiers":2840},"Di Bisceglie AM, Shiffman ML, Everson GT, et al.: Prolonged therapy of advanced chronic hepatitis C with low dose peginterferon. N Engl J Med 2008, 359:2429–2441.",{"doi":2841},"10.1056\u002FNEJMoa0707615",{"id":26,"text":2843,"url":26,"identifiers":2844},"• Berenguer J, Alvarez-Pellicer J, Martín PM, et al.: Sustained Virological Response to Interferon Plus Ribavirin Reduces Liver Related Complications and Mortality in Patients Coinfected with HIV and HCV. Hepatology 2009, 50:407–413. The long-term clinical effects of achieving SVR are only now becoming evident as time passes for the cohort of successfully treated individuals with HCV–HIV. This article demonstrates improved mortality from SVR in coinfected patients.",{"doi":2845},"10.1002\u002Fhep.23020",{"id":26,"text":2847,"url":26,"identifiers":2848},"Mauss S, Valenti W, DePamphilis J, et al.: Risk factors for hepatic decompensation in patients with HIV\u002FHCV coinfection and liver cirrhosis during interferon-based therapy. AIDS 2004, 18:F21–F25.",{"doi":2849},"10.1097\u002F00002030-200409030-00002",{"id":26,"text":2851,"url":26,"identifiers":2852},"Danta M, Dusheiko GM.: Acute HCV in HIV-positive individuals—a review. Curr Pharm Des 2008, 14:1690–1697.",{"doi":2853},"10.2174\u002F138161208784746761",{"id":26,"text":2855,"url":26,"identifiers":2856},"Duclos-Vallée JC, Féray C, Sebagh M, et al.: Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2008, 47:407–417.",{"doi":2857},"10.1002\u002Fhep.21990",{"id":26,"text":2859,"url":26,"identifiers":2860},"••McHutchison JG, Everson GT, Gordon SC, et al.: Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection [published erratum appears in N Engl J Med 2009, 361:1516]. N Engl J Med 2009, 360:1827–1838. PROVE-1 and PROVE-2 were large randomized clinical trials strongly suggesting superior efficacy of telaprevir, when combined with pegylated interferon and ribavirin, versus pegylated interferon and ribavirin, in achieving SVR in chronic hepatitis C infection.",{"doi":2861},"10.1056\u002FNEJMoa0806104",{"id":26,"text":2863,"url":26,"identifiers":2864},"•• Hezode C, Forestier N, Dusheiko G, et al.: Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009, 360:1839–1850. PROVE-1 and PROVE-2 were large randomized clinical trials strongly suggesting superior efficacy of telaprevir, when combined with pegylated interferon and ribavirin, versus pegylated interferon and ribavirin, in achieving SVR in chronic hepatitis C infection.",{"doi":2865},"10.1056\u002FNEJMoa0807650",{"id":26,"text":2867,"url":26,"identifiers":2868},"Manns MP. Prove 3 Data. Presented at the 60th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA; October 30–November 3, 2009.",{},{"id":26,"text":2870,"url":26,"identifiers":2871},"•• Ge D, Fellay J, Thompson AJ, et al.: Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399–401. The single nucleotide polymorphism at the gene locus for the IL28B gene is demonstrated, in this landmark publication, to be a major predictor of treatment response.",{"doi":2872},"10.1038\u002Fnature08309",{"id":26,"text":2874,"url":26,"identifiers":2875},"Thomas DL, Thi oCL, Martin MP, et al.: Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461:798–801.",{"doi":2876},"10.1038\u002Fnature08463",{"id":26,"text":2878,"url":26,"identifiers":2879},"Rauch A, Kutalik Z, Descombes P, et al.: Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010, 138:1338–1345.",{"doi":2880},"10.1053\u002Fj.gastro.2009.12.056",{"id":2882,"createTime":2883,"updateTime":2884,"relativeEntities":2885,"slug":2886,"properties":2887,"entityType":725,"verifyStatus":25,"verifyTime":2884,"verifyNote":726,"syncStatus":28,"languages":2898,"translateLanguages":26,"viewCount":36,"primaryUrl":2899,"fullTextUrl":26,"authors":2900,"publicationType":768,"publisherRelationship":2921,"citationCount":114,"citationInfo":2948,"publishDate":1098,"publishYear":1099,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":2950,"isForceReanalyzing":1000},"ed1f02f5-a93f-4127-9a46-79c839a9dc56","2024-04-16T11:04:58.839+00:00","2025-01-12T21:35:56.625+00:00",[],"Chronic-hepatitis-C-in-the-Latino-population",{"mag":2888,"keywords":2890,"openalex":2891,"abstract":2893,"title":2894,"doi":2896},{"VOID":2889},"2051935378",{},{"VOID":2892},"W2051935378",{},{"EN":2895},"Chronic hepatitis C in the Latino population",{"VOID":2897},"10.1007\u002Fs11901-008-0023-1",[102],"http:\u002F\u002Flink.springer.com\u002F10.1007\u002Fs11901-008-0023-1",[2901],{"id":2902,"sortIndex":36,"researcher":26,"roles":2903,"affiliations":2904,"properties":2916},"9612dcd6-1292-4150-991a-e7ed423b5499",[],[2905],{"id":2906,"sortIndex":36,"affiliation":2907,"properties":26},"9306b9bd-bb28-47ba-b4c9-b286f9a75233",{"id":2908,"createTime":2909,"updateTime":2910,"relativeEntities":2911,"slug":2912,"properties":2913,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"095b971a-3b08-4760-bd7c-2c130b6c7792","2024-04-16T11:04:58.848+00:00","2025-06-11T22:18:20.970+00:00",[],"Fundaci%C3%B3n-de-Investigaci%C3%B3n-de-Diego-Santurce-Puerto-Rico-Spain",{"title":2914},{"EN":2915},"Fundación de Investigación de Diego, Santurce, Puerto Rico, Spain",{"openalex":2917,"title":2919},{"VOID":2918},"A5054070286",{"EN":2920},"Maribel Rodrı́guez-Torres",{"url":26,"publisher":2922,"properties":2942},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":2923,"slug":663,"properties":2924,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":2928,"manageAffiliations":2929,"indexDatabases":2930,"url":691,"thumbnailPath":26,"statistic":2937,"gsStatistic":26,"type":175,"analyzePriority":26},[],{"issn":2925,"eissn":2926,"title":2927},{"VOID":666},{"VOID":668},{"EN":670},[],[],[2931],{"id":675,"indexDatabase":2932,"url":688,"indexYears":689,"academicFieldIds":26,"indexDatabaseRanking":690},{"id":677,"createTime":678,"updateTime":679,"relativeEntities":2933,"label":2934,"description":2935,"key":685,"publicationTags":2936,"standard":26},[],{"EN":682,"VI":682},{"EN":682,"VI":684},[687],{"impactFactor":36,"impactFactorByYear":2938,"i10Index":59,"i10IndexLast5Year":36,"totalPublication":694,"totalPublicationByYear":2939,"totalCitation":536,"totalCitationByYear":2940,"totalCitationPerPublication":132,"totalCitationPerPublicationByYear":2941,"hindexLast5Year":162,"hindex":162},{"2012":231,"2013":229,"2014":39},{"2002":111,"2003":336,"2004":173,"2005":234,"2006":234,"2007":162,"2008":234,"2009":237,"2010":241,"2011":516,"2012":241,"2013":51},{"2003":114,"2004":114,"2005":59,"2006":53,"2007":50,"2008":234,"2009":115,"2010":285,"2011":114,"2012":135,"2013":115},{"2003":404,"2004":206,"2005":57,"2006":698,"2007":699,"2008":115,"2009":230,"2010":266,"2011":108,"2012":477,"2013":110},{"volume":2943,"pages":2944,"issue":2946},{"VOID":2168},{"VOID":2945},"106-112",{"VOID":2947},"3",{"total":114,"publishYear":26,"statisticByYear":2949},{"2015":115},[2951,2954,2957,2960,2964,2968,2972,2975,2979,2982,2985,2988,2991,2995,2999,3003,3007,3011,3015,3019,3023,3027,3030,3034,3038,3042,3046,3050,3054,3058,3062,3066,3069,3073,3077,3081,3085,3089,3093,3097,3101,3104,3108,3112,3115,3119,3123,3127,3131,3135,3139],{"id":26,"text":2952,"url":26,"identifiers":2953},"US Department of Commerce Economics and Statistics Administration, US Census Bureau: The Hispanic population in the United States. March 2002. Available at http:\u002F\u002Fwww.census.gov\u002Fpopulation\u002Fwww\u002Fhispanic\u002Fho02tabs.html . Accessed June 29, 2004.",{},{"id":26,"text":2955,"url":26,"identifiers":2956},"US Census Bureau: Census 2000 brief: overview of race and Hispanic origin, 2000. Available at http:\u002F\u002Fwww.census.gov\u002Fprod\u002F2001pubs\u002Fc2kbr01-1.pdf . Accessed May 28, 2008.",{},{"id":26,"text":2958,"url":26,"identifiers":2959},"Alter MJ, Kruszon-Moran MS, Nainan O, et al.: The prevalence of hepatitis C virus infection in the United Status, 1988 through 1994. N Engl J Med 1999, 341:556–562.",{"doi":2436},{"id":26,"text":2961,"url":26,"identifiers":2962},"Bonacini M, Groshen MD, Yu MC, et al.: Chronic hepatitis C in ethnic minority patients evaluated in Los Angeles County. Am J Gastroenterol 2001, 96:2438–2441.",{"doi":2963},"10.1111\u002Fj.1572-0241.2001.04050.x",{"id":26,"text":2965,"url":26,"identifiers":2966},"Mallet DB, Jeffers L: The natural history of HCV infection in African Americans [editorial]. Am J Gastroenterol 2002, 97:520–522.",{"doi":2967},"10.1111\u002Fj.1572-0241.2002.05584.x",{"id":26,"text":2969,"url":26,"identifiers":2970},"Bonds DE, Zaccaro DJ, Karter AJ, et al.: Ethnic and racial differences in diabetes care: The Insulin Resistance Atherosclerosis Study. Diabetes Care 2003, 26:1040–1046.",{"doi":2971},"10.2337\u002Fdiacare.26.4.1040",{"id":26,"text":2973,"url":26,"identifiers":2974},"The Health Care Challenge: Acknowledging Disparity, Confronting Discrimination and Ensuring Equality. Volume 1, The Role of Governmental and Private Health Care Programs and Initiatives. Washington, DC: US Commission on Civil Rights; 1999.",{},{"id":26,"text":2976,"url":26,"identifiers":2977},"Smith CA, Barnett E: Diabetes-related mortality among Mexican Americans, Puerto Ricans and Cuban Americans in the United Status. Rev Panam Salud Publica 2005, 18:381–387.",{"doi":2978},"10.1590\u002FS1020-49892005001000001",{"id":26,"text":2980,"url":26,"identifiers":2981},"Rawls RA, Vega KJ: Viral hepatitis in minority America. J Clin Gastroenterol 2005, 39:144–151.",{},{"id":26,"text":2983,"url":26,"identifiers":2984},"McQuillan GM, Alter MJ, Moyer LA, et al.: A population based serologic study of hepatitis c virus infection in the United States. In Viral Hepatitis and Liver Disease. Edited by Rizzetto M, Purcell RH, Gerin JL, Verme G. Turin, Italy: Edizioni Minerva Medica; 1997:267–270.",{},{"id":26,"text":2986,"url":26,"identifiers":2987},"Centers for Disease Control and Prevention: HIV\u002FAIDS Surveillance Report, vol 15. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2003.",{},{"id":26,"text":2989,"url":26,"identifiers":2990},"Perez CM, Suarez E, Torres EA: Epidemiology of hepatitis C infection and its public health implications in Puerto Rico. PR Health Sci J 2004, 23(Suppl):11–28.",{},{"id":26,"text":2992,"url":26,"identifiers":2993},"Thomas DL: The challenge of hepatitis C in the HIV-infected person. Annu Rev Med 2008, 59:473–485.",{"doi":2994},"10.1146\u002Fannurev.med.59.081906.081110",{"id":26,"text":2996,"url":26,"identifiers":2997},"Strader DB: Coinfection with HIV and hepatitis C virus in injection drug users and minority populations. Clin Infect Dis 2005, 41(Suppl 1):S7–S13.",{"doi":2998},"10.1086\u002F429489",{"id":26,"text":3000,"url":26,"identifiers":3001},"Wise M, Bialek S, Finelli L, et al.: Changing trends in hepatitis C-related mortality in the USA, 1995–2004. Hepatology 2008, 47:1128–1135.",{"doi":3002},"10.1002\u002Fhep.22165",{"id":26,"text":3004,"url":26,"identifiers":3005},"Rodriguez-Torres M, Rios-Bedoya CF, Rodriguez-Orengo J, et al.: Progression to cirrhosis in Latinos with chronic hepatitis C: differences in Puerto Ricans with and without human immunodeficiency virus and along gender. J Clin Gastroenterol 2006, 40:358–366.",{"doi":3006},"10.1097\u002F01.mcg.0000210105.66994.dc",{"id":26,"text":3008,"url":26,"identifiers":3009},"Reyes JC, Colon HM, Robles RR, et al.: Prevalence and correlates of hepatitis C virus infection among street-recruited injection users in San Juan, Puerto Rico. J Urban Health 2006, 83:1105–1113.",{"doi":3010},"10.1007\u002Fs11524-006-9109-7",{"id":26,"text":3012,"url":26,"identifiers":3013},"Fisher DG, Reynolds GL, Jaffe A, Perez MJ: Hepatitis and human immunodeficiency virus co-infection among injection drug users in Los Angeles County, California. J Addict Dis 2006, 25:25–32.",{"doi":3014},"10.1300\u002FJ069v25n02_04",{"id":26,"text":3016,"url":26,"identifiers":3017},"Estrada AL: Health disparities among African Americans and Hispanic drug injectors-HIV, AIDS, hepatitis B virus and hepatitis C virus; a review. AIDS 2005, 19(Suppl 3):S47–S52.",{"doi":3018},"10.1097\u002F01.aids.0000192070.95819.7c",{"id":26,"text":3020,"url":26,"identifiers":3021},"Estrada AL: Drug use and HIV risks among African-American, Mexican-American, and Puerto Rican drug injectors. J Psychoactive Drugs 1998, 30:247–253.",{"doi":3022},"10.1080\u002F02791072.1998.10399699",{"id":26,"text":3024,"url":26,"identifiers":3025},"Diaz T, Des Jarlais DC, Vlahov D, et al.: Factors associated with prevalent hepatitis C: differences among young adult injection users in lower and upper Manhattan, New York City. Am J Pub Health 2001, 91:23–30.",{"doi":3026},"10.2105\u002FAJPH.91.1.23",{"id":26,"text":3028,"url":26,"identifiers":3029},"Rodriguez-Perez F, Suarez-Perez E, Alvarez-Rohena M, Toro DH: Prevalence of chronic hepatitis C virus genotypes among patients between 21 to 65 years old in Puerto Rico. PR Health Sci J 2004, 23(2 Suppl):49–56.",{},{"id":26,"text":3031,"url":26,"identifiers":3032},"Cheung RC, Currie S, Shen H, et al.; VA HCV-001 Study Group: Chronic hepatitis C in Latinos: natural history, treatment eligibility, acceptance, and outcomes. Am J Gastoenterol 2005, 100:2186–2193.",{"doi":3033},"10.1111\u002Fj.1572-0241.2005.00240.x",{"id":26,"text":3035,"url":26,"identifiers":3036},"Bachus LI, Boothroyd D, Deyton LR: HIV, hepatitis C virus co-infection in vulnerable populations. AIDS 2005, 19(Suppl 3):S13–S19.",{"doi":3037},"10.1097\u002F01.aids.0000192065.09281.01",{"id":26,"text":3039,"url":26,"identifiers":3040},"Lepe R, Layden-Almer JE, Layden TJ, Cotler S: Ethnic differences in the presentation of chronic hepatitis. C J Viral Hepat 2006, 13:116–120.",{"doi":3041},"10.1111\u002Fj.1365-2893.2005.00672.x",{"id":26,"text":3043,"url":26,"identifiers":3044},"Verma S, Bonacini M, Govindarajan S, et al.: More advanced hepatic fibrosis in Hispanics with chronic hepatitis C infection: role of patient demographics, hepatic necroinflammation, and steatosis. Am J Gastroenterol 2006, 101:1817–1823.",{"doi":3045},"10.1111\u002Fj.1572-0241.2006.00682.x",{"id":26,"text":3047,"url":26,"identifiers":3048},"Afdhal NH: The natural history of hepatitis C. Semin Liver Dis 2004, 24(Suppl 2):3–8.",{"doi":3049},"10.1055\u002Fs-2004-832922",{"id":26,"text":3051,"url":26,"identifiers":3052},"Crosse K, Omeadi OG, Anana FA, et al.: Racial differences in liver inflammation and fibrosis related to chronic hepatitis C. Clin Gastroenterol Hepatol 2004, 2:463–468.",{"doi":3053},"10.1016\u002FS1542-3565(04)00162-4",{"id":26,"text":3055,"url":26,"identifiers":3056},"Di Bisceglie AM, Lyra AC, Reddy RK, et al.: Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol 2003, 98:2060–2063.",{"doi":3057},"10.1016\u002FS0002-9270(03)00552-5",{"id":26,"text":3059,"url":26,"identifiers":3060},"Bhattacharya R, Shuhart MC: Hepatitis C and alcohol: interactions, outcomes, and implications. J Clin Gastroenterol 2003, 36:242–252.",{"doi":3061},"10.1097\u002F00004836-200303000-00012",{"id":26,"text":3063,"url":26,"identifiers":3064},"Lee DJ, Markides KS, Ray LA: Epidemiology of self reported past heavy drinking in Hispanic adults. Ethn Health 1997, 2:77–88.",{"doi":3065},"10.1080\u002F13557858.1997.9961817",{"id":26,"text":3067,"url":26,"identifiers":3068},"Drugs and Alcohol in Puerto Rico. Puerto Rico Substance Abuse Program. Hato Rey, PR: Mental Health and Anti-addiction Services Administration; 2003.",{},{"id":26,"text":3070,"url":26,"identifiers":3071},"Adinolfi L, Gambardella M, Andreana A, et al.: Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001, 33:1358–1364.",{"doi":3072},"10.1053\u002Fjhep.2001.24432",{"id":26,"text":3074,"url":26,"identifiers":3075},"Castera L, Hezode C, Roudot-Thoraval F, et al.: Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut 2003, 52:288–292.",{"doi":3076},"10.1136\u002Fgut.52.2.288",{"id":26,"text":3078,"url":26,"identifiers":3079},"Vidali M, Tripodi MF, Ivaldi A, et al.: Interplay between oxidative stress and hepatic steatosis in the progression of chronic hepatitis C. J Hepatol 2008, 48:399–406.",{"doi":3080},"10.1016\u002Fj.jhep.2007.10.011",{"id":26,"text":3082,"url":26,"identifiers":3083},"Weston SR, Leyden W, Murphy R, et al.: Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology 2005, 41:372–379.",{"doi":3084},"10.1002\u002Fhep.20554",{"id":26,"text":3086,"url":26,"identifiers":3087},"Caballero AE: Diabetes in the Hispanic or Latino population: genes, environment, culture, and more. Curr Diab Rep 2005, 5:217–225.",{"doi":3088},"10.1007\u002Fs11892-005-0012-5",{"id":26,"text":3090,"url":26,"identifiers":3091},"Ford ES: Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 2005, 28:2745–2749.",{"doi":3092},"10.2337\u002Fdiacare.28.11.2745",{"id":26,"text":3094,"url":26,"identifiers":3095},"Haffner SM, D’Agostino R, Saad MF, et al.: Increased insulin resistance and insulin secretion in nondiabetic African-Americans and Hispanics compared with non-Hispanic whites. The Insulin Resistance Atherosclerosis Study. Diabetes 1996, 45:742–748.",{"doi":3096},"10.2337\u002Fdiab.45.6.742",{"id":26,"text":3098,"url":26,"identifiers":3099},"Langefeld CD, Wagenknecht LE, Rotter JI, et al.: Linkage of the metabolic syndrome to 1q23-q31 in Hispanic families: the Insulin Resistance Atherosclerosis Study Family Study. Diabetes 2004, 53:1170–1174.",{"doi":3100},"10.2337\u002Fdiabetes.53.4.1170",{"id":26,"text":3102,"url":26,"identifiers":3103},"Kirby JB, Taliaferro G, Zuvekas SH: Explaining racial and ethnic disparities in health care. Med Care 2006, 44(5 Suppl):I64–I72.",{},{"id":26,"text":3105,"url":26,"identifiers":3106},"Butt AA, Justice AC, Skanderson M, et al.: Rate and predictors of treatment prescription for hepatitis C. Gut 2007, 56:385–389.",{"doi":3107},"10.1136\u002Fgut.2006.099150",{"id":26,"text":3109,"url":26,"identifiers":3110},"Trooskin SB, Navarro VJ, Winn RJ, et al.: Hepatitis C risk assessment, testing and referral for treatment in urban primary care: role of race and ethnicity. World J Gastroenterol 2007, 13:1074–1078.",{"doi":3111},"10.3748\u002Fwjg.v13.i7.1074",{"id":26,"text":3113,"url":26,"identifiers":3114},"Fried MW, Shiffman ML, Reddy KR, et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975–982.",{"doi":2061},{"id":26,"text":3116,"url":26,"identifiers":3117},"Hepburn MJ, Hepburn LM, Cantu NS, et al.: Differences in treatment outcome for hepatitis C among ethnic groups. Am J Med 2004, 117:163–168.",{"doi":3118},"10.1016\u002Fj.amjmed.2004.02.043",{"id":26,"text":3120,"url":26,"identifiers":3121},"Brown RS, Jacobson IM, Afdhal N, et al.: Differences in treatment outcome to antiviral therapy based on genotype and viral load in hepatitis C genotypes 2 and 3 in the WINR trial. Presented at Digestive Disease Week 2006. Los Angeles, CA; May 20–25, 2006.",{"doi":3122},"10.1016\u002FS0168-8278(06)80042-5",{"id":26,"text":3124,"url":26,"identifiers":3125},"Rodriguez-Torres M, Jeffers LJ, Sheikh MY, et al.; on behalf of the LATINO. Virologic responses to peginterferon alfa-2a\u002Fribavirin in treatment-naïve Latino vs. non-Latino Caucasians infected with HCV genotype 1: the Latino Study. Presented at the 42nd Annual Meeting of the European Association for the Study of the Liver. Milan, Italy; April 23–27, 2008.",{"doi":3126},"10.1016\u002FS0168-8278(08)60832-6",{"id":26,"text":3128,"url":26,"identifiers":3129},"Conjeevaram HS, Kleiner DE, Everhart JE, et al.: Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology 2007, 45:80–87.",{"doi":3130},"10.1002\u002Fhep.21455",{"id":26,"text":3132,"url":26,"identifiers":3133},"Gupta K, Romney D, Briggs M, Benker K: Effects of a brief educational program on knowledge and willingness to accept treatment among patients with hepatitis C at innercity hospitals. J Community Health 2007, 32:221–230.",{"doi":3134},"10.1007\u002Fs10900-007-9046-8",{"id":26,"text":3136,"url":26,"identifiers":3137},"Schackman BR, Teixeira PA, Beeder AB: Offers of hepatitis C care do not lead to treatment. J Urban Health 2007, 84:455–458.",{"doi":3138},"10.1007\u002Fs11524-007-9180-8",{"id":26,"text":3140,"url":26,"identifiers":3141},"Cohen MH, Grey D, Cook JA, et al.: Awareness of hepatitis C infection among women with and at risk for HIV. J Gen Intern Med 2007, 22:1689–1694.",{"doi":3142},"10.1007\u002Fs11606-007-0395-x"]